



Submission to the
Department of Health and Ageing

*Review of the Australian Government Rebate on Private
Health Insurance for Natural Therapies*

Prepared by the

Australian Register of Homœopaths Ltd.

and its corporate member associations:

Australian Homœopathic Association Inc.

Homeopathic Education and Research Association

Australian Association of Professional Homeopaths Inc.

March 2013, version 3

AUSTRALIAN REGISTER OF HOMŒOPATHS LTD

122 Church St Wollongong NSW 2500

Phone: 0488 060 145

Email: admin@aroh.com.au Website: www.aroh.com.au

ABN: 69 088 314 818

Executive Summary

We thank you for giving the Australian Register of Homoeopaths Ltd. (AROH) the opportunity to present this body of work. This Submission by AROH, the peak body for the homoeopathic profession in Australia, presents an overview of homoeopathic research over the last 10 years and beyond, within the constraints of the Review guidelines.

This Submission documents the interactions between the homoeopathic profession and the National Health and Medical Research Council (NHMRC) since the announcement of the NHMRC's intention to develop a position statement on homoeopathy.

This Submission provides evidence of a body of research in support of the efficaciousness, safety, quality and cost effectiveness of homoeopathy, not just in Australia but around the globe.

This Submission identifies well documented positive findings for homoeopathic treatment in a number of pathological conditions, and positive outcomes of randomised controlled trials and systematic reviews of homoeopathic research.

This Submission provides the compellingly positive data derived from observational studies of homoeopathic treatment, and of preclinical trials and the veterinary application of homoeopathy.

This Submission, whilst adhering to the NHMRC guidelines, is also constrained by these limitations, as they do not allow us to accurately or adequately represent our profession. Homoeopathy is a holistic medical practice, and provides a substantial evidence base covering evidence gathered from a much broader base than that required by this Review. AROH feels it has supplied more than adequate evidence to support the continued tax rebate, despite the disadvantage placed upon it by the limited scope of this Submission. It is of some concern that the requested evidence does not take this into consideration. The requested evidence is almost completely restricted to research of a quantitative nature. Qualitative research is a well-accepted method of building a picture of evidence, and it is our understanding that, had it been taken into account, this Submission would give a more complete account of homoeopathic practice.

There is a discussion on the benefits of continuing access to private health tax rebates for patients who choose to use homoeopathy in the management of their health. AROH supports the retention of private health insurance rebates for homoeopathic consultations, and offers considerable evidence as the foundation for this support.

Table of Contents

Executive Summary	i
List of Tables	iv
List of Abbreviations	v
List of Appendices	vi
Notes to the Reader.....	vii
The Australian Register of Homœopaths Ltd.	vii
The spelling of homoeopathy	vii
Background reading on homoeopathy.....	viii
1. Introduction	1
2. Context of the Review	3
2.1. WHO Statement on Traditional Medicine	3
2.2. The use of CAM therapies and homoeopathy world-wide.....	4
2.3. The use of CAM therapies and homoeopathy in Australia.....	7
2.4. Health care rebates.....	8
2.5. The political context of the review	9
3. Research Challenges for Homoeopathic Medicine	13
4. Homoeopathy Research	17
4.1. RCTs of homoeopathy	17
4.2. Efficacy of homoeopathy.....	18
4.3. Trial evidence by pathology	20
4.4. Clear evidence of an action greater than placebo	31
4.5. Homoeopathy as good as or better than conventional medical care?	32
4.6. Onset of improvement faster in homoeopathically treated patients	35
4.7. Satisfaction rated high by homoeopathic patients.....	36
4.8. Prior dissatisfaction with conventional medical treatment.....	38
4.9. Homoeopathy ameliorates the effects of environmental toxins	39
4.10. Homoeopathy in Epidemics	40
5. Cost-effectiveness of homoeopathic medicine.....	42
5.1. The cost-effectiveness of homoeopathy	43
5.2. Cost-effectiveness and clinical effectiveness	51
5.3. Reductions in expenditure on conventional drug treatments	52
5.4. Patient satisfaction measures high in homoeopathic care	54
5.5. Reduced general practitioner consultations following homoeopathic care.....	55
5.6. Lower costs of homoeopathic care across a range of measures.....	56
6. Safety.....	58
6.1 Safety of homoeopathic medicines	58
6.2. Homoeopathic remedy responses.....	59
6.3. Adverse events in homoeopathy.....	60
6.4. Professional education of homoeopaths in Australia	64

7. Ethical Considerations.....	67
7.1. Friends of Science in Medicine	67
7.2. The NHMRC, the Natural Therapies Review Advisory Committee and the process of the inquiries into homoeopathy	71
8. Conclusions.....	73
Acknowledgements	75
References	76

List of Tables

Table 1. Strongly positive evidence in twelve conditions (RCT indicates where information is lacking to discriminate between Level II and III-1).....	21
Table 2. Sixty-one conditions with lower degrees of positive evidence for homoeopathy	24
Table 3. Summary of studies of the cost-effectiveness of homoeopathy (studies older than 10 years have been highlighted).....	45
Table 4. Observational studies published after 1995 considering possible adverse events and homoeopathic aggravation (studies older than 10 years are highlighted)	62
Table 5. Experimental studies published after 2003 considering possible adverse events from homoeopathic treatment.....	64

List of Abbreviations

AROH	Australian Register of Homœopaths Ltd.
CAM	complementary and alternative medicine
GP	general practitioner
NHMRC	National Health and Medical Research Council
RCT	randomised controlled trial
UK	United Kingdom
USA	United States of America
WHO	World Health Organization

List of Appendices

Appendix 1. *The Submission of the Australian Homoeopathic Association Inc. to the National Health & Medical Research Council: review of the evidence towards the development of a position statement on Homoeopathy*

Appendix 2. Summary of Reviewed Studies

Appendix 3. Letter from the Australian Medical Fellowship of Homoeopathy to the National Health and Medical Research Council's Australian Health Ethics Committee

Notes to the Reader

The Australian Register of Homœopaths Ltd.

The Australian Register of Homœopaths Ltd. (AROH) is a company limited by guarantee, providing a framework for professional standards and the accreditation of educational courses for homoeopaths since 1999. It also facilitates communication between the profession and Government agencies, private health insurance companies and the general public. On behalf of the public and its registrants AROH liaises with the private health insurance industry to facilitate eligibility requirements for health insurance rebates on homoeopathic consultations. One of AROH's main functions is to receive, investigate and resolve complaints concerning its registrants.

AROH has 683 registrants for whom homoeopathy is their primary professional health care modality. All AROH registered homoeopaths meet the national competency standards established by the profession (Homoeopathic Industry Reference Group, 1999) and training endorsed by the Federal Government. Registrants also meet the criteria as “recognised professional” recommended in the 2003 Government report: *Complementary Medicines in the Australian Health System* (Expert Committee on Complementary Medicines in the Health System, 2003). This requirement was subsequently endorsed by the Federal Government in their 2005 response to the Expert Committee's report (Australian Government, 2005).

AROH registrants are bound by a Code of Professional Conduct and are required to have current indemnity insurance, engage in continuing professional development and possess a current Senior First Aid certification. Homoeopathy is the only non-government registered complementary and alternative medicine (CAM) modality that has a register of practitioners.

The spelling of homoeopathy

Many organisations have chosen to simplify the spelling of *homœopathy* by replacing the diphthong “œ” with an “e”. AROH favours the spelling homoeopathy in all its documents, only using the diphthong “œ” in the company name. In this Submission, variations in spelling will occur where source texts are directly quoted and for the names of organisations and publications.

Background reading on homoeopathy

Background reading on the history, theory and clinical practice of homoeopathy is attached as Appendix 1: *The Submission of the Australian Homoeopathic Association Inc. to the National Health & Medical Research Council: review of the evidence towards the development of a position statement on Homoeopathy*. This was submitted in 2011 by the Australian Homœopathic Association Inc. for consideration by the National Health and Medical Research Council (NHMRC) in the development of their position statement on homoeopathy.

The Submission includes a discussion on ultra-molecular dilutions used in homoeopathic medicine, and cites a substantial body of research evidence supporting the biological activity of ultra-molecular dilutions. These studies used various biological models such as isolated cells, plants and animals, and demonstrate responses to ultra-molecular substances, with several studies yielding repeatable results.

1. Introduction

AROH, Australia's peak homoeopathic body, has prepared this Submission for the *Review of the Australian Government Rebate on Private Health Insurance for Natural Therapies*. This review is being conducted by Australia's Chief Medical Officer through the agency of the Natural Therapies Review Advisory Committee, and is advised by the Homoeopathy Working Committee of the NHMRC.

This Submission presents a detailed analysis of the evidence for the clinical efficacy, cost-effectiveness, safety and quality of homoeopathic medicine to be used in the review of the evidence base for a range of natural therapies currently eligible for rebates under the Australian Government Private Health Insurance Rebate scheme.

This Submission addresses the following areas related to homoeopathic health care:

- positive findings for homoeopathic treatment in 96 human randomised controlled trials (RCTs)
- we also provide a sample of 51 positive pre-clinical and veterinary trials, 5 case series, and systematic reviews and catalogues of trials containing references to a considerably larger number of trials
- compellingly positive data derived from observational studies of homoeopathic treatment at a population level
- relative safety of homoeopathic medicine and few side-effects from professionally executed homoeopathic care
- cost-effectiveness of homoeopathic treatment due to the lower costs of homoeopathic medicines compared to conventional drugs, through reduced expenditure by homoeopathically treated patients on Pharmaceutical Benefit Scheme listed products and through reductions in consultations with General Practitioners (GPs)
- further savings potential through improved patient health as a result of homoeopathic care, and related reductions in patient's time away from productive activity and associated costs
- that the very limited benefit of savings which may be derived from the removal of rebates for homoeopathic consultations would be defrayed through subsequent loss of taxation payments by the homoeopathic profession
- the quality of production of homoeopathic medicines world-wide.

The extension of private health insurance rebates for CAM therapies was established primarily in response to community demand. The removal of private health insurance

rebates will significantly affect both privately insured patients and the profession of homoeopathy in Australia. Patients' freedom of choice in health care would be curtailed by such a measure, and arrangements through which privately insured consumers currently receive coverage of their health costs would be undermined by any substantial removal of the current rebates scheme. The viability of hundreds of small homoeopathic practices across Australia would also be adversely affected by the removal of rebates for homoeopathic health care.

AROH and its corporate member organisations support the retention of private health insurance rebates for homoeopathic consultations, and offers the evidence provided in this Submission as the foundation for that support.

2. Context of the Review

It is important to consider the world-wide and Australian context of the use of CAM and homoeopathic medicine. In this section, we present the World Health Organization (WHO) Statement on Traditional Medicine; a discussion of the world-wide and Australian use of CAM and homoeopathic medicine followed by a discussion of health care rebates, and the current political and media environment as it affects the profession of homoeopathy in Australia.

2.1. WHO Statement on Traditional Medicine

The Beijing Declaration was adopted by the WHO Congress on Traditional Medicine, Beijing, in November 2008.

Participants at the WHO Congress on Traditional Medicine, meeting in Beijing on 8 November 2008 adopted the following in that they:

- Recalled the International Conference on Primary Health Care at Alma Ata thirty years ago and noting that people have the right and duty to participate individually and collectively in the planning and implementation of their health care, which may include access to traditional medicine
- Recalled World Health Assembly resolutions promoting traditional medicine, including WHA56.31 on Traditional Medicine of May 2003
- Noted that the term “traditional medicine” covers a wide variety of therapies and practices which may vary greatly from country to country and from region to region, and that traditional medicine may also be referred to as alternative or complementary medicine
- Recognised traditional medicine as one of the resources of primary health care services to increase availability and affordability and to contribute to improved health outcomes including those mentioned in the Millennium Development Goals
- Recognised that Member States have different domestic legislation, approaches, regulatory responsibilities and delivery models
- Noted that progress in the field of traditional medicine has been obtained in a number of Member States through implementation of the WHO Traditional Medicine Strategy 2002–2005
- Expressed the need for action and cooperation by the international community, governments, and health professionals and workers, to ensure proper use of traditional

medicine as an important component contributing to the health of all people, in accordance with national capacity, priorities and relevant legislation

In accordance with national capacities, priorities, relevant legislation and circumstances the following Declaration was made:

- I. The knowledge of traditional medicine, treatments and practices should be respected, preserved, promoted and communicated widely and appropriately based on the circumstances in each country.
- II. Governments have a responsibility for the health of their people and should formulate national policies, regulations and standards, as part of comprehensive national health systems to ensure appropriate, safe and effective use of traditional medicine.
- III. Recognising the progress of many governments to date in integrating traditional medicine into their national health systems, we call on those who have not yet done so to take action.
- IV. Traditional medicine should be further developed based on research and innovation in line with the “Global strategy and plan of action on public health, innovation and intellectual property” adopted at the Sixty-first World Health Assembly in resolution WHA61.21 in 2008. Governments, international organizations and other stakeholders should collaborate in implementing the global strategy and plan of action.
- V. Governments should establish systems for the qualification, accreditation or licensing of traditional medicine practitioners. Traditional medicine practitioners should upgrade their knowledge and skills based on national requirements.
- VI. The communication between conventional and traditional medicine providers should be strengthened and appropriate training programs be established for health professionals, medical students and relevant researchers.

2.2. The use of CAM therapies and homoeopathy world-wide

Research carried out by Professor Edzard Ernst on behalf of the WHO (Ernst, 2000) found that the prevalence of the use of CAM therapies ranged from 9% to 65% when studies from Australia, Austria, Canada, China, Germany, Scotland and the USA were reviewed.

According to the report, the practice of homoeopathy is widespread across the globe, and is the first or second most popular form of CAM in many countries, several of which include reimbursement for homoeopathic treatment in mandatory or private health insurance.

Homoeopathy is practiced in the following countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Costa Rica, Cuba, Cyprus, Czech Republic,

Denmark, Ecuador, Finland, France, Hungary, Germany, Greece, India, Italy, Japan, Kenya, Latvia, Luxembourg, Malaysia, Netherlands, Nepal, New Zealand, Nicaragua, Norway, Philippines, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Sweden, Switzerland, South Africa, United Kingdom (UK), United States of America (USA) and Venezuela, amongst others.

Swiss researchers, Bornhoft and Matthiesen (2012) analysed the use of CAM in 52 studies from nine countries. They found that, one-third of respondents used CAM therapies for one year, while for two-thirds of respondents the use of CAM therapies was life-long. More than half of the CAM therapy users were satisfied with their treatment, and 80% gave a positive answer when asked if their condition had improved due to CAM therapy usage. The take-up of CAM therapy options in health care was found to be increasing in the countries studied.

The Complementary Medicine Evaluation Programme, undertaken by Bornhoft and Matthiesen (2012) on behalf of the Swiss government, found that about half of the Swiss population uses and values CAM therapies, and that half of physicians, the majority of CAM therapy users and 40% of cancer patients consider CAM to be effective treatments. Different surveys in Switzerland have suggested that between 11% and 27% of GPs and internists prescribe homoeopathic medicines. In the Netherlands, 45% of physicians consider homoeopathic medicines effective and 47% of medical doctors use one or more CAM therapies, with homoeopathy being the most popular (Fisher & Ward, 1994).

Other European studies found that three out of four Europeans know about homoeopathy and that 29% use it for their own health care, representing 100 million Europeans (di Sarsina & Isapatto, 2009). Studies with more detail about the use of homoeopathic medicine in just a few countries gives insight into the prevalence of CAM therapies and homoeopathic health care and provides evidence of the considerable growth in the use of homoeopathy over the past two to three decades.

Homoeopathy is the leading complementary therapy in France, where the percentage of homoeopathy users grew from 16% in 1982, to 29% in 1987 and to 36% in 1992 (Fisher & Ward, 1994). A survey by French pharmacists in 2004 found that 94.5% of pharmacists reported advising pregnant women to use homoeopathic medicine (Damase-Michel et al., 2004). The French medical profession is well-disposed towards homoeopathy: 70% of physicians consider homoeopathy effective and 25,000 French doctors prescribe homoeopathic medicines for their patients (Ullman, 2010). Homoeopathy is taught in at least seven medical schools and there are numerous postgraduate training programs. Courses in

homoeopathy are taught in 21 of France's 24 pharmacy schools, in two dental schools, in two veterinary medical schools and in three midwifery schools.

CAM has considerable support in Germany at both community and institutional levels. The German Government has mandated that all medical school curricula include information about natural medicine. In 2002, a study in the *British Medical Journal* reported that 75% of Germans have used complementary medicine (Tuffs, 2002). The number of medical practitioners training in homoeopathy has grown considerably in recent years. In 1993 there were 1,993 medical doctors who had formal qualifications in homoeopathy, and this figure had increased to 6,073 by 2006 (Joos et al., 2008). In a national health care survey in 2005, it was found that 38% of German doctors prescribed homoeopathic medicine (Stange et al., 2008). Sales of homoeopathic medicines in Germany were worth approximately \$US 428 million in 1991, growing at a rate of about 10% per year. The support for homoeopathy in the German medical community is evident in the fact that 85% of sales of homoeopathic medicines were from physician prescriptions. A study of obstetric hospitals in North-Rhine Westphalia found that almost 96% of obstetric departments offered homoeopathic medicines for obstetric care, principally provided by midwives on the basis of observed effectiveness and patient demand (Munstedt et al., 2009).

A study undertaken in Italy in 2009 provided data on the uptake of CAM therapies within conventional medical settings (di Sarsina & Iseppato, 2011). The authors found that the use of CAM therapies was increasing among the Italian population, as in the rest of Europe. Sales of alternative remedies are growing, and likewise the number of medical doctors who practice non-conventional medicine. There are 20,000 medical doctors with homoeopathic training in Italy (ECHAMP, 2009). A survey conducted in 2004 showed that a total of 7.5 million Italians use homeopathic medicines, 2.5 million more than a similar survey showed in 2000 (Ullman, 2010). Thirty homoeopathic laboratories produce homoeopathic medicines, and almost half of the pharmacies in Italy sell these medicines.

In 2005, David Reilly, the consultant physician at the Glasgow Homeopathic Hospital and honorary senior lecturer in medicine at Glasgow University, reported that public demand for homoeopathy had soared, and with it interest from medical professionals (Reilly, 2005). In 2000, approximately 20% of Scotland's GPs had completed basic training in homoeopathy: by 2003–2004, 49% of 323 general practices in Scotland were prescribing homoeopathic remedies. Reilly also suggested that the views of hospital consultants were reflecting reduced medical scepticism in that country.

The sales of homoeopathic and anthroposophical medicines in Europe grew by 60% between 1995 and 2005, from 590 million Euros in 1995, to 775 million Euros in 2001 and to \$930 million Euros in 2005, according to figures provided by the European Coalition on Homoeopathic and Anthroposophic Medicinal Products (ECHAMP, 2007). The percentage of pharmacies in Europe selling homoeopathic medicine rose from 14% in 1980 to 43% in 2000. France and Germany lead sales of homoeopathic and anthroposophical medicines, followed by Italy. Approximately 49% of French people, 46% of German people and 35% of British people use CAM therapies. There are an estimated 54,000 specialist homoeopathic medical doctors and practitioners in Europe (ECHAMP, 2009). Some of the five homoeopathic hospitals working within the UK National Health Service have a two-year waiting list for non-emergency visits to a homoeopath. This population of patient consumers of homoeopathic medicine would have been negatively affected had the Sense About Science push to have homoeopathy removed from the National Health Service not have failed so resoundingly in 2010 (Ullman, 2010).

In India, over 100 million people depend solely on homoeopathic medicine. There are hundreds of State and Central government-owned homoeopathic hospitals in India that provide both inpatient and outpatient facilities (Prasad, 2007). According to an AC Neilsen survey in India, 62% of current homoeopathy users have never tried conventional medicines, and 82% of homoeopathy users would not switch to conventional treatments (Business Standard, 2007).

2.3. The use of CAM therapies and homoeopathy in Australia

In Australia, two out of three Australians used complementary medicines in 2010-2011 (National Institute of Complementary Medicine, 2009). Consumers appear sensitive to anecdotal evidence (the health care experiences of family members, friends and acquaintances) in making their health care choices, with formal research being a less important guide to their uptake of CAM therapies.

The Department of Health and Ageing's Expert Committee on Complementary Medicines in the Health System (2003) advised that Government has a social responsibility to fund complementary medicine research given the high community use of these therapies and medicines. Australia, otherwise renowned internationally for the strength of its medical research, provides one of the lowest levels of investment for research of CAM therapies (National Institute of Complementary Medicine, 2009). Such research would play a vital role

in responding to consumer trends, facilitate better-informed consumer choice and provide a guide to public policy development reflecting the Australian context.

An absence of funding for genuine research inquiry into CAM therapies in general and homoeopathy in particular promotes a public policy environment wherein hasty, ill-informed decisions may be made. While the NHMRC website informs us that almost \$69 million (National Health and Medical Research Council, 2013) has been set aside for complementary medicine research during the 2010–2012 triennium, AROH is unaware of any publically funded research in homoeopathy that is currently being undertaken in Australia.

The enquiry into the public provision of health rebates for natural therapies takes place at a time of continuing growth in the use of CAM therapies in Australia. Numerous local studies have been conducted into this community-led phenomenon (Xue et al., 2006; Xue et al., 2007; Xue et al., 2008; Zhang et al., 2007). As described above, international studies have shown that the demand for CAM therapies has risen at similar rates across different countries in Europe and North America over the past thirty years (Andrews et al., 2003; Dixon et al., 2003; Eisenberg et al., 1993; Eisenberg et al., 1998). Australian studies show that the uptake of CAM therapies has increased: over half of all medicine users use complementary medicines (Morgan et al., 2012) and the amount of money spent on CAM medicines and treatments grew by 62% between 1996 and 2002 (MacLennan et al., 2002).

2.4. Health care rebates

Currently in Australia, the majority of private health insurers offer rebates for a range of natural therapies consultations, including homoeopathic consultations. The current review concerns the question about whether the government will withdraw its contribution to insurance premiums via the tax rebate. In a study investigating the coverage of health care costs by private health insurance providers and other funding agencies, Pelletier and Astin (2002) found the following motivators for this provision, in order of importance: market research, retention of members, demand by members or consumers, incentives for new members, possible savings, a possibly less invasive care model and demand by providers and companies.

It is apparent that the wishes of the consumers of health insurance play a key role in informing the decision-making of insurers. Australian research has shown that consumers of CAM therapies are predominantly female, better educated, have higher incomes and are more likely to be employed than non-users (MacLennan et al., 2002; Morgan et al., 2012).

This is similar to findings from European research (Bornhoft & Matthiesen, 2012), and it is to this demographic that private health insurers have responded in extending rebates to CAM therapies. While it is a regrettable matter of gross inequity that lower income, less well-educated health consumers have restricted access to health care choice, the mostly female, better educated, higher income users of CAM therapies may be particularly negatively impacted by any restriction of rebates in this field.

In Switzerland, a Health Technology Assessment (Bornhoft & Matthiesen, 2012) was initiated following the Swiss government's decision to provisionally include various complementary medicine disciplines in the services covered by the Swiss national statutory health insurance scheme. The Health Technology Assessment was part of that government's Complementary Medicine Evaluation Programme and found that the majority of the Swiss population would prefer to have access to a CAM hospital, and 85% of respondents supported a continuation of national health insurance for CAM treatments. As a result of these investigations, the Swiss Government resumed health insurance compensation for homoeopathy and other CAM therapies. The authors noted that the use of CAM therapies in the countries investigated (USA, Germany, UK and France) was not marginal, but has been steadily increasing over the years.

The evolution of consumer choice towards increasing use of holistic forms of health care is mirrored in statements on health care by the European Commission. Its White Paper titled *Together for Health: A Strategic Approach for the EU 2008-2013* emphasises citizens' empowerment as a core value (European Parliament, 2008). It states that, "healthcare is becoming increasingly patient-centred and individualised, with the patient becoming an active subject rather than a mere object of healthcare", and that, "community health policy must take citizens' and patients' rights as a key starting point". Choice of health care among the privately insured, as indeed among all health care consumers, is such a right.

2.5. The political context of the review

2.5.1. The information and media environment

The media environment in which the current inquiry into natural therapies is being conducted has generated considerable concern amongst the homoeopathic profession. In relation to homoeopathy, media comment has been highly vituperative, relying primarily on name-calling as a means of de-legitimising homoeopathy, rather than contributing to informed discussion of relevant issues. Our otherwise highly valued (and publically funded)

national radio has been a regular source of misinformation directed at CAM in general, and at homoeopathy in particular.

In a manner which clearly pre-empted findings of the then merely proposed NHMRC inquiry into homoeopathy, front pages of our national newspapers quoted the NHMRC and reported that, "... [it is] unethical for health practitioners to treat patients using homoeopathy, for the reason that homoeopathy (as a medicine or procedure) has been shown not to be efficacious" (Medew, 2012; O'Brien, 2012). Government agencies, having publically initiated the inquiry into homoeopathy in these negative terms, have failed to act to halt the degrading level of public debate being advanced through the media. Coverage of the 2012–2013 Federal Budget reported the removal of rebates for CAM therapies as a fait accompli, and not as an eighteen-month-long genuine cost-benefit analysis of CAM therapies on behalf of the community and the public purse. That important matters of public policy are able to be carried out in such a manner is suggestive of prejudice rather than rational inquiry, and of decisions being reached prior to the work of government agencies being duly and fairly undertaken.

2.5.2. The influence of international events

It has been of concern to the Australian homoeopathic profession that the report on homoeopathy by the UK House of Commons Science and Technology Committee, *Evidence Check 2: Homoeopathy, 2010* (House of Commons Science and Technology Committee, 2010) was identified by the NHMRC as the principal source of information for the inquiries of the NHMRC and its related agencies.

The work and conclusions of the UK House of Commons Science and Technology Committee were widely criticised, and its recommendations were not endorsed by the Parliament of the UK. The NHMRC, however, appeared to repeat both the language and opinion of this source, and named the discredited UK House of Commons Science and Technology Committee report as the basis of the NHMRC inquiry (Medew, 2012).

In Submissions to the NHMRC in 2011, the Australian Homœopathic Association Inc. and the Australian Medical Fellowship of Homoeopathy outlined serious reasons for caution regarding the findings of the UK House of Commons Science and Technology Committee. The proceedings and protocols were widely criticised on the following grounds: the selection of its members, the protocols engaged for its meetings and hearings, a perceived bias in its appraisal of the evidence before it and the restricted number of committee members who voted to pass its recommendations.

It is important to emphasise that a recommendation of the House of Commons Science and Technology Committee – to restrict the availability of homoeopathy through the National Health Service – did not receive the support of the UK Parliament, and that homoeopathy remains a funded arm of the UK National Health Service.

In its idiosyncratic and highly unscientific approach to research, the House of Commons Science and Technology Committee relied on a single research study of homoeopathic medicine (Shang et al., 2005) in reaching its negative conclusions on homoeopathy, with only three members out of thirteen presiding over this decision. The study by Shang et al. (2005) has received comprehensive criticism due to the inferior methodology applied to its research (Rutten & Stolper, 2008). The reporting of research trials has a profound effect on the reception of such results (Goldacre, 2012). In an effort to avoid reporting of biased results, a checklist of standards to improve the quality of reporting of meta-analyses and RCTs was devised by a group of clinical epidemiologists, clinicians, statisticians, editors and researchers (Moher et al., 1999). This checklist is referred to as the QUOROM (Quality of Reporting of Meta-analyses) guidelines. In accepting Shang's paper, *The Lancet* overlooked the failure of that study to conform to the QUOROM guidelines which *The Lancet* otherwise espouses. Such an action damages the prestige of that journal and leaves it open to questions about the integrity of both scientific inquiry and the championing of such publication protocols by the research community.

Sir Paul Nurse, Nobel Laureate and head of the UK Royal Society, in a recent address to scientists in Melbourne emphasised how important it is for science to refrain from 'cherry picking' data. (Nurse, 2013). He pointed out that science should seek the consensus view of scientists expert in the field investigated, and that it is important to keep science as far as possible from political and ideological influence. The House of Commons Science and Technology committee may well have been compromised in this regard by the participation on its review panel of Ms Tracey Brown, the director of Sense About Science. The Sense About Science website revealed that over one-third of money raised for the organisation between 2004 and 2009 came from the pharmaceutical industry (Ullman, 2011). Several leading homoeopathic researchers and clinicians were frustrated in their attempts to address the Science and Technology Committee by the apparent absence of neutrality in the committee's key investigators (Baldwyn, 2010; Sumner, 2010). The controversies surrounding the study by the Shang group were discussed in considerable detail in the 2011 Australian Homeopathic Association Inc. Submission to the NHMRC (see Appendix 1, p.30).

AROH and its corporate member organisations rely upon the Natural Therapies Review Advisory Committee, the Homoeopathy Working Committee and the NHMRC to conduct a detailed review of the full body of available research evidence for homoeopathy and to reach their conclusions in a fair and unprejudiced manner. This Submission draws widely on homoeopathic sources to provide an accurate overview of research based evidence in homoeopathy. Much of the cited homoeopathic research evidence has been analysed and categorised according to the Levels of Evidence hierarchy adopted by the NHMRC in assessing the scientific adequacy of medical research.

3. Research Challenges for Homoeopathic Medicine

Homoeopathic best practice uses an integrated approach to health and disease, and takes into account the complex relationships between the biological, psychological and environmental factors characterising the individual patient. It is through this focus on the whole patient (rather than solely on the disease), and through the scrupulous attention given to the selection of the *similimum* (or most similar medicine), that homoeopathy embodies the complexity paradigm in medicine (Bellavite & Signorini, 1995).

While the concept of evidence is multi-faceted, the RCT is accepted as the highest level of evidence in contemporary medical research, and seeks to prove the efficacy of a single agent in a specific disease. There is an inherent paradigm clash when the whole-person/whole-medicine approach of homoeopathy is measured within the parameters of the single disease focus of a typical drug trial (Ivanovas, 2012a). While it is clearly necessary for homoeopathy to exhibit efficacy within this model, and there is evidence that this has been achieved in some studies in spite of these challenges, it is imperative that the methodological complexities peculiar to homoeopathy are understood by those reviewing the homoeopathic research literature, and future RCTs need to take this complexity into account. In the conventional research model, high methodological quality is defined by high internal validity. Requirements for external validity are ignored in what has been called the “quiet, dismal scandal” (Goldacre, 2012, p.179) of the irrelevance of many trials to real-world populations. In placebo-controlled RCTs, high internal validity is achieved at the expense of external validity.

These important issues relate to the distinction between the efficacy and effectiveness of medical interventions (Fisher, 2008). Efficacy can be established under the restricted ideal conditions that may apply in a research trial, while effectiveness describes real-world conditions. The clinical effectiveness of a treatment pertains to the multiplicity of factors met in population usage, where length of use, side effects, co-morbidities and drug interactions are ultimately displayed. A drug deemed highly efficacious from RCT evidence may later be withdrawn once real-world conditions of its use exhibit effects beyond those seen in the original trial, and there have been many high-profile examples of such drug withdrawals. Assessments of clinical effectiveness and responsiveness to findings at this level of evidence (real world effectiveness) are clearly so vital as to warrant a change of status for population-level or outcomes studies which may more accurately report treatment effects.

These considerations place RCTs in context as a valuable research tool, but inadvisable as the principal deciding factor in health care delivery. In homoeopathic research, more comprehensive measures encompassing clinical effectiveness may be established through comparisons of usual care with the new intervention, and through observational studies, where real-world conditions are more readily reflected. A holistic, real-world application of evidence-based medicine would have the capacity to integrate individual clinical expertise with the best available evidence from systematic research (Sackett et al., 1996). Widely regarded as the father of evidence-based medicine, David Sackett (1997) is explicit in his description of what constitutes evidence-based medicine:

... [it] requires a bottom-up approach that integrates the best external evidence with individual clinical expertise and patient choice, it cannot result in slavish, “cook-book” approaches to individual patient care. External clinical evidence can inform, but can never replace, individual clinical expertise, and it is this expertise that decides whether the external evidence applies to the individual patient at all and, if so, how it should be integrated into a clinical decision. Similarly, any external guideline must be integrated with individual clinical expertise in deciding whether and how it matches the patient's clinical state, predicament, and preferences, and thus whether it should be applied. Finally, in terms of study designs, evidence-based medicine is not restricted to randomized trials and meta-analyses. It involves tracking down the best external evidence with which to answer our clinical questions.

An evidence-based medicine that is based on RCTs and meta-analyses to the exclusion of other study designs might provide a method of standardising care, aiming to address standard patterns of pathology. By contrast, Sackett focuses his attention on the uniqueness of every patient and each clinical encounter, and emphasises clinical expertise and the judicious use of a wide range of external evidence in addressing an individual's clinical needs. Sackett's prescription for a greater equality across the range of research evidences holds particular relevance to homoeopathic research. The design of many RCTs have been found to limit a full evaluation of the effect of a homoeopathic prescription (Ward, 2012): these research findings are often in stark contrast to surveys of patient satisfaction with homoeopathic treatment which find satisfaction levels to be typically very high (Marian et al., 2008; Rodrigues-Neto et al., 2009; van Wassenhoven & Ives, 2004) and in contrast to observational studies of patients at large homoeopathic hospitals which also identify very positive outcomes (International Data Collection Centres for Integrative Medicine, 1998; Richardson, 2001; Spence et al., 2005; Witt et al., 2005).

Many attempts at adequate research of homoeopathy have been stymied by the absence of the individualised approach typical of whole-person/whole-remedy homoeopathic practice. In many studies, prescribing may be based on pathology rather than the patient's characteristics, for example, or isopathic preparations or combinations (complexes) of homoeopathic medicines may be employed, contradicting the principles of traditional (simplex or single simillimum) homoeopathy. The inclusion of trials with different homoeopathic prescribing methods (individualised, complex or isopathic) compromises the validity of systematic reviews or meta-analyses, which rely on both the quality of the RCTs included in the reviews and on the homogeneity of the studies included.

Our review of 192 human RCTs in homoeopathy (see Appendix 2: 2.1–2.6) shows the heterogeneous nature of homoeopathic research, the trials involved differing prescribing models as follows: 61 individualised, 61 complex, 15 isopathy and 55 single remedy. Many of the RCTs in this appendix are the only one investigating homoeopathy in a particular pathology, but where more than one trial has been performed, different modes of treatment may have been used, or a homoeopathic complex prescribed. In the absence of multiple trials of very similar trial design, studies cannot be combined into a meta-analysis with any reliable degree of research rigor. To more easily satisfy internal trial validity requirements, many systematic reviews also incorporate trials testing homoeopathic methodologies not typically used in clinical practice.

As well as variability in the type of homoeopathic prescribing practice investigated, other unmatched variables may include: disease definition; trial inclusion and exclusion criteria; end-point definition; placebo versus treatment equivalence methodology and trial randomisation or blinding criteria. Trial size, a critical factor in assessing validity, may be influenced by economic factors in a way that is disadvantageous to homoeopathy. For example, the largest trials are likely to be those testing isopathic preparations or homoeopathic complexes. The preference for researching these forms of homoeopathic medicine is commercially driven – these products may be marketable as over-the-counter medicines, and are therefore attractive to investors.

Systematic reviews incorporating highly heterogeneous trials or trials which fail to represent homoeopathic usual-practice are inadequate for measuring the efficacy of homoeopathy. These commonly encountered obstacles in homoeopathic research potentiate the Yule–Simpson effect. Known as Simpson's paradox, this phenomenon is common in medical research: it describes the effect where an effect appearing in different groups of

data, disappears when these groups are combined, and the reverse effect appears for the aggregate data.

Current developments in research in homoeopathy seek to address the issues particular to homoeopathic research to improve model validity (Mathie et al., 2012). Mathie et al. identified relevant judgmental domains to use in assessing the model validity of homoeopathic treatment. The authors defined model validity of homoeopathic treatment as the extent to which a homoeopathic intervention and the main measure of its outcome, as implemented in a RCT, reflect state-of-the-art homoeopathic practice.

Elsewhere, consensus guidelines for reporting homoeopathic methods and treatments were established. Dean et al. (2007) identified 28 items to supplement the *Consolidated Standards for Reporting Trials* statement items 2, 3, 4 and 19. The requirement that published reports describe the details of prescribing strategies and treatments would improve the capacity of reviewers to more accurately assess homoeopathic research (Dean et al., 2007). The observation that research disturbs and alters the subject of that research is a phenomena long recognised in the social sciences and in applied scientific and medical research. Research developments by Mathie and Dean seek to minimise this potential in the context of homoeopathic research.

The requirement that reviewers have a good understanding of the field they interpret is an issue stressed by Charlton (1996) for medical research in general. He states:

... the prestige of meta-analysis is based upon a false model of scientific practice. Interpreting empirical research is an extremely complex activity requiring clinical and scientific knowledge of the field in question; and teams of professional 'meta-analysts' with a primary skill base in information technology and biostatistics cannot take over this role ... the summary estimate from a meta-analysis can only be directly applied to a target population when the "meta-protocol" and "meta-population" match the target situation in all relevant particulars. These constraints can rarely be satisfied in practice, so the results of meta-analysis typically require adjustment – which is a complex, assumption-laden process that negates many of the statistical power advantages of a meta-analysis. Lacking any understanding or acknowledgement of the need for adjustment, most meta-analyses must be regarded as an abuse of the technique.

These matters relate particularly to homoeopathic research. Statistical methods may be especially limited when applied to regulatory therapies such as homoeopathy (Ivanovas, 2012a), and adequate trial design for homoeopathic research needs to be based on a sufficient understanding of the healing processes that homoeopathic therapy stimulates (Ivanovas, 2012b).

4. Homoeopathy Research

4.1. RCTs of homoeopathy

Tables 2.1–2.6 in Appendix 2 include RCTs of homoeopathy treatment and prevention that have been published from 1950 to 2012. We included RCTs that used any form of homoeopathy (individualised or non-individualised) and studies in any language. The majority of studies were identified from the Faculty of Homoeopathy website page (Faculty of Homeopathy, 2011a) where they are identified as an RCT if they used prospective random assignment to treatment groups. For placebo-controlled trials, explicit mention of double-blinding was required, and for trials that were not placebo-controlled, observer-blinding was sufficient for inclusion. They also required that inter-group statistical analyses had been reported, with a minimum of five subjects per group. Studies were considered statistically significant if they reported a 95% confidence interval that excluded zero, or a p-value <0.05. RCTs reporting statistically significant findings were considered positive or negative if the homoeopathic treatment group was superior or inferior to the control group, respectively. Statistically non-significant trials were considered inconclusive.

A total of 81 different medical conditions were investigated by the RCTs noted in this Submission. Two or more papers have described investigations into each of 31 (38%) conditions, and the other 50 (62%) have each been discussed in a single publication. A clearly positive direction of evidence, only on the basis of RCTs, was seen for nine (11%) of the conditions: ADHD, fibromyalgia, heavy metal toxicity, influenza, insomnia, seasonal allergic rhinitis, osteoarthritis, otitis media and sinusitis. A tentatively positive direction of evidence was seen for 36 (44%): anal fissure, aphthous ulcers (recurrent), asthma, blood coagulation, brain injury, bronchitis, childhood diarrhoea, chronic fatigue syndrome, depression, extended sports recovery time, fracture healing, immune function, low back pain, non-allergic rhinitis, oral dryness, oral lichen planus, perennial allergic rhinitis, plantar fasciitis, post-operative infection, post-operative oedema, post-operative wound healing, postpartum bleeding, postpartum lactation, premenstrual syndrome, pulmonary tuberculosis rehabilitation, radiodermatitis, renal failure, seborrhoeic dermatitis, sepsis, snoring, stomatitis, tracheal secretions, urinary tract infections, uraemic pruritus, varicose veins and vertigo.

Of the 192 RCTs noted in this Submission, classical or individualised homoeopathy was investigated in 61 (35 positive, 24 inconclusive and two negative), a mixture of remedies

(complexes) was investigated in 61 (31 positive, 29 inconclusive and one negative), isopathy was investigated in 15 (10 positive, four inconclusive and one negative) and pathological prescribing was investigated in 55 (20 positive, 31 inconclusive and four negative).

4.2. Efficacy of homoeopathy

When reviewing the research in homoeopathy, it is possible, depending on the criteria used, to conclude that homoeopathy is more effective than placebo. The reverse claim, that homoeopathy is nothing but placebo, cannot be substantiated as long as every positive trial is not over-ridden by a larger negative trial: it takes just one positive trial to reject the nothing-but-placebo claim. There are at least 96 human RCTs and a minimum of 51 pre-clinical and veterinary RCTs that are positive for homoeopathy. As discussed above, undertaking systematic reviews in homoeopathy encounters several problems. The UK Faculty of Homeopathy (2011b) summarised these difficulties:

The small number of original research papers, the differing criteria reviewers have used for data extraction, the disparate styles of homoeopathy used, and the fact that a diverse range of medical conditions has been examined collectively, all restrict the value of formal comprehensive systematic review, such as those attempted by Linde's and Shang's groups.

The problem of heterogeneity of medical conditions has been avoided in 29 systematic reviews focused on RCTs of homoeopathy in specific clinical areas (Faculty of Homeopathy, 2011b). Eleven of the 29 systematic reviews yielded conclusions broadly positive for homoeopathy. These reviews were of studies of: allergies and upper respiratory tract infections (Bornhöft et al., 2006; Bellavite et al., 2006a); childhood diarrhoea (Jacobs et al., 2003); influenza treatment (Vickers & Smith, 2006); post-operative ileus (Barnes et al., 1997); rheumatic diseases (Jonas et al., 2000); seasonal allergic rhinitis (Bellavite et al., 2006b; Ernst, 2011; Taylor et al., 2000; Wiesenauer & Ludtke, 1996); and vertigo (Schneider et al., 2005).

Bornhöft and Ammon (2012) provide a detailed discussion of the complexities encountered in systematic reviews of homoeopathy, and despite these limitations they concluded that, "... the effectiveness of homoeopathy has to be rated as 'likely'". The relevance of a systematic review prevails only until another trial is discovered or published which fulfils the relevant inclusion criteria. Approximately 100 RCTs, many in languages other than English, have just been acknowledged (Mathie et al., 2013). The findings of these trials are likely to affect the state of knowledge in homoeopathic research once they are translated and reviewed. Ward (2012) discussed the frequently misleading conclusions of

systematic reviews in relation to the homoeopathic treatment of asthma. In her non-exhaustive review of 32 research papers in asthma there were: four systematic reviews; seven RCTs; nine observational and qualitative studies; five pilot and open studies; and 147 case studies. Ward found that:

Research outcomes considered to be highest in the hierarchy of evidence are mostly negative or inconclusive, whereas all others are positive. This clearly identified trend is analysed against trial designs and treatment strategy. It was found that usually the designs of RCTs limit the full evaluation of the effect of a homeopathic prescription and recommendations for future trials and research designs are made. (p.281)

Trials investigating individualised homoeopathy present particular challenges to double-blinded RCT design, where internal validity is favoured over external validity. These challenges occur when treating patients with chronic disease: patient assessments are made on multiple occasions, and treatment decisions are made under trial conditions, where it is not known if the patient had received the active remedy or placebo. These conditions add an extra variable to an already complex clinical decision, a variable not present in normal practice. If trial design does not avoid these confounding issues, then ambiguous conclusions may result. The following 28 RCTs, which suffered from this design problem, reached the following conclusions:

- 10 were positive (Adler et al., 2011; Bell et al., 2004; Campistrous Lavaut, 1999; Cavalcanti et al., 2003; Gibson et al., 1980; Naude et al., 2010; Rastogi et al., 1999; Riveron-Garrote, 1998; Sharma & Sharma, 2012; Weatherley-Jones et al., 2004)
- 17 were inconclusive (Andrade et al., 1991; Bonne et al., 2003; Brien et al., 2011; Jacobs et al., 2005b; de Lange de Klerk et al., 1994; Fisher et al., 2006; Gaucher et al., 1994; Jacobs et al., 2005a; Kainz et al., 1996; Katz et al., 2005; Lokken et al., 1995; Rastogi et al., 1999; Siebenwirth et al., 2009; Straumsheim et al., 2000; White et al., 2003; Whitmarsh et al., 1997; Thompson et al., 2005)
- one was negative (Fisher & Scott, 2001).

It is remarkable that 36% of these trials reached significantly positive results, despite this obstacle, and most were non-conclusive. However, it is even more enlightening to compare these findings with the group of trials of individualised homoeopathy that were designed to avoid this problem, either because all the critical treatment decisions were made prior to placebo randomisation, or they were comparison trials to regular care, which didn't involve placebo.

Of the 33 individualised RCTs that compared one prescribing episode with usual care, 76% produced results that are significantly in favour of homoeopathy:

- 25 were positive (Bell et al., 2011; Brigo & Serpelloni, 1991; Chapman et al., 1999; Colau et al., 2012; Fisher, 1986; Fisher et al., 1989; Frass et al., 2005a; Frass et al., 2005b; Frei et al., 2005; Gmunder & Kissling, 2002; Haila et al., 2005; Harrison et al., 1999; Jacobs et al., 1994; Jacobs et al., 2000; Jacobs et al., 2001; Kundu et al., 2012; Kuzeff, 1998; Lamont, 1997; Manchanda et al., 1997; Mousavi et al., 2009a; Mousavi et al., 2009b; Relton et al., 2009; Sinha et al., 2012; Sharma & Sharma, 2012; Steinsbekk & Ludtke, 2005; Yakir et al., 2001)
- seven were inconclusive (Brooks et al., 2010; Fisher et al., 2006; Jacobs et al., 1993; Thompson et al., 2011; van Erp & Brands, 1996; Friesse et al., 1997; Walach et al., 1997)
- one was negative (Witt et al., 2009a).

If of these 33 RCTs, only the placebo-controlled trials are considered, then 20 of 25 RCTs (80%) are positive. Gmunder and Kissling (2002); Harrison et al. (1999); Relton et al. (2009); Sinha et al. (2012); Thompson et al. (2011); Steinsbekk et al. (2005b); van Erp and Brands (1996); Witt et al. (2009a) were not placebo-controlled. Investigations of usual homoeopathic practice gives clearer and more accurate evidence of efficacy, as these studies demonstrate. Conversely, when research questions are restricted to trials that are easier to perform, and which may be classified as of higher quality given internal validity measures (Nicolai, 2005), outcomes may obscure, rather than exemplify usual homoeopathic practice. An example appears in the clinical trials in this Submission: In eight RCTs, Arnica was given to groups of runners in races, with seven inconclusive and one positive result. Similarly, in 14 trials investigating the peri-operative usefulness of Arnica, six were positive, six inconclusive and two negative. These researches did not focus on the main sphere of action of this remedy, which is principally used to treat bruising rather than lacerations or muscle fatigue. It may be better to trial Arnica in boxers. It is noteworthy that the 22 trials mentioned above are of a marginal therapeutic utility pertaining to 11% of the human RCTs in this Submission.

4.3. Trial evidence by pathology

Research conducted in homoeopathy on specific medical conditions is summarised below. Each trial has been categorised according to the Levels of Evidence (I-IV). Evidence is strongly positive where there is confirmation (ideally independent) of a significantly positive RCT result ($p < 0.05$), in the absence of over-riding negating evidence. Trials with lower evidential grades, especially III-2 may contribute to the overall impression of the

strength of the evidence. This does not replace formal assessment procedures, such as systematic review and meta-analysis (which also determine a trial's intrinsic quality and the size of treatment effect for a specified outcome measure), yet provides an overall impression of the nature of the evidence for each medical condition.

The following two tables summarise the research evidence supporting homoeopathic treatments in 73 conditions. Table 1 covers those 12 conditions where the evidence is strongest, and Table 2 covers 61 conditions where the evidence is weaker. One must bear in mind that Level IV studies follow patients over time without controls, and so their positive results must be treated with caution.

Table 1. Strongly positive evidence in twelve conditions (RCT indicates where information is lacking to discriminate between Level II and III-1)

Study by condition	Direction of evidence	Therapeutic intervention	LOE
ADHD			
Bolognani (2011)	Positive	Zincum Met 12C	IV
Frei and Thurneysen (2001a)	Positive	Individualised	III-3
Frei et al. (2005)	Positive	Individualised	II
Jacobs et al. (2005b)	Inconclusive	Individualised	II
Lamont (1997)	Positive	Individualised	III-1
Ramchandani (2010)	Positive	Zincum Met 30	III-1
Strauss (2000)	Positive	Complex	II
Allergic rhinitis			
Aabel (2000)	Negative	Isopathy homeopathic aggravation in low pollen season	II
Aabel (2001)	Inconclusive	Isopathy	II
Aabel et al. (2000)	Positive	Isopathy	II
Ammerschlagel et al. (2005)	Positive	Euphorbium complex	III-2
Colin (2006)	Positive	Individualised	IV
Kim et al. (2005)	Positive	Isopathy	RCT
Reilly et al. (1986)	Positive	Isopathy	II
Taylor et al. (2000)	Positive	Isopathy	II
Teixeira (2009)	Positive	Individualised	III-3
Weiser et al. (1999)	Positive	Luffa comp-Heel	RCT
Wiesenauer and Ludtke (1995)	Inconclusive	Galphimia	RCT
Wiesenauer et al. (1983)	Positive	Galphimia	RCT

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Wiesenauer et al. (1990)	Positive	Galphimia	RCT
Childhood diarrhoea			
Berchieri et al. (2006)	Positive	Veterinarian Isopathy	III-2
Camerlink et al. (2010)	Positive	Veterinarian Isopathy	II
Jacobs et al. (1993)	Inconclusive	Individualised	II
Jacobs et al. (1994)	Positive	Individualised	II
Jacobs et al. (2000)	Positive	Individualised	II
Jacobs et al. (2006)	Inconclusive	Complex	II
Fibromyalgia			
Bell et al. (2004)	Positive	Individualised	II
Fisher (1986)	Positive	Individualised	III-1
Fisher et al. (1989)	Positive	Individualised	II
Relton et al. (2009)	Positive	Individualised	II
Heavy metal toxicity			
Belon et al. (2006)	Inconclusive	Isopathy	III-1
Belon et al. (2007)	Positive	Isopathy	II
Beringhs-Bueno et al. (2006)	Positive	Isopathy	II
Datta et al. (1999)	Positive	Laboratory Isopathy	III-1
Datta et al. (2001)	Positive	Laboratory Isopathy	III-1
Khuda-Bukhsh et al. (2005)	Positive	Isopathy	IV
Khuda-Bukhsh et al. (2011a)	Positive	Isopathy	III-2
Khuda-Bukhsh et al. (2011c)	Positive	Isopathy	III-2
Padilha et al. (2011)	Inconclusive	Isopathy	II
Influenza Treatment			
Attena et al. (1995)	Inconclusive		RCT
Brydak and Denys (1999)	Positive	Gripp-Heel	II
Derasse et al. (2005)	Positive	Gripp-Heel	III-2
Ferley et al. (1989)	Positive	Oscillococcinum	II
Nahler et al. (1998)	Positive	Gripp-Heel	III-2
Papp et al. (1998)	Positive	Oscillococcinum	II
Vincent et al. (2012)	Positive	Various	III-2
Insomnia			
Bell et al. (2011)	Positive	Individualised	III-1
Brooks et al. (2010)	Positive	Individualised	III-1
Carlini et al. (1987)	Inconclusive		RCT
Hellhammer and Schubert (2012)	Positive	Dysto-loges S	II

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Naude et al. (2010)	Positive	Individualised	II
Ruiz-Vega et al. (2003)	Positive	Laboratory	III-2
Waldschütz and Klein (2008)	Positive	Neurexan	III-2
Osteoarthritis			
Hielm-Bjorkman et al. (2009)	Positive	Zeel complex Veterinarian	II
Maronna (2000)	Positive	Zeel complex	III-1
Nahler et al. (1998)	Positive	Zeel complex	III-2
Neumann et al. (2011)	Positive	Veterinarian	II
Shealy et al. (1998)	Positive	Individualised	II
Shipley et al. (1983)	neg/ In-c	Different remedies	RCT
Strosser and Weiser (2000)	Positive	Zeel complex	II
van Haselen and Fisher (2000)	Positive	Complex gel	III-1
Otitis media			
Frei and Thurneysen (2001a)	Positive	Individualised	III -3
Friese et al. (1997)	Positive	Individualised	III -2
Haidvogel et al. (2007)	Positive	Individualised	III -2
Harrison et al. (1999)	Positive	Individualised	III -2
Jacobs et al. (2001)	Positive	Individualised	III-1
Riley et al. (2001)	Positive	Individualised	III-2
Sinha et al. (2012)	Positive	Individualised	II
Taylor and Jacobs (2011)	Positive	Ear drops	II
Sinusitis			
Adler (1999)	Positive	Another complex	IV
Bawden (2012)	Positive	Individualised	IV
Friese and Zabolotnyi (2007)	Positive	Sinfrontal	RCT
Kneis and Gandjour (2009)	Positive	Sinfrontal	II
Weiser and Clasen (1994)	Positive	Euphorbium complex nasal spray	III-1
Wiesenauer et al. (1989)	Inconclusive	Complex	III-1
Witt et al. (2009d)	Positive	Individualised	IV
Zabolotnyi et al. (2007)	Positive	Sinfrontal	RCT
URTIs, common cold			
Ammerschlagel et al. (2005)	Positive	Euphorbium complex	III -2
de Lange de Klerk et al. (1994)	Inconclusive	Individualised	RCT
Gassinger et al. (1981)	Positive	Eup-per D2	III -2
Haidvogel et al. (2007)	Positive	Individualised	III -2
Maiwald et al. (1988)	Positive	Gripp-Heel	RCT

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Nayak et al. (2010)	Positive	Individualised	IV
Rabe et al. (2004)	Positive	Gripp-Heel	III-2
Ramchandani (2010)	Positive	Individualised	IV
Riley et al. (2001)	Positive	Individualised	III-2
Schmiedel and Klein (2006)	Positive	Engystol	III-2
Steinsbekk et al. (2005a)	Inconclusive	Pathological prescribing by parents	II
Steinsbekk et al. (2005b)	Positive	Individualised	II
Trichard et al. (2004)	Positive	Various	III -2
Trichard et al. (2005)	Positive	Various	III -2
Vertigo			
Issing et al. (2005)	Positive	Vertigoheel	RCT
Klopp et al. (2005)	Positive	Vertigoheel	III-2
Weiser et al. (1998)	Positive	Vertigoheel	RCT
Wolschner et al. (2001)	Positive	Vertigoheel	III-2

Note. LOE = level of evidence

Table 2. Sixty-one conditions with lower degrees of positive evidence for homoeopathy

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Allergies			
Colin (2006)	Positive	Individualised	IV
Frenkel and Hermoni (2002)	Positive		IV
Grundling et al. (2012)	Positive	Individualised	IV
Anxiety			
Baker et al. (2003)	Inconclusive	Argentum nitricum 12x	RCT
Bellavite et al. (2011)	Positive	Laboratory	II
Bellavite et al. (2012)	Positive	Laboratory	II
Bonne et al. (2003)	Inconclusive	Individualised	RCT
Davidson et al. (1997)	Positive	Laboratory	IV
Lakshmipathy Prabhu et al. (2012)	Positive	Laboratory	II
McCutcheon (1996)	Inconclusive	Complex	III-1
Paris et al. (2012)	Inconclusive	Gelsemium 5CH & 15CH	RCT
Tavares Carvalho et al. (2009)	Positive	Laboratory complex	III-2
van den Meerschaut and Sunder (2009)	Positive	Laboratory	III-2

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Anal fissure			
Bignamini et al. (1991)	Positive	Nitric acid 9CH	III-1
Asthma			
Castellsagu (1992)	Positive	Individualised	IV
Castellsague and Sturza (1998)	Positive	Individualised	IV
Colin (2006)	Positive	Individualised	IV
Gariboldi et al. (2009)	Positive	Laboratory Isopathy	IV
Lewith et al. (2002)	Inconclusive	Isopathy	RCT
Matusiewicz (1997)	Positive	Complex	III-2
Mohan (2007)	Positive	Individualised	IV
Reilly et al. (1994)	Positive	Isopathy	II
Riveron-Garrote (1998)	Positive	Individualised	III-1
Shafei et al. (2012)	Positive	Individualised	IV
Autistic spectrum disorder			
Barvalia (2011)	Positive	Individualised	IV
Blood coagulation			
Baillargeon et al. (1993)	Inconclusive	Arnica 5CH	RCT
Eizayaga et al. (2005)	Positive	Laboratory	III-2
Heusser et al. (2009)	Positive	Antimonium crud 6x	II
Kundu et al. (2012)	Positive	Individualised	II
Brain injury			
Chapman et al. (1999)	Positive	Individualised	RCT
Bronchitis			
Diefenbach et al. (1997)	Positive	Complex	RCT
Burn scars regression			
Harrison et al. (1993)	Positive	Graphites	IV
Cancer			
Banerjee et al. (2010b)	Positive	Laboratory	II
Bhattacharjee et al. (2009)	Positive	Laboratory	II
Biswas and Khuda-Bukhsh (2004)	Positive	Laboratory	II
Biswas et al. (2005)	Positive	Laboratory	II
Chatterjee et al. (2011)	Positive	Psorinum 6x	IV
Datta et al. (1999)	Positive	Laboratory	III-1
Datta et al. (2001)	Positive	Laboratory	III-1
Frenkel et al. (2010)	Positive	Laboratory	III-1

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Guimarães et al. (2009)	Positive	Laboratory	III-1
Khuda-Bukhsh et al. (2011b)	Positive	Laboratory	III-2
Kumar et al. (2007)	Positive	Laboratory	III-2
Pathak et al. (2003)	Positive	Ruta 6c	IV
Pathak et al. (2006)	Positive	Laboratory Lycopodium 30c	III-2
Sunila et al. (2007)	Positive	Laboratory single remedy	III-2
Chronic fatigue Syndrome			
Weatherley-Jones et al. (2004)	Positive	Individualised	RCT
Crohn's Disease			
Jack (1993)	Positive	Individualised	IV
Maas (1993)	Positive	Individualised	IV
Depression			
Adler et al. (2011)	Positive	Individualised	II
Davidson et al. (1997)	Positive	Individualised	IV
Katz et al. (2005)	Inconclusive	Individualised	II
Eczema			
Eizayaga and Eizayaga (2012)	Positive	Individualised	IV
Fisher et al. (2006)	Inconclusive	Individualised	II
Itamura (2007)	Positive	Individualised	IV
Itamura and Hosoya (2003)	Positive	Individualised	IV
Rossi et al. (2012)	Positive	Individualised	IV
Siebenwirth et al. (2009)	Inconclusive	Individualised	IV
Spence (1991)	Positive	Individualised	IV
Fever in children			
Derasse et al. (2005)	Positive	Gripp-Heel	III-2
Foot and mouth disease			
Lotfollahzadeh et al. (2012)	Positive	Veterinarian	III-1
Fracture healing			
Mazzocchi and Montanaro (2012)	Positive	Symphytum	III-2
Sharma et al. (2012)	Positive	Individualised	II
Spin-Neto et al. (2010)	Positive	Laboratory Symphytum	II
Headache (including migraine)			
Brigo and Serpelloni (1991)	Positive	Individualised	II
Danno et al. (2012)	Positive	Individualised	IV
Muscari-Tomaioli et al. (2001)	Positive	Individualised	IV

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Straumsheim et al. (2000)	Inconclusive	Individualised	RCT
Walach et al. (1997)	Inconclusive	Individualised	RCT
Whitmarsh et al. (1997)	Inconclusive	Individualised	RCT
HPV infection			
Gimeno (1996)	Positive	Individualised	IV
Jaeger et al. (2008)	Positive	Complex	IV
Hypertension			
Bignamini et al. (1987)	Inconclusive	Baryta carb 15CH	II
Campistrous Lavaut (1999)	Positive	Individualised	III-1
Hitzenberger and Rehak (2005)	Inconclusive	Complex	RCT
Immune function			
Kuzeff (1998)	Positive	Individualised	II
de Oliveira et al. (2011)	Positive	Laboratory	II
Bonamin et al. (2012)	Positive	Laboratory	II
Guimarães et al. (2009)	Positive	Laboratory	III-1
Chandrakant Nimgulkar et al. (2011)	Positive	Laboratory	III-2
Rastogi et al. (1999)	Positive	Individualised	II
dos Santos et al. (2007)	Positive	Laboratory	III-2
Infectious disease prevention remedy			
Attena et al. (1995)	Inconclusive		RCT
Bandyopadhyay et al. (2010)	Positive	Laboratory	III-2
Berchieri et al. (2006)	Positive	Veterinarian	II
Bracho et al. (2010)	Positive	Isopathy	III-3
Camerlink et al. (2010)	Positive	Veterinarian	II
de Souza et al. (2012)	Positive	Complex	III-3
Glatthaar-Saalmuller (2007)	Positive	Laboratory	III-2
Jacobs et al. (2007)	Inconclusive	Complex	RCT
Lyrio et al. (2011)	Positive	Complex Isopathy	II
Marino (2008)	Positive	Single remedy	III-3
Mroninski et al. (2001)	Positive	Isopathy	III-3
Varshney and Naresh (2005)	Positive	Veterinarian	III-2
Irritable bowel syndrome			
Rahlfs and Mössinger (1976)	Inconclusive	Individualised	RCT
Rahlfs and Mössinger (1979)	Positive	Individualised	RCT

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Labour time and complications			
Beer and Heiliger (1999)	Inconclusive	Caulophyllum D4	RCT
Dorfman et al. (1987)	Positive	Complex	II
Eid et al. (1993)	Positive	Caulophyllum	III-3
Low back pain			
Gmunder and Kissling (2002)	Positive	Individualised	RCT
Stam et al. (2001)	Positive	Complex	RCT
Witt et al. (2009b)	Positive	Individualised	IV
Malaria			
Bagai et al. (2012)	Positive	Laboratory Isopathy	III-2
van Erp and Brands (1996)	Positive	Individualised	IV
Male infertility			
de Souza et al. (2012)	Positive	Veterinarian	IV
Gerhard and Wallis (2002)	Positive	Individualised	IV
Malnutrition			
Villanueva et al. (2012)	Positive	Calcium complex	III-2
Menopausal hot flushes			
Clover and Ratsey (2002)	Positive	Individualised	IV
Colau et al. (2012)	Positive	Complex	RCT
Jacobs et al. (2005a)	Inconclusive	Individualised	RCT
Thompson et al. (2005)	Inconclusive	Individualised	RCT
Musculoskeletal diseases / injury			
Oryan (2012)	Positive	Laboratory	III-2
Rossignol et al. (2012)	Positive	Individualised	III-2
van Wassenhoven (1996)	Positive	Individualised	IV
Neuropathy			
Cairo et al. (2001)	Positive	Complex	IV
Mohammadi et al. (2012)	Positive	Laboratory	II
Pomposelli et al. (2009)	Positive	Individualised	III-2
Neuralgia post tooth extraction			
Albertini et al. (1985)	Positive	Alternating singles	III-2
Non-allergic rhinitis			
Bernstein et al. (2011)	Positive	Complex	
Oral Lichen planus			
Mousavi et al. (2009b)	Positive	Individualised	III-2
Ovarian cysts			

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Gimeno (1991)	Positive	Individualised	IV
Parasites			
Chaudhuri and Varshney (2007)	Positive	Veterinarian	III-2
Silva et al. (2008)	Positive	Veterinarian	III-2
Sukul et al. (2005)	Positive	Laboratory	III-1
Plantar fasciitis			
Clark and Percivall (2000)	Positive	Ruta 30	II
Post-op pain			
Alibeu and Jobert (1990)	Positive	Aconite	RCT
Hart et al. (1997)	Inconclusive	Arnica 30	RCT
Lokken et al. (1995)	Inconclusive	Individualised	RCT
Mazzocchi and Montanaro (2012)	Positive	Symphytum 5CH	III-2
Paris et al. (2008)	Negative	Complex	RCT
Robertson et al. (2007)	Positive	Arnica 30	II
Singer et al. (2010)	Inconclusive	Traumeel S	II
Stevinson et al. (2003)	Inconclusive	Arnica	RCT
Wolf et al. (2003)	Inconclusive	Arnica	RCT
Post-op bruising, wound healing, oedema, infection			
Bononi (2000)	Positive	Complex	III-2
Brinkhaus et al. (2006)	Positive	Arnica 30x	II
Cornu et al. (2010)	Inconclusive	Complex	RCT
Karow et al. (2008)	Positive	Arnica D4	RCT
Kazi (1984)	Negative	Arnica	RCT
Kotlus et al. (2010)	Inconclusive	Arnica	RCT
Seeley et al. (2006)	Positive	Arnica	RCT
Totonchi and Guyuron (2007)	Positive	Arnica	RCT
Postpartum bleeding			
Oberbaum et al. (2005)	Positive	Complex	RCT
Postpartum lactation			
Berrebi et al. (2001)	Positive	Complex	RCT
Premenstrual syndrome			
Danno et al. (2013)	Positive	Individualised	IV
Martinez (1990)	Positive	Folliculinum	IV
Yakir et al. (2001)	Positive	Individualised	RCT
Prostatism			
Hati et al. (2012)	Positive	Various	IV

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Vozianov and Simeonova (1990)	Positive	Individualised	IV
Psoriasis			
Witt et al. (2009c)	Positive	Individualised	IV
Pulmonary tuberculosis recovery			
Sharma and Sharma (2012)	Positive	Individualised	RCT
Radio-dermatitis			
Balzarini et al. (2000)	Positive	Complex	RCT
Kulkarni et al. (1988)	Positive	Single remedies	II
Schlappack (2004)	Positive	Individualised	IV
Renal failure			
Saruggia and Corghi (1992)	Positive	China rubra	II
Rheumatoid arthritis			
Andrade et al. (1991)	Inconclusive		RCT
Brien et al. (2011)	Inconclusive	Individualised	II
Fisher and Scott (2001)	Negative	Individualised	RCT
Gibson et al. (1980)	Positive	Individualised	III-1
Gibson et al. (1978)	Positive	Individualised	III-2
Patil et al. (2011)	Positive	Laboratory	II
Patel et al. (2012)	Positive	Laboratory	II
Seborrhoeic dermatitis			
Smith et al. (2002)	Positive	Complex	II
Sepsis			
Frass et al. (2005b)	Positive	Individualised	II
Snoring			
Lipman et al. (1999)	Positive	Complex	RCT
Stomatitis			
Mousavi et al. (2009a)	Positive	Individualised	III-1
Oberbaum et al. (2001)	Positive	Traumeel S	RCT
Supra-ventricular tachycardia			
van Wassenhoven (1998)	Positive	Individualised	IV
Thalassaemia			
Banerjee et al. (2010a)	Positive	Individualised	III-2
Tracheal secretions			
Frass et al. (2005a)	Positive	Kali bichromicum C30	II
Uraemic pruritis			
Cavalcanti et al. (2003)	Positive	Individualised	RCT

Study by condition	Direction of evidence	Therapeutic intervention	LOE
Uterine fibroids			
Popov (1992)	Positive	Individualised	IV
Varicose veins			
Ernst et al. (1990)	Positive		RCT
Warts			
Reilly et al. (1986)	Inconclusive	Individualised	RCT
Labrecque et al. (1992)	Inconclusive	Individualised	RCT
Manchanda et al. (1997)	Positive	Individualised	II
Xerostomia			
Haila et al. (2005)	Positive	Individualised	III-2
Zinc deficiency			
Badulici et al. (1994)	Positive	Isopathy	IV

Note. LOE = level of evidence

There is clear evidence of efficacy in nine conditions: attention deficit hyperactivity disorder with individualised homoeopathy; allergic rhinitis with isopathy (plus two related RCTs with *Galphimia glauca* D4); fibromyalgia with individualised homoeopathy; heavy metal toxicity with isopathy; influenza with *Oscillococcinum*; insomnia with individualised homoeopathy; osteoarthritis with *Zeel comp* (two human and two veterinary RCTs) and one RCT with each of individualised treatment and a gel (complex homoeopathic); otitis media with individualised homoeopathy; and sinusitis with the complex remedy *Sinfrontal*. There is very close to clear evidence in three conditions: upper respiratory tract infections with one RCT with each of two remedies, both having independent cohort study confirmation; vertigo with two RCTs (*Vertigoheel*) from similar authors and independent confirmation from cohort studies; and childhood diarrhoea in two RCTs with individualised prescribing from a similar team (and with some veterinary studies using isopathy).

4.4. Clear evidence of an action greater than placebo

In considering the 192 RCTs identified in this Submission (Appendix 2, 2.1–2.6), if homoeopathy were identical to placebo, one would expect a maximum of nine trials to favour homoeopathy with $p < 0.05$, or fewer considering that several had values down to 0.01 and smaller. Ninety-six trial results with positive findings for homoeopathy, more than ten times the possible chance occurrence, counters the argument that it is a placebo effect. Of the 149 RCTs that used placebo as a comparison, 74 were statistically significant with $p < 0.05$,

where one would expect only seven to be positive if the homoeopathic medicines were placebos. If the 67 RCTs with homoeopathic potencies as or more dilute than 12c vs. placebo are examined, 36 were statistically significant with $p < 0.05$, whereas chance would dictate that only three would be positive if those remedies were placebos.

A recently published paper by Mathie et al. (2013) identified a total of 263 journal papers describing approximately 285 RCTs investigating homoeopathy in humans, of which 41 placebo controlled studies were eligible for, but were missed by Shang et al. (2005), 30 of which Linde et al. (1997) also did not include in that meta-analysis. Consequently there are also approximately another 100 clinical RCTs (mostly in German, French, Italian, Russian and Portuguese) investigating homoeopathy that are not included in this Submission, but will be subject to further systematic review during 2013. In the unlikely event that none of all the extra 100 RCTs turn out to be positive for homoeopathy, one would then expect only 14 of the total to be positive if the homoeopathic interventions were indeed placebos. With 96 already known to be positive, there is evidence against the proposition that prescribed homoeopathic medicines are placebos. The addition of veterinary and laboratory RCTs (see Appendix 2) strengthens the conclusion that homoeopathic medicines exhibit an action greater than placebo.

4.5. Homoeopathy as good as or better than conventional medical care?

The following studies report benefits from homoeopathic treatment that are as good as, or better than, conventional care, either by direct comparison or as an additional treatment: Adler et al. (2011); Ammerschlager et al. (2005); Banerjee et al. (2010a); Bignamini et al. (1991); Bononi (2000); Cairo et al. (2001); Chapman et al. (1999); Chaufferin (2000); Derasse et al. (2005); Dorfman et al. (1987); Eid et al. (1993); Frass et al. (2005a); Frass et al. (2005b); Frenkel and Hermoni (2002); Frei and Thurneysen (2001b); Friesse et al. (1997); Gerhard and Wallis (2002); Gimeno (1996); Goldstein and Glik (1998); Haidvogel et al. (2007); Harrison et al. (1999); Iannotti and Melo (2012); Jacobs et al. (2003); Karow et al. (2008); Kundu et al. (2012); Marian et al. (2008); Pomposelli et al. (2009); Rabe et al. (2004); Relton et al. (2009); Riley et al. (2001); Rodrigues-Neto et al. (2009); Rossignol et al. (2012); Sinha et al. (2012); Sharma and Sharma (2012); Sharma et al. (2012); Schmiedel and Klein (2006); Studer and Busato (2011); Totonchi and Guyuron (2007); Trichard et al. (2004); Trichard et al. (2005); van den Meerschaut and Sunder (2009); van Wassenhoven (1998); van Wassenhoven and Ives (2004); Villanueva et al. (2012); Vincent et al. (2012); Witt et al. (2008); (Witt et al., 2009a).

The post-treatment impairment of pulmonary tuberculosis patients was improved by homoeopathic treatment in a study conducted in 2012 (Sharma & Sharma, 2012). Individualised homoeopathic treatment was given to 61 patients, while 57 patients received identical placebo treatment in this double-blind RCT. After six months treatment, significant improvement was observed in the homoeopathy group: forced expiratory volume in one second ($p<0.001$), forced vital capacity ($p<0.001$) and the ratio of the two measures ($p=0.002$). Increased body weight ($p<0.0001$) and improved quality of life ($p<0.05$) scores were better in the homoeopathy group compared with the control group ($p=0.003$). The placebo group deteriorated after one year, while the homoeopathy group maintained their improvements. Physician visits were reduced by 58.0% ($p=0.002$) in the homoeopathically treated patients compared with the control ($p<0.0001$) (Kundu et al., 2012).

The usefulness of individualised homoeopathy was investigated in the management of haemophiliac patients. Twenty-eight patients with moderate to severe disease received standard management for one year, then standard management plus homoeopathy for a subsequent year. Transfusion requirements, bleeding scores and pain scores were evaluated by independent experts. Homoeopathic medicines reduced the frequency and extent of bleeding and the quantity of blood products consumed. Pain scores also improved ($p<0.0001$), along with improved well-being in these patients.

Banerjee et al. (2010a) examined the potential benefits of homoeopathic treatment of thalassaemic patients on Hydroxyurea therapy. Blood examinations were conducted before treatment and three months post-treatment to determine differences in 38 patients treated with homoeopathy plus Hydroxyurea therapy and those treated only with Hydroxyurea therapy (38 patients). Homoeopathic remedies were prescribed on the basis of similarity. There was a significant decrease in serum ferritin and an increase in foetal haemoglobin in the group receiving combined treatment. In most patients with splenomegaly, there was a significant decrease in the size of the spleen and improvements in general health. Gaps between transfusions were greater for those on the combined treatment. Banerjee concluded that homoeopathy may be a useful adjunctive therapy for thalassaemic patients, particularly in developing countries where the safety conditions of blood transfusions may be compromised.

Homoeopathy may be useful in optimising metabolic functioning in cases of malnutrition. A mixture of potencies of calcium (Calcium carbonate, Calcium fluoride and Calcium phosphate) was shown to be beneficial in establishing normal weight in a group of malnourished children in Cuba (Villanueva et al., 2012). The children in the study were

below the third percentile for height-weight ratio and they were randomly assigned the standard protocol for malnourishment (dietary in nature) or that protocol plus the standardised homoeopathic treatment. After one year, 84% of the children given homoeopathic treatment reached normal weight compared with 30% of those receiving the standard diet.

Symptoms of diabetic neuropathy improved in both conventionally treated and homoeopathically treated groups in an observational study (Pomposelli et al., 2009). The homoeopathy group however made improvements which were significantly better than their baseline scores ($p=0.016$), and only the homoeopathically treated patients had scores for quality of life improve.

A homoeopathic complex, Grip-Heel was compared with acetaminophen in the treatment of acute febrile conditions in 198 children treated at 38 clinics in Belgium (Derasse et al., 2005). The homoeopathic complex was found to be as effective as acetaminophen, and it was better tolerated.

Jacobs et al. (2003) conducted three double-blind RCTs of 242 children experiencing acute diarrhoea. Individualised homoeopathy was compared with placebo, with doses taken after each episode of unformed stool. Both parents and visiting health workers monitored the children's progress. Duration of diarrhoea was defined as the time until there were less than three unformed stools per day for two consecutive days, and a meta-analysis of the effect size of the three studies was conducted. The combined analysis showed duration of diarrhoea of 3.3 days in the treated group compared with 4.1 days in the placebo group ($p=0.008$).

A homoeopathic complex Euphorbium compositum nasal drops was compared with xylometazoline in patients suffering from inflammatory diseases of the upper respiratory tract (Ammerschlagel et al., 2005). The homoeopathic complex was found to be comparably effective as xylometazoline for these conditions.

The treatment of mild viral infections was investigated in a cohort of 485 patients in an observational, prospective study using the complex homoeopathic medicine Grip-Heel (Rabe et al., 2004). Fever, headache, muscle pain, and sore throat were found to be responsive to Grip-Heel, with 67.9% of this group considered asymptomatic at the end of Grip-Heel therapy compared with 47.9% of patients in the control group. The homoeopathy group were considered successfully treated in 78.1% of cases compared with 52.2% of the placebo group. In terms of compliance and tolerability, 88.9% of the verum group judged this as "very good" compared with 38.8% in the control group.

Patients who had failed to respond to vitamin therapy for neuropathy were treated with various potencies of Carbon sulphate and Tabacum (Cairo et al., 2001). Fifteen patients with optic neuropathy improved by 73% and sixteen patients with peripheral neuropathy improved 12.5% within three months of treatment.

Patients who had previous unsuccessful microsurgical treatment of human papilloma virus were treated with individualised homoeopathy (Gimeno, 1996). Cytology assessments were made before treatment, during treatment and after one year of use of homoeopathy. At the final assessment, 11 of the 14 patients were assessed as cured of the human papilloma virus. Gimeno (1991) also studied the effects of homoeopathic treatment of patients with menstrual symptoms related to diagnoses of ovarian cysts. Forty cases were followed over a nine-month period with the following results: 24/25 had improvements in menstrual regularity; 18/18 had disappearance of pelvic pain; 6/6 had improvement in the incidence of spotting between menstrual periods; 10/10 had improvement in prolonged or heavy bleeding; 21/21 experienced improved moods; 6/6 had relief of pre-menstrual migraines, while 31/33 had improvements in other symptom presentations.

Homoeopathic care of women in labour was found to shorten the time of labour (5.1 hours vs. 8.5 hours) and the rate of post-delivery complications (11.3% vs. 40%) (Dorfman et al., 1987).

4.6. Onset of improvement faster in homoeopathically treated patients

In several of these studies, where the outcomes are similar for conventional and homoeopathic interventions, the rate of onset of improvement was found to be faster for the homoeopathically treated groups. In a study of homoeopathic treatment compared with conventional treatment in acute respiratory and ear complaints (Haidvogel et al., 2007), patients using homoeopathy improved faster than those treated conventionally, and the homoeopathically treated adults experienced fewer adverse events than those treated conventionally. The onset of improvement within the first seven days after treatment was significantly faster in children ($p=0.0488$) and in adults ($p=0.0001$) than in the conventional group. Schmiedel and Klein (2006) compared homoeopathy with allopathic treatment in upper respiratory infections, and while outcomes were similar, the homoeopathy group improved faster (77.1% better within 3 days compared with 61.7%). Fewer adverse events were recorded in research comparing conventional and homoeopathic treatments for upper respiratory and ear complaints (Riley et al., 2001). While outcomes were again similar, the

homoeopathically treated patients not only reached resolution of the illness more quickly but experienced fewer adverse events from treatment than those conventionally treated.

Frei and Thurneysen (2001a) compared the rate of resolution of a homoeopathically treated group of children with otitis media with a similar group receiving placebo. After 72 hours, the group receiving homoeopathy experienced significant relief of symptoms, which was 2.4 times faster than the response to placebo.

Homoeopathic treatment achieves improvements across a range of measures as shown in the study by Trichard et al. (2005). This study of treatment for acute rhinopharyngitis found that homoeopathic treatment was superior to antibiotics in terms of medical effectiveness. The number of episodes of acute rhinopharyngitis was 2.71 vs. 3.97 for the group treated with antibiotics ($p=0.001$), while there were fewer complications in the homoeopathy group than the antibiotic group (1.25 vs. 1.95, $p=0.0001$). The global quality of life score was better in the homoeopathy group (21.38 vs. 30.43, $p=0.001$), and medical costs were lower for the homoeopathically treated patients (88 Euros vs. 99 Euros, $p=0.05$). Fewer parents required sick leave on behalf of the homoeopathically treated children (9.5%) compared with the antibiotic group (31.6%).

4.7. Satisfaction rated high by homoeopathic patients

There is a range of positive evidence of efficacy and effectiveness in 73 conditions as outlined in Tables 1 and 2. Across the broad spectrum of patients consulting homoeopaths, 67–89% are satisfied with their choice of health care (Adler, 1999; Bawden, 2012; Cairo et al., 2001; Clover, 2000; di Sarsina & Iseppato, 2011; Goldstein & Glik, 1998; Marian et al., 2008; Reilly et al., 2007; Richardson, 2001; Robinson, 2006; Rodrigues-Neto et al., 2009; Rossi et al., 2009b; Sevar, 2005; Spence et al., 2005; Steinsbekk & Ludtke, 2005; Witt et al., 2008; van Wassenhoven & Ives, 2004).

A Brazilian study (Rodrigues-Neto et al., 2009) analysed 3,080 responses to a questionnaire, and found that 73% of homoeopathy patients were satisfied or very satisfied with the treatment received. The primary reason for seeking homoeopathy for this group was that “conventional treatment did not have any effect”.

Long-term follow-up of data was achieved in a Swiss-German multi-centre study of 103 primary care practices where a total of 3,709 patients were studied and 73% contributed to an eight-year follow-up (Witt et al., 2008). The most common complaints were allergic rhinitis and headache in adults and atopic dermatitis and multiple recurrent infections in children. Disease severity decreased significantly ($p=0.0001$) between the baseline and at two

years and at eight years and quality of life scores also increased significantly. Researchers found that younger age, female gender and more severe disease at baseline were predictive of better therapeutic success.

Similar high levels of satisfaction were recorded for patients treated homoeopathically when compared to those treated conventionally in a primary care setting (Marian et al., 2008). A survey of 6,778 patients achieved a 46.1% response rate. Statistically significant differences were found in health status (homoeopathy patients had a higher incidence of chronic and severe complaints), in the perception of side effects (2–3 times higher reporting of side effects in the conventionally treated group) and in patient satisfaction, where the percentage of patients satisfied with treatment was higher in the homoeopathy patients.

van Wassenhoven and Ives (2004) found patient satisfaction with homoeopathy was very high in 782 patients from 80 medical practices in Belgium. Ninety-five per cent of patients were fairly or very satisfied with their treatment, and rates of improvement were high by both patient and physician assessments (89%).

Seventy-eight per cent of 489 homoeopathy patients achieved a positive clinical response in a study of data collected over a 12 month period in a UK National Health Service general practice clinic (Robinson, 2006). Various homoeopathic treatment strategies were used in this setting (problem-based, patient-based, context-based and combined strategies) and the beneficial effects of homoeopathy were delivered within ten-minute consultation time-frames. In a much larger study of 6,544 patients being treated for chronic complaints in a university out-patient observational study, 70.7% of patients reported positive health changes, with 50% of these changes graded as +2 or +3 for the degree of change (Spence et al., 2005). In an earlier study by Spence (1991), 130 cases of eczema were followed for up to 11 years: 91% of these patients were either better or much better, while 7.4% were unchanged and 1.6% had deteriorated.

In the Norwegian study by Steinsbekk and Ludtke (2005), 70% of patients recorded a meaningful improvement in their main complaint after six months of homoeopathic treatment. This degree of improvement was matched in a similar study of homoeopathic patients in nine clinics in Los Angeles where 71% reported improvement in their health status after four months of treatment (Goldstein & Glik, 1998). These outcomes contrasted with the patient's previous experience of orthodox treatment for the same complaints, which was unsuccessful.

Patient self-rating of improvement shows significant degrees of improvement in other large scale, hospital-based surveys. Clover (2000) conducted a patient benefit survey of 1,372

patients at Tunbridge Wells Homoeopathic Hospital. Positive changes predominate, with greater percentage change measures increasing with the degree of positive change: -3 (2%), -2 (3%), -1 (4%), 0 (17%), +1 (19%), +2 (24%) and +3 (31%). Similar results were found by Richardson (2001) who surveyed 1,100 patients at Liverpool Regional Department of Homoeopathic Medicine. Patient rankings of their improvement were: -3 (0.09%), -2 (1.3%), -1 (0.9%), 0 (21%), +1 (16.3%), +2 (27.7%), +3 (31.5%) and +4 (1.1%).

A study by Iannotti and Melo (2012) inquired into the capacity of doctors to solve the presenting problems of their patients. This research found that homoeopathic doctors were better at solving patient's problems than conventional practitioners and homoeopathic doctors also ordered fewer diagnostic tests. This study examined the influence of the doctors' speciality on primary health care problem solving in Belo Horizonte Brazil, comparing homoeopathic with family health doctors, from both the point of view of management and of patients. In Belo Horizonte, both family health and homoeopathic doctors work in primary health care. The index of resolvability is used to compare resolution of problems by doctors. Official data from the Secretariat of Health and test requests made by the doctors, plus 482 structured interviews with patients were used in this project. A total of 217,963 consultations by 14 homoeopaths and 67 family health doctors between 1 July 2006 and 30 June 2007 were analysed. It was found that the medical speciality of homoeopathy has an impact on problem solving: homoeopaths requested fewer tests and have better index of resolvability compared with family health doctors, and that specialisation in homoeopathy is an independent positive factor in problem solving at primary health care level in Belo Horizonte, Brazil.

4.8. Prior dissatisfaction with conventional medical treatment

Many patients in the following studies had been dissatisfied with the treatment which they had received prior to seeking homoeopathic treatment: Goldstein and Glik (1998); Marian et al. (2008); Rodrigues-Neto et al. (2009); Sevar (2005); van Wassenhoven and Ives (2004).

Eighty per cent of the patients enrolled in the survey by Goldstein and Glik (1998) had had previous orthodox medical treatment for their conditions, which they had found unsuccessful. The complaints of patients in this study were most commonly respiratory, gastrointestinal and female reproductive disorders. The survey was conducted at nine clinics in the Los Angeles area and 77 patients participated; while the majority of the patients in the survey were highly educated, they had little knowledge of homoeopathy

prior to their treatment. At four months of treatment, 71% of those surveyed reported improvements in their health.

In the study by van Wassenhoven and Ives (2004), all the surveyed patients had diseases of major organ systems, and for 78% of these patients, their complaints were of sufficient severity to interfere with daily living. Patient satisfaction with homoeopathic treatment was very high (95%), compared with their ratings of previous treatment (20% satisfaction rating). As noted, significant improvements in the health status of patients were recorded after homoeopathic treatment by both patients and physicians. Previous conventional treatment, on the other hand, had brought about improvements in only 13% of cases, had made no difference for 32% of patients and had worsened the condition over half of the patients (55%).

Four hundred and fifty-five patients who were unsuitable for conventional treatment or whose previous treatment was unsuccessful provided information in the study by Sevar (2005). Of these, 67% derived benefit from homoeopathy and 33% were able to stop or to maintain a substantial reduction in their use of pharmaceutical drugs. Rodrigues-Neto et al. (2009) found that the main reason that patients in their survey sought homoeopathic treatment was because conventional treatment had failed. Approximately 73% of the homoeopathic patients in this study were satisfied or very satisfied with their treatment, and for 70.2% of users, it was considered reasonable or cheap.

4.9. Homoeopathy ameliorates the effects of environmental toxins

Environmental toxins have been an increasing problem, particularly affecting developing countries where regulatory mechanisms may be lacking. Populations affected by contact with environmental toxins may benefit from treatment with homoeopathic preparations of the toxic substance (isopathy), as shown by the results of several studies. In a double-blind placebo-controlled study, a potentised remedy of homoeopathic Arsenicum album 30c and a placebo (succussed alcohol 30c) were given randomly to volunteers (Belon et al., 2007).

Arsenic contents in urine and blood were analysed, as were several widely accepted toxicity biomarkers and pathological parameters in blood, with samples taken before and after two months of administration of either verum or placebo. The administration of Arsenicum album 30c appeared to make positive modulations of these parameters, suggesting that the homoeopathic has ameliorative potential. Most of the subjects reported better appetite and improvement in general health, thereby indicating the possibility of its use in remote

arsenic-contaminated areas as an interim health support measure to a large population at risk.

Arsenic in groundwater affects populations in more than twenty countries world-wide. Potentised *Arsenicum album* was given to a group of arsenic-affected people and arsenic contents of blood and urine were subsequently tested (Khuda-Bukhsh et al., 2005). Levels of toxicity markers and enzymes in blood samples were monitored over a period of three months and the positive results suggest that a homoeopathic preparation of arsenic may alleviate the effects of arsenic poisoning.

Khuda-Bukhsh conducted further studies examining the potential of homoeopathic treatment of environmentally-induced toxicity. In 2011, 14 people living with an arsenic contaminated water supply were treated with either *Arsenicum album* LM 0/3 or placebo for two months (Khuda-Bukhsh et al., 2011a). The verum group had modulations of a number of markers for arsenic poisoning. In another study of homoeopathic arsenic, 96 people were treated with *Arsenicum album* 200c for six months, and 65 people continued the treatment for one year and 15 for two years. A period of initial improvement in the first three months was maintained in relation to general health, spirit, appetite and sleep. Biomarkers for toxicity levels remained within normal range. Those patients who had concurrent skin complaints experienced further improvements from treatment with *Arsenicum album* in homoeopathic potency.

In a study that tested whether a high dilution of homoeopathically prepared Mercury could act as a chelating agent for Mercury, 52 people exposed to mercury poisoning were treated homoeopathically (Beringhs-Bueno et al., 2006). Random assignment of either *Merc sol* 30 or placebo was given to this group. Mercury levels in blood, urine and hair samples were taken before the trial, at 30 days and 60 days after *Merc sol* or placebo delivery. Quality of life measures as well as blood, urine and hair analyses were made. Mercury content of hair samples decreased and evidence of urinary elimination was established, along with improvements in symptomatology of the mercury-affected patients.

4.10. Homoeopathy in Epidemics

The history of homoeopathy describes many instances of its use at a population level during epidemic outbreaks, such as the 1918 influenza epidemic (Winston, 1999). Recent population level uses of homoeopathy in epidemics provide contemporary evidence of its usefulness, effectiveness and very low cost relative to standard treatment protocols.

Cuban use of a homoeopathic prophylactic for the annually occurring Leptospirosis outbreak is the largest-ever research study assessing a homoeopathic medicine (Bracho et al., 2010). Leptospirosis is a potentially fatal infectious disease caused by exposure to contaminated water.

During the 2007 epidemic in Cuba, when extreme flooding worsened the potential for disease incidence and very little conventional vaccine was available, a novel approach was used. A homoeopathic medicine, *nosoLep*, was prepared from four inactivated strains of Leptospirosis-causing bacteria and given to 2.3 million people at high risk of infection, while the remaining 8.8 million of the population were untreated. The homoeopathic treatment was “strongly associated with a drastic reduction of disease incidence resulting in complete control of the epidemic” (Bracho et al., 2010), while in the untreated population, the rates of infection were as anticipated. Within weeks of the intervention being given, a dramatic decrease was seen in the number of confirmed cases, from 38 per 100,000 to 4–6 cases per 100,000 per week. The projected incidence for this period had been 111–461 cases per 100,000 per week; the homoeopathic intervention represented a decrease of between 91.8% and 65.8%. This drop in disease incidence occurred at the point when homoeopathic treatment had been received by 70% of the population. The treatment regime involved two oral doses of *nosoLEP 200c* given 7–9 days apart. Treatment was continued 10–12 months later with two oral doses of *nosoLEP 10MC* given 7–9 days apart. The protective effect extended into the 2008 rainy season, when incidence of Leptospirosis in the untreated population increased by 22% from 2007, while in the homoeopathically treated population, infection rates dropped by 84%. This population-scale use of a homoeopathic medicine was also associated with a substantial reduction in the cost of treatment compared with conventional and less effective vaccine programs.

In Brazil in 2007, a homoeopathic complex preparation (*Phosphorus 30c*, *Crotalus 30 c* and *Eupatorium 30c*) was used in a Government campaign against dengue fever. In one county in Rio de Janeiro, 156,000 doses were distributed to asymptomatic patients and 129 to symptomatic patients treated in outpatient clinics. The incidence of the disease fell by 93% in the first three months of 2008 compared with the corresponding period in 2007, while in the rest of Rio de Janeiro there was a 128% increase in the incidence of dengue fever.

In another Brazilian study (Mroninski et al., 2001), the homoeopathic nosode *Meningococcinum* was used during an outbreak of B serotype meningococcal disease. A protection rate of 95% was found from one dose of *Meningococcinum 30c*, and this protective effect extended for a period of six months from the dosing.

5. Cost-effectiveness of homoeopathic medicine

Government rebates for CAM therapies in Australia represent 0.08% of the total Federal Government expenditure on private health insurance rebates (Baggoley, 2012). Rebates for all natural therapies totalled \$87 million in 2010–2011, with \$27 million coming from the Federal Government. The greatest increase in the use of ancillary services of private health insurance were for natural therapies, which represented an 18% increase in 2011–2012 compared with the previous year (Harvey, 2012b). While CAM therapies account for a small proportion of ancillary services (5.6%), they include the widely-used modalities of acupuncture, traditional Chinese medicine, herbalism and naturopathy as well as several other smaller health care modalities. Specific figures homoeopathy are unavailable, but rebates for homoeopathic consultations are likely to represent a very small proportion of the total Federal Government private health insurance rebates for CAM therapies.

In the wider context of public health care funding, Medicare Australia provides financial support for medical consultation fees to a vastly greater extent than the Government rebate support for homoeopathic consultations. This broader perspective is informative, as the following discussion of the cost-effectiveness of homoeopathy will identify several areas of potential cost-savings from this form of treatment. These savings could represent a substantial benefit to the public purse if homoeopathic care was made more accessible to Australian health consumers. Proposals to remove the Federal Government rebates for homoeopathic health care would directly restrict accessibility and impinge upon the rights of current privately insured patients to access the range of therapies presently covered in the health care plan to which they have subscribed. Anecdotal evidence from clients informs us that the available coverage of CAM therapies has provided the impetus for many users of homoeopathy and other CAM practices to commence their subscription to private health insurance.

Adequate provision of public health care represents an ever-increasing burden on Government resources. The introduction of Federal Government rebates was designed to encourage the uptake of private health insurance, and generate a greater portion of health funding from the private sector. Support for consumer choice through rebates for homoeopathic consultations may raise more money in taxation revenue from practitioners than is spent on the rebate: a fair cost-benefit analysis would include these taxation considerations. While the proportion of the homoeopathic consultation fee covered by the health fund varies considerably, and the total offered annually is usually limited, the rebate

may be estimated at an average of 40% of the fee. Based on this figure, every dollar of Government funding directed at homoeopathic consultation fees is associated with \$2.33 of the patient's contribution to the fund, plus another \$5 of patient gap payment to the practitioner. The practitioner may therefore notionally receive \$8.33 and, depending on the applicable tax bracket, is likely to pay \$2 in taxation. On the basis of these estimates, the Federal Government doubles the value of its investment in homoeopathic consultations over approximately two years: an apparently highly judicious investment.

This likely positive cost-benefit equation of Federal Government outlays and related taxation revenue from homoeopathy can be added to the potential cost-savings to the community (public and private) which homoeopathic health care may offer. Some patients will not be deterred from attending a homoeopathic practitioner by the loss of insurance cover, but for others it is likely to result in increased GP consultations. Medicare supports approximately 85% of the doctor's fee; to this amount can be added investigation costs and medication costs (if Pharmaceutical Benefits Scheme listed) and costs for any ancillary health professionals (accessed via Health Care Plans). Less than one third of these outlays will come back to the Government as in the form of taxation payments.

5.1. The cost-effectiveness of homoeopathy

The issue of cost-effectiveness is critical in evaluating decisions about health care delivery. In 2011, the National Institute of Complementary Medicine released the results of a study demonstrating the relative value of complementary medicine interventions to the Australian community (National Institute of Complementary Medicine, 2009). This study conducted by Access Economics found that millions of health care dollars could be saved without compromising patient outcomes if complementary medicine was more widely used. These results are pertinent at a time when health care costs are rising faster than the general cost of living, and the percentage of gross national product expended on health care continues to escalate (Australian Institute of Health and Welfare, 2011).

Mirroring the findings of the Access Economics survey, a UK study by a leading economist found that significant savings to national health budgets would result from a greater use of complementary therapies (Smallwood, 2005). This study estimated that if only 4% of British GPs were to offer homoeopathy as a frontline approach to treatment, an annual saving to the National Health Service of 190 million pounds sterling would result.

Potential cost-savings attributable to community-based homoeopathic care are described in the following review of the research literature. In the absence of local studies,

Australian inquiry must rely on European and other research. A wide range of studies indicate potential savings from the provision of homoeopathic health care, with equal or improved clinical effectiveness. Multiple factors contribute to lowered costs and these include: reduced duration of illness, reduced need for drug treatments, lower cost of homoeopathic medicines compared with pharmaceutical drugs, reduced demand for GP consultations; reduced health-related costs, such as loss of productivity due to time off work; reduced compensation payments as a result of illness; savings from absence of side effects of drug therapy and subsequent treatments; and improved overall health and quality of life of homoeopathic patients.

Studies (see Table 3 below) examining the cost-effectiveness of homoeopathy show:

- reduced costs of homoeopathy with similar or improved clinical effectiveness (Bracho et al., 2010; Chaufferin, 2000; Jain, 2003; Kneis & Gandjour, 2009; Pomposelli et al., 2009; Torres et al., 2001; Trichard et al., 2005; Rodrigues-Neto et al., 2009; Swayne, 1992; van Wassenhoven & Ives, 2004)
- homoeopathic treatment is cheaper than conventional prescriptions (Bononi, 2000; Bracho et al., 2010; Chaufferin, 2000; Jain, 2003; Kneis & Gandjour, 2009; Pomposelli et al., 2009; Rodrigues-Neto et al., 2009; Rossi et al., 2009a; Studer & Busato, 2011; Torres et al., 2001; Trichard et al., 2005; van Wassenhoven & Ives, 2004)
- reduced need for other prescriptions contributes to lowered costs (Bracho et al., 2010; Chaufferin, 2000; Frei & Thurneysen, 2001b; Frenkel & Hermoni, 2002; Jain, 2003; Marino, 2008; Pomposelli et al., 2009; Rossi et al., 2009a; Rossi et al., 2009b; Sevar, 2005; Taylor et al., 2000; Trichard et al., 2005; van Haselen, 2000; van Wassenhoven & Ives, 2004; Witt et al., 2009b)
- reductions in GP consultations (International Data Collection Centres for Integrative Medicine, 1998; Sharples et al., 2003)
- reduced work-absenteeism and reduced parental absence due to child illness (Frei & Thurneysen, 2001b; Frenkel & Hermoni, 2002; Sevar, 2005; Swayne, 1992; Trichard et al., 2005; van Haselen, 2000; van Haselen et al., 1999)
- an absence of side effects due to not taking conventional medicines (Marian et al., 2008; Studer & Busato, 2011; van Wassenhoven & Ives, 2004; Zuzak et al., 2010)
- high levels of patient satisfaction (Kliems & Witt, 2011; Marian et al., 2008; Pomposelli et al., 2009; Rodrigues-Neto et al., 2009; Studer & Busato, 2011; Trichard et al., 2004; van Wassenhoven & Ives, 2004; Vincent et al., 2012; Witt et al., 2009b)

Table 3. Summary of studies of the cost-effectiveness of homoeopathy (studies older than 10 years have been highlighted).

Author	Study description	Findings
Bononi (2000)	Forte S homoeopathic formula was used for prophylaxis of post-operative infections. Forte S was compared with ceftazidime and ceftriaxone.	This homeopathic medicament proved to be equally effective and much less expensive.
Bracho et al. (2010)	In 2007, the population of a region of Cuba (2,500,000 people) were administered the homoeopathic prophylactic against Leptospirosis, due to insufficient supply of the conventional vaccination material. Leptospirosis is an annually occurring epidemic with a typically high morbidity rate, even when the usual vaccination is employed.	Only ten people developed the disease, in marked contrast to the tens of thousands normally infected each year. No lives were lost and the program was highly cost-effective in comparison to the conventional and less effective vaccine programs. The protective effect continued (without re-dosing) into 2008 with an 84% reduction in leptospirosis cases for the treated area. Leptospirosis infections in non-homoeopathically treated areas increased by 22% in 2008.
Chauferin (2000)	The financial crisis of health insurance systems sometimes drives public policy-makers to take precipitate action dominated by economic imperatives. The question addressed here consists in defining homoeopathy's scope of intervention, its place in health care strategies, recourse to treatment, and especially economic data appraising homoeopathy's impact on expenditures and outlay covered by health insurance in France. We used the General Evaluation Model to define the study (to whom is the evaluation made, situations, criteria, measurement of these criteria, quality and precision).	The main results are in terms of costs, as follows: For reimbursable medicines the public sales price of homeopathic products is a quarter of the average. The total reimbursement for a prescription of allopathic products is three times more than for a prescription of homeopathic products. Homeopathic physicians incur annual reimbursement outlays which are half those of general practitioners. The differences observed cannot be explained by the patient profile or the diseases treated. Furthermore, a study carried out in France showed that 87% of patients whose physicians had prescribed homeopathic treatment did not see another physician for the same problem.
Frenkel and Hermoni (2002)	The effects of homoeopathic intervention on the consumption of medication in atopic and allergic disorders.	Fifty-six percent of patients in this study reduced their use of conventional medication following the homeopathic intervention. Patients who used conventional medications for their allergic disorders reduced their medication expense by an average of 60% in the 3-month period following the homeopathic intervention.
Jain (2003)	Data were collected for 4 years on all patients who were treated homoeopathically by one GP. Costs of homoeopathic remedies and costs of conventional drugs which otherwise would be prescribed for these patients was calculated for the total duration of treatment.	Savings were calculated. One hundred patients were included in the study. Average cost savings per patient was £60.40. The majority of patients had improved and most did not report any side-effects. Calculated costs in this study are based on drugs only, it does not take into account doctor's time, special investigations and time off sick.
Kliems and Witt (2011)	The objective of this study was to identify the factors that make a good doctor, both from a patient and a physician perspective. Is there a connection between practising homoeopathy and being a good doctor? This was a qualitative study of homoeopathically trained physicians and their patients, using observation of patient-physician interactions (n=29) and interviews with patients (n=20) and with physicians (n=4).	Patients identified the availability of time, both in itself and as a prerequisite for other physician characteristics, as the single most important factor. Other factors include scope of diagnosis/holistic approach, patient-centeredness/empathy, and perceived competence/therapeutic success. Patients did not link these factors to the homeopathic orientation of their physician, while physicians clearly made this connection.

Author	Study description	Findings
Kneis and Gandjour (2009)	Sinfrontal is a complex homeopathic medication, the efficacy and safety of which has been demonstrated in a number of clinical studies of patients with sinusitis. Sinfrontal was compared with placebo in a cost-utility analysis based on data from a randomized controlled clinical trial over 3 weeks (Sinfrontal group: n = 57; placebo group: n = 56). Trial data were analysed from a societal perspective; resource use was valued with German unit costs for 2005. In a secondary analysis, the longer-term cost utility of Sinfrontal versus placebo was estimated over a total of 11 weeks based on an 8-week post-treatment observational phase. In addition, the cost effectiveness of Sinfrontal versus antibacterials was determined based on an indirect comparison of placebo-controlled trials.	Sinfrontal led to incremental savings of euro 275 (95% CI 433, 103) per patient compared with placebo over 22 days, essentially due to the markedly reduced absenteeism from work (7.83 vs 12.9 workdays). Incremental utility amounted to 0.0087 QALYs (95% CI 0.0052, 0.0123), or 3.2 quality-adjusted life-days (QALDs). Bootstrapping showed that these findings were significant, with Sinfrontal being dominant in 99.9% of simulations. The results were robust to a number of sensitivity analyses. In the secondary analysis, Sinfrontal led to incremental cost savings of euro 511 and utility gains of 0.015 QALYs or 5.4 QALDs compared with placebo. Compared with antibacterials, Sinfrontal had a significantly higher cure rate (11% vs 59%; $p < 0.001$) at similar or lower costs. The results of this economic evaluation indicate that Sinfrontal may be a cost-effective treatment for AMS in adults.
Marian et al. (2008)	The main objective of this study is to investigate patient satisfaction and perception of side effects in homeopathy compared with conventional care in a primary care setting. A total of 6778 adult patients received the questionnaire and 3126 responded (46.1%).	Statistically significant differences were found with respect to health status (higher percentage of chronic and severe conditions in the homeopathic group), perception of side effects (higher percentage of reported side effects in the conventional group) and patient satisfaction (higher percentage of satisfied patients in the homeopathic group).
Marino (2008)	This paper describes experiences of the use of homeopathy in the prevention and treatment Dengue fever in São José do Rio Preto, São Paulo, Brazil. May 2001, a single dose of the homeopathic remedy Eupatorium perfoliatum 30cH was given to 40% of residents of the most highly affected neighbourhood.	Dengue incidence decreased by 81.5%, a highly significant decrease as compared with neighbourhoods that did not receive homeopathic prophylaxis ($p < 0.0001$). Between April and September 2007, a homeopathic complex composed of Eupatorium perfoliatum, Phosphorus and Crotales horridus 30c, were given to 20,000 city residents. This trial was aborted prematurely due to national political intervention, Dengue incidence decreased by 81.5%, a highly significant decrease as compared with neighbourhoods that did not receive homeopathic prophylaxis ($p < 0.0001$). Between April and therefore, only partial and isolated data could be recorded. However, the results suggest that homeopathy may be effective in the prevention and treatment of Dengue epidemics.
Pomposelli et al. (2009)		Diabetic neuropathy symptoms improved in both groups, but was significantly better than baseline only on the homeopathy group ($p = 0.016$). QOL scores improved only in the homeopathy group. The cost of conventional drugs decreased in the homeopathy group by 20%.

Author	Study description	Findings
Rodrigues-Neto et al. (2009)	This study analysed 3080 replies to a semi-structured questionnaire.	The prevalence of the use of homeopathy was 2.4%. The main reason that led to seeking homeopathy was "Conventional treatment did not have any effect". For 70.2% of the users, the cost of the treatment was considered reasonable or cheap. About 73% were satisfied or very satisfied with the treatment received through homeopathy.
Rossi et al. (2009a)	A retrospective observational study was conducted on 105 out of 233 patients suffering from chronic respiratory disease attending the Homeopathic Clinic of the Campo di Marte Hospital in Lucca (Tuscany, Italy) between October 1998 and May 2003. We assessed the cost of conventional medicinal products using Anatomic Therapeutic Chemical (ATC) classification, specific for the pathology in question, and the general costs in the year preceding the first appointment at the Homeopathic Clinic vs. the first and second year subsequent to homeopathic treatment. The costs of conventional drugs for a group of patients affected by asthma (8 patients) and recurrent respiratory infections (16 patients) with long term use of conventional medicine treated by homeopathy were compared with the expenses of conventional drugs of a matched group of 16 and 32 patients, respectively.	Costs of pharmacological therapy specific for respiratory diseases were reduced by 46.3% (n = 105) in the first year (P < 0.01); and by 47.5% (n = 72) in the second year (P < 0.01) of homeopathic treatment. Reduction in general drug costs during homeopathic therapy was 42.4% in the first year (P < 0.01); and 49.8 in the second year (N.S.). Costs for patients affected by chronic asthma showed a reduction in expenses of 71.1% for specific medicines relative to the group in homeopathic treatment vs. an increase of 12.3% in the group treated only with conventional drugs after the first year of follow-up and, respectively, a reduction of 54.4% for homeopathic treatment vs. +45.2% after the second year. For patients with recurrent respiratory infections we found a reduction of 35.8% in the homeopathic group in the first year, compared to an increase 8.6% of costs for specific drugs in the control group; in the second year the respective figures were 43.6% versus +7.8% in the control group. Homeopathic treatment for respiratory diseases (asthma, allergic complaints, acute recurrent respiratory infections) was associated with a significant reduction in the use and costs of conventional drugs. Costs for homeopathic therapy are significantly lower than those for conventional pharmacological therapy.
Sevar (2005)	This paper reports an audit of clinical outcome in 455 consecutive patients (1100 consultations) presenting for private homeopathic treatment of a chronic illness in which conventional treatment had either: failed, reached a plateau in effect, or was contra-indicated by side effects, age or condition of the patient.	Three hundred and four patients (66.8%) derived benefit from homeopathic treatment. One hundred and forty-eight patients (32.5%) were able to stop or maintain a substantial reduction in their conventional drugs. The 10 most frequent clinical conditions treated were eczema, anxiety, depression, osteoarthritis, asthma, back pain, chronic cough, chronic fatigue, headaches and essential hypertension. These 195 patients constitute 43% of the total, 151 of them (77%) were improved. The success rate of treatment is similar between age ranges. There was a difference in outcome between the sexes in adults: 296 females treated, success rate 71.3%; 159 males treated, success rate 58.5%. Two patients (0.4%) had prolonged aggravation of their presenting complaints apparently attributable to homeopathic treatment.

Author	Study description	Findings
Sharples et al. (2003)	To examine patients' reasons for seeking CAM in the National Health Service, including the nature and duration of the patient's main health problem, the impact of CAM on this, satisfaction with clinical care, and usage of conventional prescription medication. Survey (n=499). Out-patient Department, The Royal London Homeopathic Hospital, a National Health Service facility dedicated to CAM.	Five hundred and six questionnaires were returned, 499 were analysed. Patients' most frequent reasons for seeking CAM were that other treatment had not helped, and concerns about or experience of adverse treatment reactions. Two hundred and ninety-seven patients (63%) had had their main problem for more than 5 years. Musculoskeletal system problems were the most frequent diagnostic group (n=151, 32%). Satisfaction with clinical care was high (443/490: 90%). Three hundred and eighty patients (81%) indicated their main problem had improved very much, moderately or slightly. Of the 262 patients who had been taking prescription medicines when they first attended, 76 (29%) had stopped, and 84 (32%) had reduced their intake. The results suggest that orthodox medicine is not meeting the needs of some patients and that CAM may wholly or partly substitute for conventional medicines. Most patients indicated their problem had improved with CAM. Implications for future research are discussed.
Studer and Busato (2011)	This study sought to compare practice costs of physicians applying CAM with those of physicians applying solely conventional medicine (COM) in Swiss ambulatory care. A cross-sectional investigation of claims data of mandatory health insurance was made for the years 2002 and 2003. Practice costs of 562 primary care physicians with and without a certificate for CAM were analyzed and compared with patient-reported outcomes. Linear models were used to obtain estimates of practice costs controlling for different patient populations and structural characteristics of practices across CAM and COM.	Statistical procedures show similar total practice costs for CAM and COM, with the exception of homoeopathy with 15.4% lower costs than COM. Patients reported better quality of the patient-physician relationship and fewer adverse side effects in CAM. Higher cost-effectiveness for CAM can be deduced from this perspective.
Torres et al. (2001)	30 children with asthma were treated with homoeopathy and 30 with conventional medicine.	All 60 had a satisfactory clinical course, but the conventional treatment was 10 times more expensive.
Trichard et al. (2004)	Researchers compared the effectiveness, the quality of life of the parents, and the direct and indirect costs associated with treatment from homeopathic and non-homeopathic GPs in this pragmatic, prospective observational study.	This study produced new findings that indicate that, in France, acute rhinopharyngitis is handled differently by homeopathic GPs and non-homeopathic GPs: homeopathic GPs prescribe fewer antibacterials than non-homeopathic GPs for the treatment of recurrent acute rhinopharyngitis in children aged between 18 months and 4 years. Moreover, homeopathic treatment gave better results in terms of pragmatic medical effectiveness (fewer episodes and fewer complications) and the parents' quality of life, with similar total medical costs to social security.

Author	Study description	Findings
Trichard et al. (2005)	A pharmaco-economic study to compare, in terms of: medical effectiveness, quality of life and costs two treatment strategies ('homeopathic strategy' vs 'antibiotic strategy') used in routine medical practice by allopathic and homeopathic GPs in the treatment of recurrent acute rhinopharyngitis in 18-month to 4-year-old children. Statistical analysis of data obtained from a population of 499 patients included in a previous 6-month prospective, pragmatic study. The patients were regrouped according to type of drug prescribed. Medical effectiveness was assessed in terms of (i) episodes of acute rhinopharyngitis, (ii) complications, (iii) adverse effects. Quality of life was assessed using the Par-Ent-Qol scale. Direct medical costs (medical consultations, drug prescriptions, prescriptions for further tests) and indirect medical costs (sick-leave) were evaluated from three viewpoints (society, patient, Social Security) using public prices and French Social Security tariffs.	The 'homeopathic strategy' yielded significantly better results than the 'antibiotic strategy' in terms of medical effectiveness (number of episodes of rhinopharyngitis: 2.71 vs 3.97, $P<0.001$; number of complications: 1.25 vs 1.95, $P<0.001$), and quality of life (global score: 21.38 vs 30.43, $P<0.001$), with lower direct medical costs covered by Social Security (88 Euros vs 99 Euros, $P<0.05$) and significantly less sick-leave (9.5% of parents vs 31.6% of parents, $P<0.001$). Conclusion: Homoeopathy may be a cost-effective alternative to antibiotics in the treatment of recurrent infantile rhinopharyngitis.
van Haselen (2000)	The practical implementation of a staged, multifaceted research agenda for the economic evaluation of complementary medicine (CM) at the Royal London Homeopathic Hospital (RLHH). The relative importance of economic evaluation as an evidence base of CM was assessed via a survey conducted with purchasers ($n=481$). The marginal costs of providing complementary care for patients with rheumatoid arthritis were calculated. The use, and changes in the use, of conventional medicines for patients' main complaints were established retrospectively ($n=499$) and prospectively ($n=70$). Health-related quality of life (patient utility) of newly referred patients was assessed with the EQ-5D (EuroQol) instrument ($n = 70$) on a 100 mm (0 = worst, 100 = best) scale.	Economic evaluation was rated 'important' as an evidence base, after safety and RCT data ('very important'). Consultation time (doctors and dietician) contributed 29% of the total costs of treating rheumatoid arthritis. The retrospective survey showed that many patients on conventional medication were able to stop (29%) or reduce (32%) intake in the course of treatment. The median (quartiles) health state of newly referred patients was 70 mm (50,78) in men and 60 mm (36,73) in women. Some results of an interim analysis of 6 months follow-up data are reported. Economic evaluation of CM is becoming increasingly important and should take place by using a multifaceted, staged approach. Before embarking on randomised trials, observational data on cost, effectiveness and utility should be collected. The cost-effectiveness of CM appears to be most sensitive to the duration of the consultation.

Author	Study description	Findings
van Wassenhoven and Ives (2004)	An observational study of eighty general medical practices in Belgium where physicians were members of the Unio Homoeopathica Belgica. A total of 782 patients presented with diseases of all major organ systems which were of sufficient severity to interfere with daily living in 78% of cases.	Compared to previous conventional treatment, patients reported that consultations were much longer but cost less. One or more conventional drug treatments were discontinued in over half (52%) of the patients: CNS (including psychotropic) drugs (21%), drugs for respiratory conditions (16%) and antibiotics (16%). Conventional drugs were prescribed to about a quarter of patients (27%), mostly antibiotics and cardiovascular medication. The antibiotics were almost exclusively (95%) used to treat respiratory infections. Prescription costs (including conventional medicines) were one third of the general practice average. Patients' satisfaction with their homeopathic treatment was very high (95% fairly or very satisfied), and ratings of their previous treatment was much lower (20%). The great majority (89%) said that homeopathy had improved their physical condition; 8.5% said that it had made no difference, 2.4% said that homeopathy had worsened their condition. Physicians' ratings of improvement were similar. Previous conventional treatment had improved 13% of patients, made no difference to 32%, and had worsened the condition of over half (55%). A similar pattern was seen for psychological symptoms. The study concludes that patients were very satisfied with their homeopathic treatment, both they and their physician's recorded significant improvement. Costs of homeopathic treatment were significantly lower than conventional treatment, and many previously prescribed drugs were discontinued.
Vincent et al. (2012)	Study to determine characteristics and management of patients visiting allopathic GPs (AGPs) and homeopathic GPs (HGP) with influenza-like illness (ILI). 65 HGPs & 124 AGPs recruited a total of 461 patients. Patients & GPs completed questionnaires re demographic characteristics and patient symptoms, with report of treatments occurring on day 4.	In France, homeopathy is widely accepted for the treatment of ILI and does not preclude the use of allopathic medicines. Patient satisfaction with treatment did not differ between the AGPs and the HGPs, but was highest for those treated only with homeopathic medicine.
Witt et al. (2005)	To evaluate the effectiveness of homeopathy versus conventional treatment in routine care. Analyses of 493 patients (315 adults, 178 children) were undertaken.	The results indicated greater improvement in patients' assessments after homeopathic versus conventional treatment (adults: homeopathy from 5.7 to 3.2; conventional, 5.9-4.4; $p = 0.002$; children from 5.1 to 2.6 and from 4.5 to 3.2). Physician assessments were also more favourable for children who had received homeopathic treatment (4.6-2.0 and 3.9-2.7; $p < 0.001$). Overall costs however showed no significant differences between both treatment groups.

Author	Study description	Findings
Witt et al. (2009b)	129 adults (mean age 43.6 +/- 12.7 y) were treated by 48 physicians. The patients mainly had chronic low back pain (average duration 9.6 +/- 9.0 y) and other chronic diseases. 91.3% had been pre-treated. Consultation time cumulated to 204.5 +/- 184.6 minutes. The patients received an average of 6.8 +/- 6.3 homeopathic prescriptions.	The severity of the diagnoses and complaints showed marked and sustained improvements with large effect sizes (Cohen's d from 1.67 to 2.55) and QOL improved accordingly (SF-36 physical component scale d = 0.33; mental component scale d = 0.54). The use of conventional treatment and health services decreased markedly: the number of patients using low back pain-related drugs was half of the baseline.
Zuzak et al. (2010)	The purpose of this study was to find out what experiences adults are having while treating children with complementary and alternative medicine (CAM) therapies in German-speaking Switzerland. Homoeopathy was the most frequently used form of CAM (77% of all CAM users), followed by herbal medicine (64%), anthroposophic medicine (24%), Traditional Chinese Medicine (13%), Ayurveda (5%), and others (34%).	From the respondents' point of view, the most marked difference between CAM- and Conventional Medicine therapies concerns the frequency and intensity of side-effects, which were markedly higher in the latter case.

5.2. Cost-effectiveness and clinical effectiveness

The cost-effectiveness of health interventions is relevant only if the health intervention achieves positive clinical outcomes. A sustained theme in the studies of the economics of homoeopathic care in Table 3 is the concomitance of reduced costs with good clinical results. Only one study reported here finds no statistically significant difference between the costs of conventional care compared with homoeopathic care (Witt et al., 2005), and this study reported better clinical effectiveness for the same costs as conventional care. This study was commissioned by a German health insurance company to inform decisions about their continuance of rebates for homoeopathy. Using data provided by the health insurer, the study inquired into the treatment of common chronic conditions such as: lower back pain; headache; insomnia; depression and sinusitis in adults; and dermatitis, allergic rhinitis and asthma in children. Information was collected on symptom severity as rated by patients and doctors, quality of life and costs of consultations, medication, physiotherapy, hospitalisation, sick pay and medical devices at 6 and 12 months. The effectiveness of homoeopathic treatment was compared with conventional treatment in 493 patients with chronic conditions (315 adults and 178 children). While cost-neutral, patient assessments in the Witt et al. (2005) study showed greater improvement in the homoeopathically treated group and physician assessments were statistically significantly more positive for child patients in the homoeopathic treatment group.

In a study by Kneis and Gandjour (2009), a higher rate of cure (59% vs. 11%) was achieved in the treatment of acute maxillary sinusitis using a homoeopathic complex medicine, Sinfrontal, compared with a placebo, along with cost savings due to reduced time away from work for those treated homoeopathically (7.8 days compared with 12.9 days).

A French study of children treated for acute rhinopharyngitis compared homoeopathic treatment with antibiotic therapy (Trichard et al., 2005) and found positive outcomes across a range of variables in the homoeopathically treated children. Homoeopathically treated patients had better medical effectiveness (fewer episodes and fewer complications), higher quality of life measures and lower direct medical costs. Parents' sick-leave requirements were reduced for the homoeopathically treated children, resulting in further indirect cost savings.

In a study of 499 children aged between 18 months and four years by Trichard et al. (2005), homoeopathic and conventional treatment of acute recurrent rhinopharyngitis was compared. Homoeopathic treatment gave better results than antibiotics in terms of general medical effectiveness (the number of episodes of illness) with lower direct costs (88 Euros compared with 99 Euros) along with the need for significantly less sick leave (9.5% of parents of homoeopathically treated children took leave, compared with 31.6% of parents taking of children in the antibiotic group). In 2003, the same research group compared homoeopathic and allopathic treatments for anxiety disorder and both strategies were found to be equally effective, with the homoeopathic treatments offering potential cost savings (Trichard & Chaufferin, 2003).

Pomposelli et al. (2009) found similar positive outcomes from the homoeopathic treatment of diabetic neuropathy, with this study showing that while both groups achieved symptom improvements, only the homoeopathy patients had improvements that were significantly better than their baseline symptoms. In the homoeopathically treated group, quality of life measures showed improvement and the cost of conventional drugs decreased by 20%.

5.3. Reductions in expenditure on conventional drug treatments

Cost savings due to effective substitution of homoeopathic medicine for pharmaceutical drugs emerge in several studies. A homoeopathic GP compared the costs for 100 patients treated homoeopathically, with the costs for pharmaceuticals they would otherwise have required and demonstrated savings of sixty pounds sterling per patient (Jain, 2003). Patients were assessed using the Glasgow Homoeopathic Hospital Outcomes Measure, and 92

patients improved without any side-effects, demonstrating both clinical effectiveness and cost-effectiveness, along with the safety of homoeopathic medicine.

In a retrospective observational study in Tuscany, costs for two groups of patients with similar chronic respiratory complaints were surveyed over a four and a half year period (Rossi et al., 2009a). Chronic asthmatics in the homoeopathically treated group reduced their conventional drug expenses by 71.1% after the first year of follow-up, compared with a 12.3% increase in drug expenses for the conventionally treated group. The second year of treatment continued to produce cost savings for the homoeopathy patients: their costs were reduced by 54%, while the control group had a 45% increase in their costs of medicines. Similar patterns of significant reductions in drug costs were reflected in patients treated with homoeopathy for recurrent respiratory infections at the same hospital.

In a pilot project at the Royal London Homoeopathic Hospital, van Haselen (2000) evaluated the cost effectiveness of homoeopathic treatments and identified cost-savings through reductions in expenditure on conventional medicines. Here, 29% per cent of patients were able to cease conventional medicines, 33% reduced their reliance on conventional treatments and 32% per cent reported no change in other medications whilst on homoeopathic medicine.

UK economist Christopher Smallwood (2005) estimated that dramatic reductions in drug costs were possible if homoeopathic health care was to be offered as frontline treatment. Smallwood referenced the findings of a 1992 study by Swayne (1992) which compared the National Health Service prescribing costs of 22 GPs using homoeopathy with those using conventional drug therapies. The 12% reduction in prescription items under homoeopathic treatment identified by Swayne was extrapolated to national levels by Smallwood, who estimated that the number of prescription items would be reduced by 41.5 million if homoeopathic treatment was more widely available.

Similarly, another UK study by Sharples et al. (2003) found that cost savings are achieved through reduced reliance on pharmaceutical medicines. Questionnaires from 499 patients who had CAM treatment within the National Health Service were analysed. Of the 262 patients who had been taking prescription medicines at the commencement of treatment, 76 (29%) had stopped and 84 (32%) had reduced their intake as a result of that treatment. Sixty-three per cent of patients in this study had had their main complaint for more than five years and a 90% patient satisfaction rating of their clinical care was achieved. Improvements were rated very much improved, moderately improved or slightly improved in 380 (81%) of the 499 patients surveyed. The authors concluded that orthodox treatment

fails to meet the needs of some patients, and that CAM may wholly or partly substitute for conventional medicines.

5.4. Patient satisfaction measures high in homoeopathic care

Lowered costs and high ratings of patient satisfaction (95% fairly or very satisfied) characterised the outcomes of a large observational study of 80 homoeopathic practices in Belgium (van Wassenhoven & Ives, 2004). Seven hundred and eighty-two patients were surveyed, 78% of whom had ailments of sufficient severity to interfere with activities of daily life. More than half of these patients were able to discontinue one or more conventional drugs, and 89% reported that homoeopathy had improved their physical condition, assessments that were matched by similar physician ratings of patient improvement. Psychological symptoms mirrored the extent of physical symptom relief in this group of patients, and this simultaneous improvement in the physical and psychological state of homoeopathic patients is a characteristic of this form of medicine. These responses reflect the nature of holism in health care: a well-prescribed homoeopathic medicine addresses the whole state of the patient and achieves a response at that level. In the study by van Wassenhoven and Ives (2004), only 13% had improved under previous conventional treatment, compared with 89% who improved when treated homoeopathically. For 55% of these patients, their condition had worsened under previous conventional care.

Rodrigues-Neto et al. (2009) found that the main reason that patients sought homoeopathic care was the failure of conventional care. Seventy-three per cent of homoeopathic patients in this study were satisfied or very satisfied with their treatment, and for 70.2% of those treated homoeopathically, the cost of treatment was considered reasonable or cheap. Patient satisfaction was also rated as high in homoeopathy patients in the study by Marian et al. (2008), where 3,126 patients were surveyed in a primary care setting comparing homoeopathy with conventional care.

Studer and Busato (2011) reported that CAM therapies resulted in a better quality of the patient-physician relationship, lower costs and fewer adverse effects. In a 2011 study to identify the characteristics of a good doctor, by Kliems and Witt (2011) found that patient-centeredness, a holistic approach and the competence of the practitioner were all important factors for both patients and physicians, while the availability of time was important as a prerequisite for other physician qualities.

5.5. Reduced general practitioner consultations following homoeopathic care

A 45% reduction in GP consultations for homoeopathically treated patients was found in a review of complementary and integrative care at the Glasgow Homoeopathic Hospital. This research was conducted by the International Data Collection Centres for Integrative Medicine (1998), an evidence-based action research program for assessing and improving patient care. In this review of the care of very ill patients, 85% had health problems severe enough to cause major disruptions to activities of daily life: the study generated a range of very positive findings for the use of complementary and integrative health care for these patients whose problems had resisted orthodox treatment. These patients received a range of therapies, with 95% receiving homoeopathic treatment. The researchers concluded that an integrative approach to patient care “interrupts the cycle of escalating Health Service costs associated with these patients. In addition to [this] cost containment there is striking evidence of long term reductions in iatrogenesis and economic costs for a large proportion of these patients” (International Data Collection Centres for Integrative Medicine, 1998, p.2).

A 70% reduction in the need for GP consultations was a feature of findings by Sharples et al. (2003). While the costs of homoeopathic medications were not addressed in this study, preventing a direct cost comparison of each model of care, the study indicated the potential for very significant reductions in the demand for medical resources, both personnel and drugs, from the provision of homoeopathic care in general practice.

Reduced morbidity may reduce related health costs resulting from repeated demand for medical consultations, drug prescriptions, and time away from work or families. A study comparing the treatment of ear infections by either homoeopathy or conventional methods (Friese et al., 1997) found that only 5 (5%) of the 103 in the homoeopathically treated group required antibiotics. This group also had faster pain relief and fewer re-infections over the following year: 70% of the homoeopathic group had no recurrence over the following year, compared with a 56.5% recurrence rate in the conventionally treated group. The duration of pain in otitis media in the homoeopathic group was two days, compared with three days in the conventional group. This study, published in the *International Journal of Clinical Pharmacology*, concluded that homoeopathy should be the front line treatment in cases of childhood middle ear infections.

5.6. Lower costs of homoeopathic care across a range of measures

The findings of studies initiated by French health insurers suggest that homoeopathic treatment costs less than conventional approaches (Chaufferin, 2000; Trichard & Chaufferin, 2003). While some problems in evaluation of data were encountered in the Chaufferin (2000) study, it identified a range of cost benefits of homoeopathic medical care: homoeopathic medicines were found to be one-fifth to one-quarter of the cost of conventional drugs; health expenses from consultations with homoeopathic physicians were 42% below those of conventional practitioners; homoeopathic physicians claimed 38% less compensation for medical provisions and 45% less for medications; and homoeopathic physicians gave 68% fewer days off work to their patients.

In epidemiological studies of the use of homoeopathic prophylactic medicines in potential epidemic settings (Bracho et al., 2010; Marino, 2008), the response to homoeopathic interventions was markedly positive, suggesting that, at a population level, greater economic benefits are possible through homoeopathic treatments compared with usual vaccination programs. In San Paolo, Brazil, a protective effect was established from the use of a single dose *Eupatorium perfoliatum* 30c when given to 40% of a neighbourhood that is usually severely affected by dengue fever (Marino, 2008). Dengue fever incidence was reduced by 81.5% in the area treated with *Eupatorium* compared with neighbourhoods who did not receive the remedy.

Due to an insufficient supply of conventional vaccine, 2.5 million people in a region of Cuba prone to *Leptospirosis* infection were given the homoeopathic prophylactic against the disease (Bracho et al., 2010). This annually occurring epidemic has a high morbidity rate, even when conventional vaccines are given. While tens of thousands are usually infected each year, only 10 people in the treated area developed the infection after homoeopathic dosing in the 2007 season. The protective effect continued without re-dosing into the following season, with another reduction in disease incidence of 84% in 2008 amongst the population treated homoeopathically. The Cuban study noted the highly cost-effective nature of this intervention compared with conventional vaccine. The health benefits from homoeopathic preparations at a population level suggest marked economic benefit. In a RCT evaluating the treatment of malaria with individualised homoeopathy, van Erp and Brands (1996) found a response rate of 83% in the homoeopathically treated group compared with a response rate of 72% in the Chloroquine treated control group. It is likely that wide scale use of homoeopathy at population level would deliver substantial savings in public health provision.

In routine clinical care, physicians using homoeopathic medicine spend more time with their patients, resulting in higher consultation costs. This extra expense may be defrayed by the range of potential savings generated by homoeopathic health care provision. These include: reduced costs due to fewer pharmaceutical products; lower levels of diagnostic testing; reduced calls on the homoeopathic doctor and medical care in general over time due to the patient's improved health following treatment; and reductions due to the negligible incidence of side-effects of homoeopathic care. All of these factors may contribute to considerable potential savings using the homoeopathic model of health care.

6. Safety

6.1 Safety of homoeopathic medicines

Concern about toxicity led to the practice of diluting and the vigorous shaking of the medicinal substance referred to as succussion. This innovation by the founder of homoeopathy, Dr Samuel Hahnemann (1755–1843), continues as the principal *modus operandi* of homoeopathic pharmacology, which was controversial at the time of its inception and remains so today. Advocates and detractors of homoeopathy alike, however, concur that the repeated dilution of medicinal substances greatly reduces the likelihood of adverse reactions. This minimisation of potential toxicity is achieved through the careful preparation of homoeopathic medicines by specialist homoeopathic pharmacies worldwide.

Homoeopathic pharmacies are governed by local regulatory mechanisms that ensure appropriate conditions for the safe manufacture of homoeopathic medicines. The world-wide homoeopathic manufacturing industry adheres to internationally accepted homoeopathic pharmacopeia that provide protocols for the standardised preparation of these medicines (European Council for Classical Homeopathy, 2009). In Australia, the Therapeutic Goods Administration of the Federal Government has oversight of the conditions governing the manufacture of homoeopathic products (Therapeutic Goods Administration, 2012).

As demonstrated in the research evidence documented in section 4 above, homoeopathic medicines have biological effects, and therefore there is the potential for adverse effects. The relative safety of homoeopathic medicines is, however, frequently cited as a distinguishing feature of homoeopathy (Adler, 1999; Bornhöft et al., 2006; Dantas & Rampes, 2000; Grabia & Ernst, 2003; Thompson et al., 2004). The European Council for Classical Homeopathy (2009) undertook research into the safety of homoeopathic medicinal products and homoeopathic prescribing and concluded that, “current evidence seems to confirm the claim that [homoeopathic medicinal products] are safe to use and homoeopathic treatment provided by statutorily regulated or self-regulated homoeopaths is safe” (p.3).

When homoeopathic medicines are prescribed in a professional clinical setting, guided by the principles of similarity, potentisation and minimum dosing, adverse drug effects are generally avoided. The careful selection of a homoeopathic, most-similar, medicine targets the established response of the patient’s manifest symptoms and represents a complex form of personalised medicine that was developed well before contemporary innovations in genetic medicine (National Health and Medical Research Council, 2011). Based on the

principle of similarity, homoeopathy is thought to act through a process of reinforcing the body's inherent response: the most similar medicine in potentised form may therefore act to optimise the body's response to its pathology and so facilitates resolution of that pathology.

6.2. Homoeopathic remedy responses

A detailed knowledge of the therapeutic action of remedies derives from homoeopathic drug trials or *provings* (Dean, 2004) of medicines on healthy human subjects. This accumulation of medicinal information means that, in a given clinical situation, the action of a carefully prescribed medicine may be able to be predicted. While negative responses to homoeopathic medicines are not common (Posadzki et al., 2012), patients are informed of the typically short duration of any medicinally related effects should they occur and of management of symptoms, if required. These reactions are not the same as the side effects that are common in conventional medicine, but are the result of a particular interaction of the patient's whole state with the medicine most similar to that state. In the professional setting, potential responses to prescribed medicines are discussed with patients before treatment. Possible homoeopathic remedy reactions can be categorised as: an initial aggravation, a proving response or a return of old symptoms (Bell, 2008; Dhawale, 1967).

Whilst it is emphasised that these responses are not typical of everyday homoeopathic practice with remedy reactions which could be regarded as negative, it will be of interest to the reader that over 200 years of application, observation and empirical record of homoeopathic practice has provided an extensive knowledge base of the range of action of homoeopathic medicines. The theory derived from these observations is presented in sections 6.2.1 to 6.2.3.

6.2.1. Initial aggravation

It is within the ambit of homoeopathic laws that, in certain circumstances, a remedy response can provoke a temporary exacerbation of the presenting symptoms; referred to as an "initial aggravation". This phenomenon is most commonly mild and short-lived. These reactions may indicate systemic responses to the prescribed medicine, and may be regarded as signs of a positive response to the medicine; are rarely troublesome to the patient and are well-managed within the professional homoeopathic setting.

6.2.2. Proving response

The Homoeopathic Materia Medica has evolved from the accumulated knowledge of the capacity of homoeopathic potencies to elicit symptom responses from healthy individuals when medicines are repeatedly applied as part of a homoeopathic drug proving or homoeopathic drug trial (Dean, 2004). The capacity for a proving response to occur in a sensitive patient is clearly understood on the rare occasions that it may occur.

Highly sensitive patients, from whom a marked drug reaction such as a proving may be elicited, are identified from data derived via homoeopathy's very detailed case-taking. High sensitivity in a patient guides the choice of medicinal potency and frequency of use; both of these therapeutic strategies are employed to minimise potential reactions.

Despite these typical cautions, some highly sensitive patients may react by displaying a range of remedy effects similar to those emerging in a formal proving or homoeopathic drug trial of the medicine being administered. These effects are typically of very short duration and only rarely require a homoeopathic antidote or the recourse to other treatments. Similarly, if a prescribed medicine is taken very frequently over an extended period of time, a proving response may result. In the treatment of chronic conditions, remedy dosing may range from infrequent to more frequent depending on the degree and type of pathology, and in the treatment of acute conditions, repeat dosing usually occurs over a limited period of time for example three to four days, usually with instructions that the remedy be reduced or ceased as an improvement in symptoms occurs.

6.2.3. Return of prior symptoms

A return of prior symptoms after the application of a simillimum is a process described by Dr Constantine Hering (1800–1880) and known as Hering's Law. This retracing response is regarded as a positive indication of remedy's action and represents typically mild reprisal of symptoms experienced in earlier episodes of illness (Endrizzi et al., 2005; Swayne, 2002; Thompson et al., 2004). This process is understood to be an effect of the homoeopathic remedy activating a response, and is signalling an improvement in health.

6.3. Adverse events in homoeopathy

The potential remedy reactions described above are recognised as a potential feature of professional homoeopathic practice, but their occurrence is relatively rare. A limited number of studies have explored the incidence of adverse events in homoeopathy. A review of reports of adverse events conducted by Dantas and Rampes (2000) identified 19 clinical

trials, 19 case reports and 15 homoeopathic pathogenic trials or provings published from 1970–1995. In the clinical trials, the mean incidence of adverse events was 9.4 for homoeopathy groups, compared with 6.1 in the placebo groups. The authors concluded that adverse events in homoeopathy were comparable to placebo-induced adverse events, and were rare and transient in homoeopathic treatment.

A meta-analysis of 3,437 patients from 24 placebo-controlled RCTs from 1966–2002 showed only 63 (1.5%) adverse events for patients treated with homoeopathic medicines and 50 (1.5%) for the placebo group (Grabia & Ernst, 2003). The conclusion reached was that there was insufficient evidence to establish predictable homoeopathic aggravations.

Elsewhere, Cardinali et al. (2004) found that the repetition of low potencies of toxic substances may provoke systemic toxic effects. Prescriptions of low potency toxic substances are uncommon in professional homoeopathic care so that toxicity effects are extremely rare. The majority of medicines used in homoeopathic practice are in potencies beyond Avogadro's number, that is, where no molecules of the original substance remain.

A more recent study of adverse events was undertaken by Posadzki et al. (2012) who searched 378 articles published from 1978–2010. They identified 35 reports of possible adverse events in 1,142 patients, and in a further 17 cases, the withdrawal of conventional medicines may have resulted in indirect adverse events. In a case series involving the majority of these patients (1,070 patients), a causal relationship could not be clearly established. In 27 patients, a causal relationship “was almost certain” or “certainly” due to the medicines taken. Of these, the majority were allergic or toxicity effects; in three of these patients, however, the mode of causation of an adverse event was unclear.

In nine patients cited by Posadzki et al. (2012), substitution or neglect of conventional care was “almost certain” or “certainly” the cause of adverse events. In 46 patients, a causal relationship was considered “likely”, but in 12 of these, there was no explanation of potential reasons which could establish a causal relationship. In 94.7% of cases, the dilutions involved were in the molecular finite range, which is unavailable for sale in Australia under the Therapeutic Goods Administration regulations. In Posadzki, et al (2012) the authors concluded:

Our review ... is thus not comprehensive. Crucially, it does not tell us anything about the incidence of adverse events. Considering the widespread use of homoeopathy worldwide and the relative paucity of the reported adverse events, it might be very low (p.1187).

Posadzki's team surveyed the global homoeopathic literature over a 32 year period, during which in excess of a billion homoeopathic treatments may have occurred. While it is likely

that many more adverse events occur in both conventional and homoeopathic medicine than are reported, the incidence of homoeopathic adverse events identified by Posadzski was low. In contrast, it was reported that 20% of the UK National Health Service drug bill is spent treating adverse events resulting from the prescription of conventional medicines (Bruck, 2012).

Observational studies by the European Council for Classical Homoeopathy to examine the incidence of adverse events found that, while adverse events can occur, no serious adverse events were found (European Council for Classical Homeopathy, 2009). Tables summarising the literature review of adverse events and homoeopathic aggravations by the European Council for Classical Homoeopathy provide the reader with a comprehensive overview of research in this field. The tables are reproduced here with permission.

Table 4. Observational studies published after 1995 considering possible adverse events and homoeopathic aggravation (studies older than 10 years are highlighted)

Author	Study design	Sample size	Indication	Homeopathic treatment	Adverse events	Homeopathic aggravation
Anelli et al. (2002)	Prospective multi-centre observational	1025 6 countries	All complaints	Individualised	2.7%	33.2%
Endrizzi et al. (2005)	Prospective observational	335	All complaints	Individualised	2.68%	26.3%
Everett et al. (2005)	Prospective observational	31	Postoperative complications	Unclear	None	Not specified
Güthlin et al. (2004)	Prospective observational	900	All complaints	Unclear	7.4%	(incl. in AE)
Haidvogel et al. (2007)	Prospective parallel group comparative	857	Acute respiratory and ear complaints	Individualised	3.1% 2.0% ¹	Not specified
Jain (2003)	Prospective observational	109	All complaints	Individualised	1 case	Not specified
Keil et al. (2008)	Prospective parallel group comparative	118	Eczema	Individualised	None	Not specified
Lacroix et al. (2005)	Prospective comparative	18	Effects on newborn children receiving breast milk	Unclear	None	Not specified
Li et al. (2003)	Prospective observational	13	Asthma	Isopathy	None	
Molassiotis et al. (2005a)	Descriptive cross-sectional survey on CAM therapies in general (incl. homoeopathy)	126	Colorectal cancer	Unclear	None for homoeopathy 1 patient for other CAM	

Author	Study design	Sample size	Indication	Homeopathic treatment	Adverse events	Homeopathic aggravation
Molassiotis et al. (2005b)	Descriptive cross-sectional survey on CAM therapies in general (incl. homoeopathy)	956	Cancer	Unclear	None for homoeopathy 4.4% for other CAM	
Pomposelli et al. (2003)	Prospective	55	Arthritis/rheumatism osteoporosis	Unclear	None	30.8%
Reilly (2005)	Unclear	1000	Acute complaints	Unclear	2%	Not specified
Riley et al. (2001)	Prospective parallel group comparative	281	RTI, allergies and ear complaints	Individualised	7.8%	Not specified
Schmiedel and Klein (2006)	Prospective parallel group comparative	397	Common cold	Complex HMP	None	Not specified
Sevar (2005)	Prospective observational	455	All complaints	Individualised ²	2 patients	Not specified
Thompson and Reilly (2002)	Prospective observational	100	Cancer	Individualised	None	17%
Thompson et al. (2004)	Prospective observational	116	All complaints	Individualised	11%	24%
Trichard et al. (2004)	Prospective parallel group comparative	268	Acute rhinopharyngitis	Individualised	4.9%	Not specified
Trichard et al. (2005)	Prospective parallel group comparative	241	Recurrent acute rhinopharyngitis	Individualised	4.6%	Not specified

¹ Results were separated out for adults/children

² Presumed individualised based in description of results

Reproduced with permission from *The Safety of Homoeopathy* , European Council for Classical Homoeopathy , page 14. Copyright © 2009 by European Council for Classical Homoeopathy .

Table 5. Experimental studies published after 2003 considering possible adverse events from homoeopathic treatment

Author	Study design	Sample size	Indication	Homoeopathic treatment	Adverse events
Brinkhaus et al. (2006)	Randomised, double-blind placebo-controlled	227	Recovery after knee surgery	Single remedy	Low No difference to placebo
Frass et al. (2005b)	Randomised, double-blind placebo-controlled	70	Severe sepsis knee surgery	Individualised	None No interference with conventional treatment
Furuta et al. (2003)	Randomised, double-blind placebo-controlled	40	Obstructive adenoid knee surgery	Three remedies	None
Jacobs et al. (2005a)	Randomised, double-blind placebo-controlled	83	Hot flashes after conventional cancer treatment	Individualised	None Transitory
Jacobs et al. (2005b)	Randomised, double-blind placebo-controlled	43	ADHD knee surgery	Individualised	None
Katz et al. (2005)	Randomised, double-blind placebo-controlled (homoeopathy, Fluoxetine, placebo)	6	Depression	Individualised (max. 30 remedies)	None
Kim et al. (2005)	Randomised, double-blind placebo-controlled	40	Seasonal allergic rhinitis	Potentised pollen	None
Stevenson et al. (2003)	Randomised, double-blind placebo-controlled	62	Prevention of pain and bruising in hand surgery	Single remedy	Similar to placebo ¹
Thompson et al. (2005)	Randomised, double-blind placebo-controlled	53	Symptoms of oestrogen withdrawal in breast-cancer survivors	Individualised	No difference to placebo
White et al. (2003)	Randomised, double-blind placebo-controlled	96	Childhood asthma oestrogen withdrawal in breast-cancer survivors	Individualised	Similar to placebo ²

¹ Placebo (3): heartburn, sore throat, flu-like symptoms, faintness, headache. Arnica 30C (4): feeling unhappy/low, dry mouth, headache, feeling throbbing in head/neck. Arnica 6C (2): drowsiness, sore tongue

² Cases of AE: homoeopathy 13, placebo 10

Reproduced with permission from *The Safety of Homoeopathy*. European Council for Classical Homoeopathy, page 15. Copyright © 2009 by European Council for Classical Homoeopathy .

6.4. Professional education of homoeopaths in Australia

AROH's registrants must satisfy the Register's requirement regarding minimum levels of education, which is currently an Advanced Diploma of Homoeopathy, continued professional education and adherence to the professional ethics and standards of the organisation (see www.aroh.com.au). AROH stipulates that reasonable duty of care demands medical referral of patients with clinical indicators. Homoeopathic education in

Australia contains educational components designed to minimise the potential risks which might otherwise arise through substitution or neglect of conventional care. University-based education for professional homoeopaths would further improve the delivery of quality care for patients, and it is regrettable that bodies such as the Friends of Science in Medicine (MacLennan & Morrison, 2012) deride the homoeopathic profession and express concern about patient safety, whilst simultaneously lobbying to limit the access of this profession to university-based higher education.

6.4.1. The homoeopathic profession: support for improved education and training

The Australian homoeopathic profession has been actively improving the standards of education and training in homoeopathy during the past twenty years, and was the first of the CAM therapies to self-fund the development of nationally formulated and accepted competency standards (Homoeopathic Industry Reference Group, 1999). While homoeopathic practice across the globe is most commonly undertaken by medical practitioners, the majority of homoeopaths in Australia are professional homoeopathic practitioners. The safest and most effective use of homoeopathic medicine depends upon the depth and rigor of practitioner education and training.

During the 1990s, the Australian homoeopathic profession began a lengthy process of consultation and development in the area of education and training, towards the goal of producing Australian homoeopaths capable of the highest practitioner standards. In 1994, the profession united under the banner of the Homoeopathic Industry Reference Group. With the support of the Australian National Training Authority and the National Community Services and Health Industry Training Advisory Board, the Homoeopathic Industry Reference Group developed the National Competency Standards for homoeopathic education in Australia (Homoeopathic Industry Reference Group, 1999).

A four-year full time Advanced Diploma of Health Science (Homoeopathy) (CNF82) was being delivered in a number of the Vocational Education and Training organisations in 1994. The National Competency Standards published in 1999 incorporated and expanded the content of CNF82. This was integrated into the first Health Training Package HLT02 in 2002, as the unendorsed component of the training package. HLT60602, the Advanced Diploma of Homoeopathy superseded CNF82. The current training package is HLT07 containing the Advanced Diploma of Homoeopathy: HLT606012. The introduction of training packages has seen a regrettable erosion in course delivery time, developments that AROH vigorously resisted as the course can now be delivered in 2.5 years full-time study.

AROH accredited courses deliver the current training package in three years and comply with the unendorsed component of the training package. AROH participates in regular reviews of the National Training Package. These reviews are conducted by the Community Service and Health Industry Skills Council.

AROH assesses the qualifications and training of overseas trained homoeopaths through VETASSESS. For a graduate or overseas trained homoeopath to become an AROH registrant, the following is required:

- satisfy minimum levels of education (currently an Advanced Diploma in Homoeopathy)
- comply with the triennium continued professional development requirements
- adhere to the professional ethics and standards of practice outlined by AROH
- maintain appropriate levels of professional indemnity insurance
- hold current qualifications in Senior First Aid.

Registered Training Organisations within the Vocational Education and Training and Higher Educational sectors delivering courses which AROH assesses for course accreditation must include components of the current training package designed to minimise risks, which might otherwise arise through substitution or neglect of conventional care. Neglect of conventional care is a common risk factor for patients using CAM therapies (Harvey, 2012a). Anecdotal experience of homoeopathic practice in Australia informs the profession that patients seeking homoeopathic care do so to complement conventional medical care, rather than as substitute care. The Swiss study undertaken by (Bornhoft & Matthiesen, 2012) found that fewer than 6% of patients were likely to rely solely on homoeopathic care.

Undergraduate degrees in homoeopathy are currently offered by private providers. University-based education for professional homoeopaths is a goal towards which the profession aspires, and which the community appropriately expects of health-care professionals. Access to university-based education for homoeopaths would further enhance patient care and provide important pathways for graduate research in the field of homoeopathy. Many Australian homoeopaths currently pursue higher degrees and research opportunities within mainstream institutions, improving the human resources of the homoeopathic community and furthering the standards of patient care.

7. Ethical Considerations

7.1. Friends of Science in Medicine

The debate around the science of CAM, or indeed what comprises science and good medicine, frequently provokes passionate argument. Towards the end of 2011, a group of doctors, medical researchers and scientists united to form a lobby group, Friends of Science in Medicine. An early task of the FSM was an open letter to the private health funds. This letter demanded that the insurers confirm "... that you will withdraw insurance support for all modalities which the CMO determines to lack an evidence base". This letter then added that the health insurer's response will be posted on the Friends of Science in Medicine website.

This very directive letter demands an intrusion into the contractual relationship between the private health funds and their members. Democracy affords its citizens the right to choose their particular health insurance: they should also expect to have the right to choose health cover for the treatment modalities of their choice.

The lobby group FSM states that the health insurers support for CAM, "... frequently delay[s] correct diagnosis and effective treatment, resulting in unnecessary morbidity and expenditure, something insurers would wish to avoid". This statement, made without any supporting evidence, is extremely concerning to AROH and we expect that those conducting this inquiry will share this concern. The Friends of Science in Medicine lobby group asserts that people choosing CAM therapies are at increased risk of ill-health because of the choice they make, when available evidence – some of which is detailed in this submission – suggests that the opposite is the case.

The findings of a review conducted in New Zealand are of interest in this context. In 2006, the New Zealand Government asked Dr William Bain, pharmacist and coroner, to research and review Coronial records to identify whether complementary medicines, natural and traditional products, supplements and vitamins together with prescription and other drugs, had been involved in Coronial Inquests and deaths.

Dr Bain reported on an Australian study which showed that 10% of patients presenting to a GP had an adverse drug event in the preceding six months with 50% being in the moderate to severe range and 8% hospitalised as a result. A 2006 New Zealand study showed that one-third of hospital admissions were avoidable. The associated costs at just one Christchurch hospital were estimated at \$96.6 million (Bain, 2006). Other studies showed that prescription drug errors double a person's risk of dying in hospital with costs

estimated at 2 billion a year. After an exhaustive investigation of the records, Bain concluded:

What is ironic here is that what is being held out as a justification for high regulation and compliance in the area of Complementary Medicines, Natural Products, Traditional Products, Supplements, Vitamins etc, is public safety and risk. Despite a diligent search of Coronial records and the literature, no instances have been found to demonstrate that in fact with these products in NZ there is any serious public health issue or risk to the public. The problem is clearly with prescription and other drugs and no demonstrable risk at all with these natural products ... The Coronial and literature searches in so far as natural products etc are concerned and linkages to public safety and risk can be described legally as *De minimis non curat lex*. That is-- of minimal risk importance. The law (regulations etc) does not and should not concern itself with trifles (Bain, 2006).

Lobby groups such as Friends of Science in Medicine argue that CAM therapies should demonstrate an evidence base for their practices, while simultaneously arguing that they have no place in public educational institutions. Such educational opportunities are pre-requisite to building a research-skilled workforce in the CAM sector. Myers et al. (2012, pp.69-70) argue in favour of the legitimacy of the inclusion of complementary medicine in the curricula of universities. They suggest that if these courses were removed from a tertiary setting it would not result in a reduced demand for complementary health practices but could well diminish the educational rigour of these courses, thus affecting the quality of the services offered to the consumer.

The following statement appears on the Friends of Science in Medicine website:

[Friends of Science in Medicine] is hoping to influence universities (at least the reputable ones) to declare their support for science courses that are in fact evidence-based and adhere to accepted scientific methodology. It will then have a go at trying to influence the government, which helps fund these courses and uses taxpayers' money to allow health fund rebates for "treatments" with these demonstrably ineffective pseudoscientific therapies.

A declared conflict of interest is acknowledged by one member of Homoeopathy Working Committee, who was until recently a member of Friends of Science in Medicine. AROH has raised the question of what measures are to be taken to deal with this acknowledged conflict of interest in relation to the Review.

It can be argued that a key purpose of universities is to offer a range of ideas which reflect of diversity of the community in which they are situated, and that this breadth of ideas is as necessary for the survival of knowledge as genetic diversity is to the survival of a

species. If universities are charged with finding creative new ways to apply knowledge, then authoritarianism, corporatism and political correctness may be principal enemies of this endeavour (Bowen & Schwartz, 2005).

Friends of Science in Medicine wrote an open letter to those universities offering chiropractic degrees questioning, "... whether or not modern chiropractic concepts and techniques taught at your institution are, in fact, evidence-based and could meet the government's requirements" (Friends of Science in Medicine, 2012). The wisdom of the push to exclude chiropractic and other CAM therapies from universities and the lobbying by Friends of Science in Medicine to remove tax rebates for these therapies has been questioned by some.

Acknowledging that science by its very nature is often a battleground of contentious views vying for possession of the truth, some doctors point out the precarious connection between knowledge and power and note that, "... the risk is always present that those who command the dominant theories or ideologies will rely on their positions of influence to overcome those who oppose them". Physician and health care ethicist, Professor Paul Komesaroff urges caution in relation the actions of pressure groups, "what concerns us is a politicised process to apply pressure on governments and educational institutions to act in accordance with the views or convictions of one particular group" (Komesaroff et al., 2012). This perspective was reflected in a recent lecture by Sir Paul Nurse (2013) who offered his prescription for appropriate protocols for the provision of scientific advice to policy-makers. Nurse, current President of the Royal Society of London, stated that such advice should be as free as possible from political and ideologically motivated concerns and that "bombastic" views may arise from those who already perceive that they have lost the scientific argument.

Lobbying by the Friends of Science in Medicine group about the legitimacy of including CAM therapies in the curricula of universities provoked an initial flurry of support for this view. It is apparent that some of the original supporters have re-considered their membership and, like the president of the Australian Medical Association, Dr Steve Hambleton, have withdrawn their support (Schwager, 2012). Dr Hambleton believes the issue has become "much fuzzier and less clear", and that rather than a complete shutdown, these courses should be judged on their individual merit. He said, "It's too big a sledgehammer", and while caution should be used to guide giving a scientific imprimatur to such courses, he stresses the need for an open-minded approach (Moynihan, 2012).

Good science is dependent on both historical and cultural mores and has always developed from these bases and not necessarily incrementally (Myers et al., 2012). Myers et

al. remind us that science does not occur in isolation, but is a social phenomenon that reflects both the society in which it develops and the power and control of those funding scientific endeavour.

The motivations of the doctors and scientists orchestrating the campaign against CAM demand some examination. It is reasonable to enquire why this cohort of medical and other scientists who generally occupy positions of power and prestige bother to attack the relatively small and underfunded cluster of natural medicine courses (Schwager, 2012) and similarly why they pursue the miniscule amount of Government expenditure on health insurance tax rebates for CAM therapies (0.08% of all tax rebates for those privately insured).

It has been shown in this Submission that the numbers of homoeopathic professionals and homoeopathic medical doctors has grown considerably in many countries of the world over the past 30 years, and that there has been considerable growth in the sales of homoeopathic and other health care products (Banerjee et al., 2010b; Bhattacharjee et al., 2009; Biswas & Khuda-Bukhsh, 2004; Biswas et al., 2005; Bracho et al., 2010; Datta et al., 1999; Datta et al., 2001; de Souza Nunes, 2008; Frenkel et al., 2010; Guimarães et al., 2009; Khuda-Bukhsh et al., 2011b; Kumar et al., 2007; Marino, 2008; Mroninski et al., 2001; Pathak et al., 2003; Pathak et al., 2006; Sunila et al., 2007). Research work in mainstream science and medicine relies substantially on investment by the pharmaceutical industry. It is possible that the growth and development of the economic base of the CAM sector raises concern in some quarters in the medical and scientific community, perhaps particularly those whose interests may be served by protecting the market share of powerful financial supporters.

The pharmaceutical industry may feel the need to protect its interests from viable alternatives, including homoeopathy. Surveys of patients who consult with homoeopathic practitioners have established that the majority are satisfied with their choice (Adler, 1999; Cairo et al., 2001; Goldstein & Glik, 1998; Marian et al., 2008; Rodrigues-Neto et al., 2009; van Wassenhoven & Ives, 2004; Vincent et al., 2012). A number of investigations have also revealed that patients choose to use homoeopathy after conventional medicine has failed to meet their needs, and for some of these patients, homoeopathy succeeds (Goldstein & Glik, 1998; Marian et al., 2008; Rodrigues-Neto et al., 2009; Sevar, 2005; van Wassenhoven & Ives, 2004). The patients who seek homoeopathic services are not a broad sample of the ill population: demographic analyses show the majority are likely to be well educated and from higher income groups. These patients have either learned, from anecdotal evidence provided by family and friends, to trust non-mainstream health care options, or they may

have actively sought complementary treatment following dissatisfaction with treatment received in conventional medical care.

7.2. The NHMRC, the Natural Therapies Review Advisory Committee and the process of the inquiries into homoeopathy

It appears the NHMRC had not conducted an investigation of its own into homoeopathy before declaring that the practice of homoeopathy was unethical (Medew, 2012). This announcement detailed the intention of the NHMRC to develop a position statement on homoeopathy. The influence of the dubious research of Shang et al. (2005) and of the much-criticised work of the UK House of Commons Science and Technology Committee was clear in the NHMRC pronouncement. Problems with these reports have been recorded in Submissions by the Australian homoeopathic profession to the NHMRC during 2011 (see Appendices 1 and 3). The NHMRC website states that “examining alternative therapy claims” has been part of its 2010–2012 strategic plan, and the NHMRC had an allocated amount of “almost \$69 million provision of funds for complementary medicine research.” None of these funds were directed at research in homoeopathy, and it was clear that the NHMRC, Australia’s leading medical science research body, had allowed itself to be informed by research of dubious quality and by recommendations arising from that research which failed to gain the support of the UK Parliament.

Best scientific practice would have demanded consultation with experts in the field under investigation (Nurse, 2013), yet no such experts were engaged before these declarations, and none have been engaged since to assist the work of the current review into natural therapies. Neither the NHMRC Homoeopathy Working Committee nor the Natural Therapies Review Advisory Committee for the Department of Health and Ageing has homoeopathic researchers or any expert practitioners as a sitting member. It is of interest that, in the absence of any publically funded research into homoeopathy in Australia, a specific Working Committee has been established for homoeopathy. AROH is unaware of the creation of committees for other natural therapies modalities under investigation. The homoeopathic community is concerned that homoeopathy has been singled out for particular attention.

The review into private health insurance rebates currently underway was initiated at the time of the May 2012 budget, although AROH was formally notified of this inquiry only at the end of November 2012. AROH as the peak body in Australia for homoeopathy was then given one month to prepare a submission for this Review. This was clearly an

inadequate timeframe in which to respond to a review which has major ramifications for the profession, a time-frame made more difficult because it coincided with the pre-Christmas period; the extensions subsequently given by the office of CMO were essential.

Our understanding is that this Submission to the Natural Therapies Review Advisory Committee will be directed to the NHMRC's Homoeopathy Working Committee, which will define the nature of a literature review of homoeopathy to be carried out by OPTUMInsight. OPTUMInsight will report back to the Homoeopathy Working Committee, which will, in turn, report to the NHMRC Council which will then report to the Natural Therapies Review Advisory Committee.

AROH has emphasised the importance of expert advice in the conduct of scientific inquiries, and the particular importance of such advice in the highly specialised field of homoeopathy. Although one member of the Homoeopathy Working Committee is a pharmacist with some knowledge of acute homoeopathic prescribing, AROH is unaware whether this person has clinical or research experience with homoeopathy. This Submission has described the nature of homoeopathic practice which demands research protocols sensitive to its patient-centred (not disease-centred) focus. Because of these characteristics, particular to homoeopathy, a review of homoeopathic research involves matters that an experienced homoeopathic clinician or researcher would be able to clarify, and which would readily escape the attention of non-homoeopathic specialists. As noted in the discussion of the methodology of systematic reviews (Charlton, 1996), specific knowledge of the area under investigation is essential. OPTUMInsight may lack personnel with such specialized knowledge and experience. No member of the Natural Therapies Review Advisory Committee (including the natural therapy association representatives) has a detailed understanding and experience in the practice of homoeopathy, which would properly equip informed comment on the NHMRC report. The absence of specialist personnel at all report writing levels of this Review is a matter of a failure of appropriate process in the conduct of a scientific inquiry (Nurse, 2013) and raises concerns about its basis in terms of ethics, as well as foundation of the inquiry's capacity to fulfil its task.

8. Conclusions

The role of the Natural Therapies Review Advisory Committee is to consider the report from the NHMRC and assess the information contained in the report of the Submissions in the context of the wider community, taking into account not only the scientific perspective summarised by the NHMRC, but also other scientific, ethical, economic, social, industrial and political realities, so that they are in a position to provide sound advice to the Government.

When seen in context, this review is concerned with the relatively small amount of money provided by the federal Government through rebates for homoeopathic consultations. This modest outlay, which can now be seen in the light of the evidence provided in this Submission as a highly cost-effective and sound method of health care providing a wise investment of public monies, and a positive contribution to community health care. These modest outlays may be compared with the massive expenditures made through Medicare Australia, the Pharmaceutical Benefits Scheme and other publically funded allied health provisions, the demand for all of which are potentially considerably reduced in relation to those patients receiving homoeopathic treatment.

This Submission has provided evidence of efficacy across a range of applications of homoeopathy, and shown that homoeopathy can be effective for over 70 pathologies. In pharmaceutical research, well over 90% of trials fail to bring a product to market: compared with these outcomes, the number of positive results in homoeopathic trials is impressive. If it is claimed that homoeopathy is ineffective because a number of trials fail to prove efficacy or cost utility, one would similarly be required to claim that pharmaceutical medicine also lacks both efficacy and cost effectiveness. Homoeopathy, especially in its individualised application, exemplifies the paradigm of person-centred medicine as discussed by di Sarsina et al. (2012). The person-centred nature of homoeopathic practice along with its clinical effectiveness, are two core qualities at the heart of the resurgence of homoeopathy over the past 40 years. While a highly skilled practice, homoeopathy provides a relatively low-cost avenue to improve the health of people who are prepared to enter into a therapeutic relationship of this type. Homoeopathy is both therapeutically effective for presenting complaints, as well as having preventative potential, as evidenced in the material provided in this Submission. Patients have a right to choose their own therapeutic care and are themselves best placed to make such decisions.

If the Government decides to withdraw the tax rebate for CAM therapies, they may expect a backlash from the users of these therapies. Homoeopathic patients, when told of this Review, have expressed such things as disbelief to outrage; about the possible interference in their ability to get insurance coverage for the health care of their choice. Patients have expressed concern to bewilderment that a modality which helps to keep them well and is preventative in nature, is not seen as a positive healthful choice, and as essentially cost-saving in both individual and community terms.

Although the Federal Government may achieve minor short-term savings from the removal of the rebate for homoeopathy services, this Submission has shown that this decision may result in net losses to government through increased health expenditures and loss of revenue. Expenditure increases would arise from a range of sources including increased use of Medicare funded services and Pharmaceutical Benefits Scheme listed drugs, from increased work leave and related costs and from a likely reduction in taxation revenue from the homoeopathic sector.

Homoeopathy is an art and a science – one which privileges its practitioners to share in patient's healing journeys. This Submission ends therefore, not with more trials, facts or figures, but with the words of a homoeopath describing the therapeutic relationship:

The action of the homeopathic medicine was intimately woven with the relationship that I had with her as a therapist. It is impossible to separate these two influences. That is what makes it very difficult to evaluate homeopathic medicines along the lines of pharmacotherapy, where this separation between the therapist and medicine is seen as essential (van Hoogtem, 2007).

Acknowledgements

The following people have been instrumental in the writing and development of this Submission: Dr Nick Goodman, Ana Lamaro, Snéhi Jarvis and Julia Twohig.

Other contributors to this Submission were: Anne MacFarlane, Shashi Reddy, Gabrielle Brodie, Monica Dunne, Dr Michael Kuzeff, Jim Veljanovski, Robert Medhurst, Dr Michael Weir, Angela Jann and the Australian Homoeopathic Association.

Edited by Dr Gillian Dite.

References

- Aabel S (2000). No beneficial effect of isopathic prophylactic treatment for birch pollen allergy during a low-pollen season: a double-blind, placebo-controlled clinical trial of homeopathic Betula 30c. *British Homoeopathic Journal*; 89(4): 169-173.
- Aabel S (2001). Prophylactic and acute treatment with the homeopathic medicine, Betula 30c for birch pollen allergy: a double-blind, randomized, placebo-controlled study of consistency of VAS responses. *British Homoeopathic Journal*; 90(2): 73-78.
- Aabel S, Laerum E, Dolvik S, Djupesland P (2000). Is homeopathic 'immunotherapy' effective? A double-blind, placebo-controlled trial with the isopathic remedy Betula 30c for patients with birch pollen allergy. *British Homoeopathic Journal*; 89(4): 161-168.
- Adler M (1999). Efficacy and safety of a fixed-combination homeopathic therapy for sinusitis. *Advances in Therapy*; 16(2): 103-111.
- Adler UC, Paiva NM, Cesar AT, Adler MS, Molina A, Padula AE, Calil HM (2011). Homeopathic Individualized Q-Potencies versus Fluoxetine for Moderate to Severe Depression: Double-Blind, Randomized Non-Inferiority Trial. *Evidence-Based Complementary and Alternative Medicine*; 2011: 520182.
- Albertini H, Goldberg W, Sanguy B, Toulza CL (1985). Homeopathic treatment of dental neuralgia by Arnica and Hypericum. *Journal of the American Institute of Homeopathy*; 3: 126-129.
- Alibeu JP, Jobert J (1990). Aconit en dilution homeopathique et agitation post-opératoire de l'enfant (Aconite in homeopathic relief of post-operative pain and agitation in children). *Pédiatrie*; 45(7-8): 46546-46546.
- Ammerschlag H, Klein P, Weiser M, Oberbaum M (2005). Behandlung von entzündungen im bereich der oberen atemwege -- Vergleich eines homöopathischen komplexpräparates mit xylometazolin (Treatment of inflammatory diseases of the upper respiratory tract -- comparison of a homeopathic complex remedy with xylometazoline). *Forschende Komplementärmedizin und Klassische Naturheilkunde*; 12(1): 24-31.
- Andrade LE, Ferraz MB, Atrá E, Castro A, Silva MS (1991). A randomized controlled trial to evaluate the effectiveness of homeopathy in rheumatoid arthritis. *Scandinavian Journal of Rheumatology*; 20(3): 204-208.
- Andrews G, Peter E, Hammond R (2003). Receiving money for medicine: some tensions and resolutions for community-based private complementary therapists. *Health and Social Care in the Community*; 11(2): 155-167.
- Anelli M, Scheepers L, Sermeus G, van Wassenhoven M (2002). Homeopathy and health related quality of life: A survey in six European countries. *Homeopathy*; 91(1): 18-21.
- Attena F, Toscano G, Agozzino E, Del Giudice N (1995). A randomized trial in the prevention of influenza-like syndromes by homeopathic management. *Revue d'Épidémiologie et de Santé Publique*; 43(4): 380-282.
- Australian Government 2005, *Government Response to the Recommendations of the Expert Committee on Complementary Medicines in the Health System* Commonwealth of Australia, Canberra.
- Australian Institute of Health and Welfare 2011, *Public health expenditure in Australia, 2008-09, Health and Welfare Expenditure Series, Number 43*, Australian Institute of Health and Welfare, Canberra.
- Badulici S, Chirulescu Z, Chirila P, Rosca A (1994). Zinc: Immunoglobulin relationship in patients with cirrhosis of the liver before and after treatment with Zincum metallicum 5cH. *British Homoeopathic Journal*; 83(2): 93.

- Bagai U, Rajan A, Kaur S (2012). Antimalarial potential of Nosode 30 and 200 against *Plasmodium berghei* infection in BALB/c mice. *Journal of Vector Borne Diseases*; 49(2): 72-77.
- Baggoley C 2012, *Australian Government reviews private health insurance rebate for natural therapies*, *Healthy Voices*, Consumers Health Forum of Australia
- Baillargeon L, Drouin J, Desjardins L, Leroux D, Audet D (1993). Les effets de l'Arnica Montana sur la coagulation sanguine. Essai clinique randomisé (The effects of Arnica Montana on blood coagulation. Randomized controlled trial). *Canadian Family Physician*; 39: 2362-2367.
- Bain W (2006). *Report to IM Health Trust: Complementary Medicines, Natural Products, Traditional Products, Supplements, Vitamins etc.*, Lamb, Bain & Laubscher, New Zealand, viewed Feb 20 2013, <<http://www.newmediaexplorer.org/sepp/BainReport2006.pdf>>.
- Baker DG, Myers SP, Howden I, Brooks L (2003). The effects of homeopathic *Argentum nitricum* on test anxiety. *Complementary Therapies in Medicine*; 11(2): 65-71.
- Baldwyn E (2010). *Science and Technology Committee*, The British Homeopathic Association, viewed Feb 6 2013, <<http://www.britishhomeopathic.org/>>.
- Balzarini A, Felisi E, Martini A, De Conno F (2000). Efficacy of homeopathic treatment of skin reactions during radiotherapy for breast cancer: a randomised, double-blind clinical trial. *British Homoeopathic Journal*; 89(1): 8-12.
- Bandyopadhyay B, Das S, Sengupta M, Saha C, Das KC, Sarkar D, Nayak C (2010). Decreased intensity of Japanese encephalitis virus infection in chick chorioallantoic membrane under influence of ultradiluted belladonna extract. *American Journal of Infectious Diseases*; 6(2): 24-28.
- Banerjee A, Chakrabarty SB, Karmakar SR, Chakrabarty A, Biswas SJ, Haque S, Das D, Paul S, Mandal B, Naoual B, Belon P, Khuda-Bukhsh AR (2010a). Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy encouraging results of a preliminary study. *Evidence-Based Complementary and Alternative Medicine*; 7(1): 129-136.
- Banerjee A, Pathak S, Biswas SJ, Roy-Karmakar S, Boujedaini N, Belon P, Khuda-Bukhsh AR (2010b). *Chelidonium majus* 30C and 200C in induced hepato-toxicity in rats. *Homeopathy*; 99(3): 167-176.
- Barnes J, Resch KL, Ernst E (1997). Homeopathy for postoperative ileus? A meta-analysis. *J Clin Gastroenterol*; 25(4): 628-633.
- Barvalia P (2011). Autism spectrum disorder: Holistic homeopathy. *Homeopathic Links*; 24(2): 31-38.
- Bawden S (2012). Running an NHS community homeopathy clinic - 10-year anniversary 2001-2011. *Homeopathy*; 101(1): 51-56.
- Beer AM, Heiliger F (1999). *Caulophyllum D4 zur geburtsinduktion bei vorzeitigem blasensprung - Eine doppelblindstudie* (Randomized, double-blind trial of caulophyllum D4 for induction of labor after premature rupture of the membranes at term). *Geburtshilfe und Frauenheilkunde*; 59(9): 431-435.
- Bell I (2008). The evolution of homeopathic theory-driven research and the methodological toolbox. *American Homeopath*; 14: 56.
- Bell IR, Howerter A, Jackson N, Aickin M, Baldwin CM, Bootzin RR (2011). Effects of homeopathic medicines on polysomnographic sleep of young adults with histories of coffee-related insomnia. *Sleep Medicine*; 12(5): 505-511.
- Bell IR, Lewis DA, 2nd, Brooks AJ, Schwartz GE, Lewis SE, Walsh BT, Baldwin CM (2004). Improved clinical status in fibromyalgia patients treated with individualized homeopathic remedies versus placebo. *Rheumatology (Oxford)*; 43(5): 577-582.

- Bellavite P, Conforti A, Marzotto M, Magnani P, Cristofolletti M, Oliosio D, Zanolin ME (2012). Testing homeopathy in mouse emotional response models: pooled data analysis of two series of studies. *Evidence-Based Complementary and Alternative Medicine*; May 2012 [Epub].
- Bellavite P, Magnani P, Zanolin E, Conforti A (2011). Homeopathic doses of gelsemium sempervirens improve the behavior of mice in response to novel environments. *Evidence-Based Complementary and Alternative Medicine*; Sep 2009 [Epub].
- Bellavite P, Ortolani R, Pontarollo F, Piasere V, Benato G, Conforti A (2006a). Immunology and homeopathy. 4. Clinical studies - Part 1. *Evidence-Based Complementary and Alternative Medicine*; 3(3): 293-301.
- Bellavite P, Ortolani R, Pontarollo F, Piasere V, Benato G, Conforti A (2006b). Immunology and homeopathy. 4. Clinical studies - Part 2. *Evidence-Based Complementary and Alternative Medicine*; 3(4): 397-409.
- Bellavite P, Signorini A (1995). *Homoeopathy: A Frontier of Medical Science*, North Atlantic Books, Berkley.
- Belon P, Banerjee A, Karmakar SR, Biswas SJ, Choudhury SC, Banerjee P, Das JK, Pathak S, Guha B, Paul S, Bhattacharjee N, Khuda-Bukhsh AR (2007). Homeopathic remedy for arsenic toxicity? Evidence-based findings from a randomized placebo-controlled double blind human trial. *Science of the Total Environment*; 384(1-3): 141-150.
- Belon P, Banerjee P, Choudhury SC, Banerjee A, Biswas SJ, Karmakar SR, Pathak S, Guha B, Chatterjee S, Bhattacharjee N, Das JK, Khuda-Bukhsh AR (2006). Can administration of potentized homeopathic remedy, Arsenicum album, alter antinuclear antibody (ANA) titer in people living in high-risk arsenic contaminated areas? I. A correlation with certain hematological parameters. *Evidence-Based Complementary and Alternative Medicine*; 3(1): 99-107.
- Berchieri A, Jr., Turco WC, Paiva JB, Oliveira GH, Sterzo EV (2006). Evaluation of isopathic treatment of Salmonella enteritidis in poultry. *Homeopathy*; 95(2): 94-97.
- Beringhs-Bueno A, Moreira HM, D'Almeida V, Pascalicchio AAE (2006). Mercury intoxication: high dilution as mercury's chelating agent. *International Journal of High Dilution Research*; 5(16): 3-6.
- Bernstein JA, Davis BP, Picard JK, Cooper JP, Zheng S, Levin LS (2011). A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. *Annals of Allergy, Asthma and Immunology*; 107(2): 171-178.
- Berrebi A, Parant O, Ferval F, Thene M, Ayoubi JM, Connan L, Belon P (2001). Traitement de la douleur de la montée laiteuse non souhaitée par homeopathie dans le post-partum immédiat (Treatment of pain due to unwanted lactation with a homeopathic preparation given in the immediate post-partum period). *Journal de Gynécologie Obstétrique et Biologie de la Reproduction*; 30(4): 353-357.
- Bhattacharjee N, Pathak S, Khuda-Bukhsh AR (2009). Amelioration of carcinogen-induced toxicity in mice by administration of a potentized homeopathic drug, Natrum Sulph 200. *Evidence-Based Complementary and Alternative Medicine*; 6(1): 65-75.
- Bignamini M, Bertoli A, Consolandi AM, Dovera N, Saruggia M, Taino S, Tubertini A (1987). Controlled double-blind trial with Baryta carbonica 15 CH versus placebo in a group of hypertensive subjects confined to bed in two old people's homes. *British Homoeopathic Journal*; 76(3): 114-119.
- Bignamini M, Saruggia M, Sansonetti G (1991). Homeopathic treatment of anal fissures using nitricum acidum. *Berlin Journal of Research in Homeopathy*; 1(4/5): 286-287.
- Biswas SJ, Khuda-Bukhsh AR (2004). Evaluation of protective potentials of a potentized homeopathic drug, Chelidonium majus, during azo dye induced hepatocarcinogenesis in mice. *Indian Journal of Experimental Biology*; 42(7): 698-714.

- Biswas SJ, Pathak S, Bhattacharjee N, Das JK, Khuda-Bukhsh AR (2005). Efficacy of the potentized homeopathic drug, Carcinosis 200, fed alone and in combination with another drug, Chelidonium 200, in amelioration of p-dimethylaminoazobenzene-induced hepatocarcinogenesis in mice. *Journal of Alternative and Complementary Medicine*; 11(5): 839-854.
- Bolognani FA (2011). Prospective study of ADHD cases with biological confirmation. *International Journal of High Dilution Research*; 10(35): 84-90.
- Bonamin LV, de Moraes CL, Sanches F, Cardoso TN, Sato C, Duran Filho C, Martini LC (2012). Rats born to mothers treated with Dexamethasone 15CH present changes in modulation of inflammatory process. *Evidence-Based Complementary and Alternative Medicine*; 29 Jul [Epub].
- Bonne O, Shemer Y, Goral Y, Katz M, Shalev AY (2003). A randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. *Journal of Clinical Psychiatry*; 64(3): 282-287.
- Bononi M (2000). Echinacea comp. Forte S in the prophylaxis of post-operative infections. A comparative study versus ceftazidime and ceftriaxone. *La Medicina Biologica*; 1: 17-22.
- Bornhöft G, Ammon K (2012). Overview of systematic reviews on the clinical efficacy of homeopathy, in G. Bornhöft and P. Matthiessen (eds), *Homeopathy In Healthcare: Effectiveness, Appropriateness, Safety, Costs*, Springer.
- Bornhoft G, Matthiessen P (2012). *Homeopathy in Healthcare: Effectiveness, Appropriateness, Safety, Costs*, Springer, Herdecke.
- Bornhöft G, Wolf U, Ammon K, Righetti M, Maxion-Bergemann S, Baumgartner S, Thurneysen A, Matthiessen PF (2006). Effectiveness, safety and cost-effectiveness of homeopathy in general practice – summarized health technology assessment. *Forschende Komplementärmedizin*; 13(suppl 2): 19-29.
- Bowen W, Schwartz M (2005). *The Chief Purpose of Universities: Academic Discourse and the Diversity of Ideas*, Mellen Press, London.
- Bracho G, Varela E, Fernandez R, Ordaz B, Marzoa N, Menendez J, Garcia L, Gilling E, Leyva R, Rufin R, de la Torre R, Solis RL, Batista N, Borrero R, Campa C (2010). Large-scale application of highly-diluted bacteria for Leptospirosis epidemic control. *Homeopathy*; 99(3): 156-166.
- Brien S, Lachance L, Prescott P, McDermott C, Lewith G (2011). Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial. *Rheumatology (Oxford)*; 50(6): 1070-1082.
- Brigo B, Serpelloni G (1991). Homeopathic treatment of Migraines: A randomised double-blind controlled study of sixty cases (homeopathic remedy vs placebo). *Berlin Journal of Research in Homeopathy*; 1(2): 98-106.
- Brinkhaus B, Wilkens JM, Ludtke R, Hunger J, Witt CM, Willich SN (2006). Homeopathic arnica therapy in patients receiving knee surgery: results of three randomised double-blind trials. *Complementary Therapies in Medicine*; 14(4): 237-246.
- Brooks AJ, Bell IR, Howerter A, Jackson N, Aickin M (2010). Effects of homeopathic medicines on mood of adults with histories of coffee-related insomnia. *Forschende Komplementärmedizin*; 17(5): 250-257.
- Bruck D (2012). *Lionel Milgrom Responds To Defamation of U.K. Chief Science Advisor and Attempt To Stop Funding Homeopathy*, Homeopathy World Community, viewed Feb 22 2013, <<http://www.homeopathyworldcommunity.com/forum/topics/milgrom-responds-defamation-uk-science-advisor>>.
- Brydak LB, Denys A (1999). The evaluation of humoral response and the clinical evaluation of a risk-group patients' state of health after administration of the homeopathic

- preparation Gripp-Heel during the influenza epidemic season 1993/94. *International Review of Allergology and Clinical Immunology*; 5(4): 223-227.
- Business Standard (2007). A C Nielsen survey backs homeopathy benefits, Business Standard, India, viewed 19 Feb 2013, <http://www.business-standard.com/article/companies/a-c-nielsen-survey-backs-homeopathy-benefits-107082701058_1.html>.
- Cairo J, Elliot BE, Barnouin J, Fleites P, Araoz A, Morales M, Verdura T, Sanchez M, Serrano C, Alvarez JL, Veillard JJ (2001). Homeopathy in Cuban epidemic neuropathy: An open clinical trial. *British Homoeopathic Journal*; 90(3): 154-157.
- Camerlink I, Ellinger L, Bakker EJ, Lantinga EA (2010). Homeopathy as replacement to antibiotics in the case of Escherichia coli diarrhoea in neonatal piglets. *Homeopathy*; 99(1): 57-62.
- Campistrous Lavaut JL (1999). Hypertension trial. *Boletin Mexicano de Homeopatía*; 32(1): 42-47.
- Cardinali C, Francalanci S, Giomi B, Caproni M, Sertoli A, Fabbri P (2004). Contact dermatitis from Rhus toxicodendron in a homeopathic remedy. *Journal of the American Academy of Dermatology*; 50(1): 150-151.
- Carlini EA, Braz S, Troncone LR, Tufik S, Romanach AK, Pustiglione M, Sposati MC, Cudizio Filho O, Prado MI (1987). Efeito hipnotico de medicacao homeopatica e do placebo. Avaliacao pela tecnica de "duplo-cego" e "cruzamento" (Hypnotic effect of homeopathic medication and placebo. Evaluation by double-blind and crossing technics). *AMB: Revista da Associacao Medica Brasileira*; 33(5-6): 83-88.
- Castellsagu API (1992). Evolution of 26 cases of bronchial asthma with homœopathic treatment. *British Homoeopathic Journal*; 81(4): 168-172.
- Castellsague API, Sturza CM (1998). Retrospective study in asthma. *Revista Homeopatica AMBH*; 37: 5-21.
- Cavalcanti AM, Rocha LM, Carillo R, Jr., Lima LU, Lugon JR (2003). Effects of homeopathic treatment on pruritus of haemodialysis patients: a randomised placebo-controlled double-blind trial. *Homeopathy*; 92(4): 177-181.
- Chandrakant Nimgulkar C, Dattatray Patil S, Dinesh Kumar B (2011). Anti-asthmatic and anti-anaphylactic activities of Blatta orientalis mother tincture. *Homeopathy*; 100(3): 138-143.
- Chapman EH, Weintraub RJ, Milburn MA, Pirozzi TO, Woo E (1999). Homeopathic treatment of mild traumatic brain injury: A randomized, double-blind, placebo-controlled clinical trial. *Journal of Head Trauma Rehabilitation*; 14(6): 521-542.
- Charlton BG (1996). The uses and abuses of meta-analysis. *Family Practice*; 13(4): 397-401.
- Chatterjee A, Biswas J, Chatterjee A, Bhattacharya S, Mukhopadhyay B, Mandal S (2011). Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: A prospective clinical study. *Evidence-Based Complementary and Alternative Medicine*; Dec 10 [Epub].
- Chaudhuri S, Varshney JP (2007). Clinical management of babesiosis in dogs with homeopathic Crotalus horridus 200C. *Homeopathy*; 96(2): 90-94.
- Chaufferin G (2000). Improving the evaluation of homeopathy: economic considerations and impact on health. *British Homoeopathic Journal*; 89 Suppl 1: S27-30.
- Clark J, Percivall A (2000). A preliminary investigation into the effectiveness of the homeopathic remedy, Ruta graveolens, in the treatment of pain in plantar fasciitis. *British Journal of Podiatry*; 3(3): 81-85.
- Clover A (2000). Patient benefit survey: Tunbridge Wells Homoeopathic Hospital. *British Homoeopathic Journal*; 89(2): 68-72.
- Clover A, Ratsey D (2002). Homeopathic treatment of hot flushes: a pilot study. *Homeopathy*; 91(2): 75-79.

- Colau JC, Vincent S, Marijnen P, Allaert FA (2012). Efficacy of a non-hormonal treatment, BRN-01, on menopausal hot flashes: A multicenter, randomized, double-blind, placebo-controlled trial. *Drugs in R and D*; 12(3): 107-119.
- Colin P (2006). Homeopathy and respiratory allergies: a series of 147 cases. *Homeopathy*; 95(2): 68-72.
- Cornu C, Joseph P, Gaillard S, Bauer C, Vedrinne C, Bissery A, Melot G, Bossard N, Belon P, Lehot JJ (2010). No effect of a homoeopathic combination of Arnica montana and Bryonia alba on bleeding, inflammation, and ischaemia after aortic valve surgery. *British Journal of Clinical Pharmacology*; 69(2): 136-142.
- Damase-Michel C, Vié C, Lacroix I, Lapeyre-Mestre M, Montastruc JL (2004). Drug counselling in pregnancy: an opinion survey of French community pharmacists. *Pharmacoepidemiol Drug Safety*; 13(10): 711-715.
- Danno K, Colas A, Masson JL, Bordet MF (2012). Homeopathic treatment of migraine in children: Results of a prospective, multicenter, observational study. *Journal of Alternative and Complementary Medicine*; Sep 14 [Epub].
- Danno K, Colas A, Terzan L, Bordet MF (2013). Homeopathic treatment of premenstrual syndrome: a case series. *Homeopathy*; 102(1): 59-65.
- Dantas F, Rampes H (2000). Do homeopathic medicines provoke adverse effects? A systematic review. *British Homoeopathic Journal*; 89(Suppl 1): S35-38.
- Datta S, Mallick P, Bukhsh AR (1999). Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: II. Comparative efficacy of an antibiotic, actinomycin D alone and in combination with either of two microdoses. *Complementary Therapies in Medicine*; 7(3): 156-163.
- Datta SS, Mallick PP, Rahman Khuda-Bukhsh AAR (2001). Comparative efficacy of two microdoses of a potentized homoeopathic drug, Cadmium Sulphoricum, in reducing genotoxic effects produced by cadmium chloride in mice: A time course study. *BMC Complementary and Alternative Medicine*; 1: 9.
- Davidson JR, Morrison RM, Shore J, Davidson RT, Bedayn G (1997). Homeopathic treatment of depression and anxiety. *Alternative Therapies in Health and Medicine*; 3(1): 46-49.
- de Lange de Klerk ES, Blommers J, Kuik DJ, Bezemer PD, Feenstra L (1994). Effect of homoeopathic medicines on daily burden of symptoms in children with recurrent upper respiratory tract infections. *British Medical Journal*; 309(6965): 1329-1332.
- de Oliveira SM, de Oliveira CC, Abud AP, Guimaraes Fde S, Di Bernardi RP, Coletto EL, Buchi Dde F (2011). Mercurius solubilis: actions on macrophages. *Homeopathy*; 100(4): 228-236.
- de Souza MF, Costa-e-Silva EV, Macedo GG, Soares BD, Zuccari CE (2012). The effect of individualized homeopathic treatment on the semen quality of bulls with reproductive disorders: a case series. *Homeopathy*; 101(4): 243-245.
- de Souza Nunes LA (2008). Contribution of homeopathy to the control of an outbreak of dengue in Macaé, Rio de Janeiro. *International Journal of High Dilution Research*; 7(25): 186-192.
- Dean ME (2004). *The trials of homoeopathy: origins, structure and development*, KVC Verlag, Essen.
- Dean ME, Coulter MK, Fisher P, Jobst K, Walach H (2007). Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT. *Journal of Alternative and Complementary Medicine*; 13(1): 19-23.
- Derasse M, Klein P, Weiser M (2005). The effects of a complex homeopathic medicine compared with acetaminophen in the symptomatic treatment of acute febrile infections in children: an observational study. *Explore (NY)*; 1(1): 33-39.
- Dhawale ML (1967). *Principles and Practice of homoeopathy*, Krishna Kurwar, Bombay.

- di Sarsina PR, Iseppato I (2011). Looking for a person-centered medicine: Non conventional medicine in the conventional European and Italian setting. *Evidence-Based Complementary and Alternative Medicine*; Dec 2011 [Epub].
- di Sarsina R, Alivia M, Guadagni P (2012). Traditional, complementary and alternative medical systems and their contribution to personalisation, prediction and prevention in medicine-person-centred medicine. *EPMA Journal*; 3(1): 15.
- di Sarsina R, Isapatto I (2009). Non-conventional medicine in Italy: The present situation. *European Journal of Integrative Medicine*; 1(2): 65-71.
- Diefenbach M, Schilken J, Steiner G, Becker HJ (1997). Homöopathische therapie bei erkrankungen der atemwege. Auswertung einer klinischen studie bei 258 patienten (Homeopathic therapy in respiratory tract diseases. Evaluation of a clinical study in 258 patients). *Zeitschrift für Allgemeinmedizin*; 73: 308-314.
- Dixon A, Riesberg A, Weinbrenner S, Saka O, Le Grand J, Busse R 2003, *Complementary and Alternative Medicine in the UK and Germany – Research and Evidence on Supply and Demand*, Anglo-German Foundation for the Study of Industrial Society, London.
- Dorfman P, Lassere NM, Tetau M (1987). Homoeopathic medicines in pregnancy and labor. *Cahiers de Biotherapie*; 94: 77-81.
- dos Santos AL, Perazzo FF, Cardoso LG, Carvalho JC (2007). In vivo study of the anti-inflammatory effect of Rhus toxicodendron. *Homeopathy*; 96(2): 95-101.
- ECHAMP 2007, *Homeopathic and Anthroposophic Medicine in Europe: Facts and Figures (Second Edition, 2007)*, European Coalition on Homeopathic and Anthroposophic Medicinal Products, Brussels.
- ECHAMP 2009, *Homeopathic and Anthroposophical Medicinal Products*, European Coalition on Homeopathic and Anthroposophic Medicinal Products, Brussels.
- Eid P, Felisi E, Sideri M (1993). Applicability of homœopathic Caulophyllum thalictroides during labour. *British Homoeopathic Journal*; 82(4): 245-248.
- Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL (1993). Unconventional medicine in the United States. Prevalence, costs, and patterns of use. *New England Journal of Medicine*; 328(4): 246-252.
- Eisenberg MD, Davis RB, Ettner S, Appel S, Wilkey S, van Rompay M, Kessler RC (1998). Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up national survey. *Journal of the American Medical Association*; 280(18): 1569-1575.
- Eizayaga FX, Aguejouf O, Belon P, Doutremepuich C (2005). Platelet aggregation in portal hypertension and its modification by ultra-low doses of aspirin. *Pathophysiology of Haemostasis and Thrombosis*; 34(1): 29-34.
- Eizayaga JE, Eizayaga JI (2012). Prospective observational study of 42 patients with atopic dermatitis treated with homeopathic medicines. *Homeopathy*; 101(1): 21-27.
- Endrizzi C, Rossi E, Crudeli L, Garibaldi D (2005). Harm in homeopathy: Aggravations, adverse drug events or medication errors? *Homeopathy*; 94(4): 233-240.
- Ernst E (2000). Prevalence of use of complementary / alternative medicine: a systematic review. *Bulletin of the World Health Organization*; 78(2): 252-257.
- Ernst E (2011). Homeopathic Galphimia glauca for hay fever: A systematic review of randomised clinical trials and a critique of a published meta-analysis. *Focus on Alternative and Complementary Therapies*; 16(3): 200-203.
- Ernst E, Saradeth T, Resch KL (1990). Complementary treatment of varicose veins - a randomized, placebo-controlled, double-blind trial. *Phlebology*; 5(3): 157-163.
- European Council for Classical Homeopathy 2009, *The Safety of Homeopathy*.
- European Parliament 2008, *Together for Health: A Strategic Approach for the EU 2008-2013*, European Union.

- Everett LL, Birmingham PK, Williams GD, Brenn BR, Shapiro JH (2005). Herbal and homeopathic medication use in pediatric surgical patients. *Pediatric Anesthesia*; 15(6): 455-460.
- Expert Committee on Complementary Medicines in the Health System 2003, *Complementary Medicines in the Australian Health System. Report to the Parliamentary Secretary to the Minister for Health and Ageing*, Commonwealth of Australia, Canberra.
- Faculty of Homeopathy (2011a). *Randomised controlled trials in homeopathy*, United Kingdom, viewed Mar 6 2013, <http://www.facultyofhomeopathy.org/research/rcts_in_homeopathy/>.
- Faculty of Homeopathy (2011b). *Systematic reviews of RCTs in homeopathy*, United Kingdom, viewed Feb 27 2013, <http://www.facultyofhomeopathy.org/research/systematic_reviews/>.
- Ferley JP, Zmirou D, D'Adhemar D, Balducci F (1989). A controlled evaluation of a homoeopathic preparation in the treatment of influenza-like syndromes. *British Journal of Clinical Pharmacology*; 27(3): 329-335.
- Fisher P (1986). An experimental double-blind clinical trial method in homeopathy: Use of a limited range of remedies to treat fibrositis. *British Homoeopathic Journal*; 75(3): 142-147.
- Fisher P 2008. Homoeopathic clinical trials, Australian Homoeopathic Association Conference, Sydney.
- Fisher P, Greenwood A, Huskisson EC, Turner P, Belon P (1989). Effect of homeopathic treatment on fibrositis (primary fibromyalgia). *British Medical Journal*; 299(6695): 365-356.
- Fisher P, McCarney R, Hasford C, Vickers A (2006). Evaluation of specific and non-specific effects in homeopathy: feasibility study for a randomised trial. *Homeopathy*; 95(4): 215-222.
- Fisher P, Scott DL (2001). A randomized controlled trial of homeopathy in rheumatoid arthritis. *Rheumatology (Oxford)*; 40(9): 1052-1055.
- Fisher P, Ward A (1994). Complementary medicine in Europe. *British Medical Journal*; 309(6947): 107-111.
- Frass M, Dielacher C, Linkesch M, Endler C, Muchitsch I, Schuster E, Kaye A (2005a). Influence of potassium dichromate on tracheal secretions in critically ill patients. *Chest*; 127(3): 936-941.
- Frass M, Linkesch M, Banyai S, Resch G, Dielacher C, Lobl T, Endler C, Haidvogel M, Muchitsch I, Schuster E (2005b). Adjunctive homeopathic treatment in patients with severe sepsis: a randomized, double-blind, placebo-controlled trial in an intensive care unit. *Homeopathy*; 94(2): 75-80.
- Frei H, Everts R, von Ammon K, Kaufmann F, Walther D, Hsu-Schmitz SF, Collenberg M, Fuhrer K, Hassink R, Steinlin M, Thurneysen A (2005). Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomised, double blind, placebo controlled crossover trial. *European Journal of Pediatrics*; 164(12): 758-767.
- Frei H, Thurneysen A (2001a). Homeopathy in acute otitis media in children: treatment effect or spontaneous resolution? *British Homoeopathic Journal*; 90(4): 180-182.
- Frei H, Thurneysen A (2001b). Treatment for hyperactive children: homeopathy and methylphenidate compared in a family setting. *British Homoeopathic Journal*; 90(4): 183-188.
- Frenkel M, Hermoni D (2002). Effects of homeopathic intervention on medication consumption in atopic and allergic disorders. *Alternative Therapies in Health and Medicine*; 8(1): 76-79.

- Frenkel M, Mishra BM, Sen S, Yang P, Pawlus A, Vence L, Leblanc A, Cohen L, Banerji P (2010). Cytotoxic effects of ultra-diluted remedies on breast cancer cells. *International Journal of Oncology*; 36(2): 395-403.
- Friends of Science in Medicine (2012). *Open Letter to Universities Offering Chiropractic Degrees*, viewed Nov 10 2012, <<http://www.scienceinmedicine.org.au/images/pdf/openchirou.pdf>>.
- Friese KH, Kruse S, Ludtke R, Moeller H (1997). The homoeopathic treatment of otitis media in children--comparisons with conventional therapy. *International Journal of Clinical Pharmacology and Therapeutics*; 35(7): 296-301.
- Friese KH, Zabalotnyi DI (2007). Homöopathie bei akuter rhinosinusitis: Eine doppelblinde, placebokontrollierte studie belegt die wirksamkeit und verträglichkeit eines homöopathischen kombinationsarzneimittels (Homeopathy in acute rhinosinusitis: a double-blind, placebo controlled study shows the efficiency and tolerability of a homeopathic combination remedy). *HNO*; 55(4): 271-277.
- Furuta SE, Weckx LLM, Figueiredo CR (2003). Prospective, randomized, double-blind clinical trial about efficacy of homeopathic treatment in children with obstructive adenoid. *Revista Brasileira de Otorrinolaringologia*; 69(3): 343-347.
- Gariboldi S, Palazzo M, Zanobbio L, Dusio GF, Mauro V, Solimene U, Cardani D, Mantovani M, Rumio C (2009). Low dose oral administration of cytokines for treatment of allergic asthma. *Pulmonary Pharmacology and Therapeutics*; 22(6): 497-510.
- Gassinger CA, Wuenstel G, Netter P (1981). Klinische prüfung zum nachweis der therapeutischen wirksamkeit des homöopathischen arzneimittels eupatorium perfoliatum D2 (wasserhanf composite) bei der diagnose "Grippaler Infekt" (A controlled clinical trial for testing the efficacy of the homeopathic drug eupatorium perfoliatum D2 in the treatment of common cold). *Arzneimittel Forschung*; 31(4): 732-736.
- Gaucher C, Jeulin D, Peycru P, Amengual C (1994). A double blind randomized placebo controlled study of cholera treatment with highly diluted and succussed solutions. *British Homoeopathic Journal*; 83(3): 132-134.
- Gerhard I, Wallis E (2002). Individualized homeopathic therapy for male infertility. *Homeopathy*; 91(3): 133-144.
- Gibson RG, Gibson SL, MacNeill AD, Buchanan WW (1980). Homoeopathic therapy in rheumatoid arthritis: Evaluation by double-blind clinical therapeutic trial. *British Journal of Clinical Pharmacology*; 9(5): 453-459.
- Gibson RG, Gibson SLM, MacNeill AD, Gray GH, Dick WC, Buchanan WW (1978). Salicylates and homoeopathy in rheumatoid arthritis: Preliminary observations. *British Journal of Clinical Pharmacology*; 6(5): 391-395.
- Gimeno MLQ (1991). Homœopathic treatment of ovarian cysts. A series of 40 cases. *British Homoeopathic Journal*; 80(3): 143-148.
- Gimeno MLQ (1996). Homoeopathic treatment of HPV infections previously treated by other methods. *British Homoeopathic Journal*; 85(4): 194-197.
- Glatthaar-Saalmüller B (2007). In vitro evaluation of the antiviral effects of the homeopathic preparation Gripp-Heel on selected respiratory viruses. *Canadian Journal of Physiology and Pharmacology*; 85(11): 1084-1090.
- Gmünder R, Kissling R (2002). Die Wirkung von klassischer Homöopathie im Vergleich mit standardisierter Physiotherapie bei der Behandlung von chronischen Kreuzschmerzen (The efficacy of homeopathy in the treatment of chronic low back pain compared to standardized physiotherapy). *Zeitschrift für Orthopädie und ihre Grenzgebiete*; 140(5): 503-508.
- Goldacre B (2012). *Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients* Fourth Estate, London.

- Goldstein MS, Glik D (1998). Use of and satisfaction with homeopathy in a patient population. *Alternative Therapies in Health and Medicine*; 4(2): 60-65.
- Grabia S, Ernst E (2003). Homeopathic aggravations: a systematic review of randomized, placebo-controlled trials. *Homeopathy*; 92(2): 92-98.
- Grundling C, Schimetta W, Frass M (2012). Real-life effect of classical homeopathy in the treatment of allergies: A multicenter prospective observational study. *Wiener Klinische Wochenschrift*; 124(1-2): 11-17.
- Guimarães FSF, Abud APR, Oliveira SM, Oliveira CC, César B, Andrade LF, Donatti L, Gabardo J, Trindade ES, Buchi DF (2009). Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication. *BMC Cancer*; 9: 293.
- Güthlin C, Lange O, Walach H (2004). Measuring the effects of acupuncture and homoeopathy in general practice: An uncontrolled prospective documentation approach. *BMC Public Health*; 4: 6.
- Haidvogel M, Riley DS, Heger M, Brien S, Jong M, Fischer M, Lewith GT, Jansen G, Thurneysen AE (2007). Homeopathic and conventional treatment for acute respiratory and ear complaints: a comparative study on outcome in the primary care setting. *BMC Complementary and Alternative Medicine*; 7: 7.
- Haila S, Koskinen A, Tenovuori J (2005). Effects of homeopathic treatment on salivary flow rate and subjective symptoms in patients with oral dryness: a randomized trial. *Homeopathy*; 94(3): 175-181.
- Harrison H, Fixsen A, Vickers A (1999). A randomized comparison of homoeopathic and standard care for the treatment of glue ear in children. *Complementary Therapies in Medicine*; 7(3): 132-135.
- Harrison RE, Burge TS, Watson ACH, Taylor-Reilly D (1993). Homœopathic treatment of burn scars-clinical enquiry. *British Homœopathic Journal*; 82(4): 252-254.
- Hart O, Mullee MA, Lewith G, Miller J (1997). Double-blind, placebo-controlled, randomized clinical trial of homoeopathic arnica C30 for pain and infection after total abdominal hysterectomy. *Journal of the Royal Society of Medicine*; 90(2): 73-78.
- Harvey K 2012a, *The evidence for complementary medicines.*, *Healthy Voices*, Consumers Health Forum of Australia.
- Harvey K (2012b). *Private health insurers natural therapy rebates in the spotlight*, The Conversation, Melbourne, viewed Mar 8 2013, <<http://theconversation.edu.au/private-health-insurers-natural-therapy-rebates-in-the-spotlight-12706>>.
- Hati AK, Paital B, Naik KN, Mishra AK, Chainy GB, Nanda LK (2012). Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. *Homeopathy*; 101(4): 217-223.
- Hellhammer J, Schubert M (2012). Effects of a homeopathic combination remedy on the acute stress response, well-being, and sleep: A double-blind, randomized clinical trial. *Journal of Alternative and Complementary Medicine*; Sep 10 [Epub].
- Heusser P, Berger S, Stutz M, Hüsler A, Haeberli A, Wolf U (2009). Efficacy of homeopathically potentized antimony on blood coagulation: A randomized placebo controlled crossover trial. *Forschende Komplementärmedizin*; 16(1): 14-18.
- Hielm-Bjorkman A, Tulamo R-M, Salonen H, Raekallio M (2009). Evaluating complementary therapies for canine osteoarthritis--Part II: A homeopathic combination preparation (Zeel). *Evidence-Based Complementary and Alternative Medicine*; 6(4): 46-471.
- Hitzenberger G, Rehak PH (2005). Zur Wirkung eines homöopathischen Fertigarzneimittels auf den Blutdruck von Hypertonikern - Eine randomisierte doppelblinde kontrollierte parallelgruppen-vergleichsstudie (The effect of a homeopathic drug on the blood

- pressure of hypertensive patients - A randomised double-blind controlled parallel group comparative trial). *Wiener Medizinische Wochenschrift*; 155(17-18): 392-396.
- Homoeopathic Industry Reference Group 1999, *National Competency Standards for Homeopathy*, Community Services and Health Training Australia, Darlinghurst NSW.
- House of Commons Science and Technology Committee 2010, *The House of Commons Science and Technology Committee Evidence Check 2: Homoeopathy. Fourth Report of the Session 2009-20*, House of Commons, London.
- Iannotti G, Melo EM (2012). The impact of the medical speciality in primary health-care problem solving in Belo Horizonte, Brazil: homeopaths versus family doctors: a preliminary quantitative study. *Homeopathy*; 101(1): 44-50.
- International Data Collection Centres for Integrative Medicine 1998, *A Review of Inpatient Care Integrating Complementary and Orthodox Medicine at Glasgow Homoeopathic Hospital*, Glasgow Homoeopathic Hospital, Glasgow.
- Issing W, Klein P, Weiser M (2005). The homeopathic preparation Vertigoheel versus Ginkgo biloba in the treatment of vertigo in an elderly population: a double-blinded, randomized, controlled clinical trial. *Journal of Alternative and Complementary Medicine*; 11(1): 155-160.
- Itamura R (2007). Effect of homeopathic treatment of 60 Japanese patients with chronic skin disease. *Complementary Therapies in Medicine*; 15(2): 115-120.
- Itamura R, Hosoya R (2003). Homeopathic treatment of Japanese patients with intractable atopic dermatitis. *Homeopathy*; 92(2): 108-114.
- Ivanovas G (2012a). Critique of pure evidence. Homeopathy and evidence-based medicine Part 1. *Homeopathic Links*; 25(1): 13-17.
- Ivanovas G (2012b). Individualisation and the practitioner's paradox. Homeopathy and evidence-based medicine Part 2. *Homeopathic Links*; 25(2): 122-125.
- Jack RAF (1993). How I treat Crohn's disease. *British Homoeopathic Journal*; 82(1): 29-36.
- Jacobs J, Fernandez EA, Merizalde B, Avila-Montes GA, Crothers D (2007). The use of homeopathic combination remedy for dengue fever symptoms: a pilot RCT in Honduras. *Homeopathy*; 96(1): 22-26.
- Jacobs J, Guthrie BL, Montes GA, Jacobs LE, Mickey-Colman N, Wilson AR, DiGiacomo R (2006). Homeopathic combination remedy in the treatment of acute childhood diarrhea in Honduras. *Journal of Alternative and Complementary Medicine*; 12(8): 723-732.
- Jacobs J, Herman P, Heron K, Olsen S, Vaughters L (2005a). Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial. *Journal of Alternative and Complementary Medicine*; 11(1): 21-27.
- Jacobs J, Jimenez LM, Gloyd SS, Gale JL, Crothers D (1994). Treatment of acute childhood diarrhea with homeopathic medicine: a randomized clinical trial in Nicaragua. *Pediatrics*; 93(5): 719-725.
- Jacobs J, Jimenez LM, Malthouse S, Chapman E, Crothers D, Masuk M, Jonas WB (2000). Homeopathic treatment of acute childhood diarrhea: results from a clinical trial in Nepal. *Journal of Alternative and Complementary Medicine*; 6(2): 131-139.
- Jacobs J, Jimenez LM, Gloyd S, Carares FE, Gaitan MP, Crothers D (1993). Homœopathic treatment of acute childhood diarrhoea. A randomized clinical trial in Nicaragua. *British Homoeopathic Journal*; 82(2): 83-86.
- Jacobs J, Jonas WB, Jimenez-Perez M, Crothers D (2003). Homeopathy for childhood diarrhea: combined results and metaanalysis from three randomized, controlled clinical trials. *Pediatric Infectious Disease Journal*; 22(3): 229-234.
- Jacobs J, Springer DA, Crothers D (2001). Homeopathic treatment of acute otitis media in children: a preliminary randomized placebo-controlled trial. *Pediatric Infectious Disease Journal*; 20(2): 177-183.

- Jacobs J, Williams AL, Girard C, Njike VY, Katz D (2005b). Homeopathy for attention-deficit/hyperactivity disorder: a pilot randomized-controlled trial. *Journal of Alternative and Complementary Medicine*; 11(5): 799-806.
- Jaeger H, Eger J, Koegl C, Wolf E, Balogh A, Jaegel-Guedes E, Naik N, Gilada I 2008. Healthy unrest: Canova stimulates CD4 cells in ART treated virologically suppressed but immunologically unresponsive HIV patients, paper presented to XVII International AIDS Conference, Mexico City, 2008.
- Jain A (2003). Does homeopathy reduce the cost of conventional drug prescribing? A study of comparative prescribing costs in general practice. *Homeopathy*; 92(2): 71-76.
- Jonas WB, Linde K, Ramirez G (2000). Homeopathy and rheumatic disease. *Rheum Dis Clin North Am*; 26(1): 117-123, x.
- Joos S, Musselmann B, Miksch A, Rosemann T, Szecsenyi J (2008). The role of complementary and alternative medicine (CAM) in Germany - a focus group study of GPs. *BMC Health Services Research*; 8: 127.
- Kainz JT, Kozel G, Haidvogel M, Smolle J (1996). Homoeopathic versus placebo therapy of children with warts on the hands: a randomized, double-blind clinical trial. *Dermatology*; 193(4): 318-320.
- Karow JH, Abt HP, Frohling M, Ackermann H (2008). Efficacy of Arnica montana D4 for healing of wounds after Hallux valgus surgery compared to diclofenac. *Journal of Alternative and Complementary Medicine*; 14(1): 17-25.
- Katz T, Fisher P, Katz A, Davidson J, Feder G (2005). The feasibility of a randomised, placebo-controlled clinical trial of homeopathic treatment of depression in general practice. *Homeopathy*; 94(3): 145-152.
- Kaziro GSN (1984). Metronidazole (flagyl) and Arnica Montana in the prevention of post-surgical complications: A comparative placebo controlled clinical trial. *British Journal of Oral and Maxillofacial Surgery*; 22(1): 42-49.
- Keil T, Witt CM, Roll S, Vance W, Weber K, Wegscheider K, Willich SN (2008). Homoeopathic versus conventional treatment of children with eczema: A comparative cohort study. *Complementary Therapies in Medicine*; 16(1): 15-21.
- Khuda-Bukhsh AR, Banerjee A, Biswas SJ, Karmakar SR, Banerjee P, Pathak S, Guha B, Haque S, Das D, De A, Das D, Boujedaini N (2011a). An initial report on the efficacy of a millesimal potency Arsenicum Album LM 0/3 in ameliorating arsenic toxicity in humans living in a high-risk arsenic village. *Zhong Xi Yi Jie He Xue Bao*; 9(6): 596-604.
- Khuda-Bukhsh AR, Biswas R, Mandal SK, Dutta S, Bhattacharyya SS, Boujedaini N (2011b). Thujone-rich fraction of Thuja occidentalis demonstrates major anti-cancer potentials: Evidences from in vitro studies on A375 cells. *Evidence-Based Complementary and Alternative Medicine*; Feb 2011 [Epub].
- Khuda-Bukhsh AR, Pathak S, Guha B, Karmakar SR, Das JK, Banerjee P, Biswas SJ, Mukherjee P, Bhattacharjee N, Choudhury SC, Banerjee A, Bhadra S, Mallick P, Chakrabarti J, Mandal B (2005). Can homeopathic arsenic remedy combat arsenic poisoning in humans exposed to groundwater arsenic contamination? A preliminary report on first human trial. *Evidence-Based Complementary and Alternative Medicine*; 2(4): 537-548.
- Khuda-Bukhsh AR, Roy-Karmakar S, Banerjee A, Banerjee P, Pathak S, Biswas SJ, Haque S, Das D, Boujedaini N, Belon P (2011c). A follow-up study on the efficacy of the homeopathic remedy Arsenicum Album in volunteers living in high risk arsenic contaminated areas. *Evidence-Based Complementary and Alternative Medicine*; Mar 9 [Epub].
- Kim LS, Riedlinger JE, Baldwin CM, Hilli L, Khalsa SV, Messer SA, Waters RF (2005). Treatment of seasonal allergic rhinitis using homeopathic preparation of common

- allergens in the southwest region of the US: a randomized, controlled clinical trial. *Annals of Pharmacotherapy*; 39(4): 617-624.
- Kliems H, Witt CM (2011). The good doctor: a qualitative study of German homeopathic physicians. *Journal of Alternative and Complementary Medicine*; 17(3): 265-270.
- Klopp R, Niemer W, Weiser M (2005). Microcirculatory effects of a homeopathic preparation in patients with mild vertigo: an intravital microscopic study. *Microvascular Research*; 69(1-2): 10-16.
- Kneis KC, Gandjour A (2009). Economic evaluation of Sinfrontal in the treatment of acute maxillary sinusitis in adults. *Applied Health Economics and Health Policy*; 7(3): 181-191.
- Komesaroff PA, Moore A, Kerridge IH (2012). Medicine and science must oppose intolerance and censorship. *Medical Journal of Australia*; 197(2): 82-83.
- Kotlus BS, Heringer DM, Dryden RM (2010). Evaluation of homeopathic Arnica montana for ecchymosis after upper blepharoplasty: a placebo-controlled, randomized, double-blind study. *Ophthalmic Plastic and Reconstructive Surgery*; 26(6): 395-397.
- Kulkarni A, Nagarkar BM, Burde GS (1988). Radiation protection by use of homoeopathic medicines. *Hahnemannian Homoeopathic Sandesh*; 12: 20-23.
- Kumar KB, Sunila ES, Kuttan G, Preethi KC, Venugopal CN, Kuttan R (2007). Inhibition of chemically induced carcinogenesis by drugs used in homeopathic medicine. *Asian Pacific Journal of Cancer Prevention*; 8(1): 98-102.
- Kundu T, Shaikh A, Kutty A, Nalvade A, Kulkarni S, Kulkarni R, Ghosh K (2012). Homeopathic medicines substantially reduce the need for clotting factor concentrates in haemophilia patients: results of a blinded placebo controlled cross over trial. *Homeopathy*; 101(1): 38-43.
- Kuzeff RM (1998). Homeopathy, sensation of well-being and CD4 levels: A placebo-controlled, randomized trial. *Complementary Therapies in Medicine*; 6(1): 4-9.
- Labrecque M, Audet D, Latulippe LG, Drouin J (1992). Homeopathic treatment of plantar warts. *Canadian Medical Association Journal*; 146(10): 1749-1753.
- Lacroix I, Arrault-Olanor A, Berrebi A, Montastruc JL, Damase-Michel C (2005). Consommation de médicaments en période périnatale: étude comparative chez des femmes allaitant ou non leur enfant (Drug use during postpartum period: A comparative study between lactating and non-lactating women). *Journal de Pédiatrie et de Puericulture*; 18(8): 379-385.
- Lakshmi Prabhakar R, Ruckmani A, Venkatesan D, Madhusudhanan N, Pavithra R (2012). Anxiolytic effect of homeopathic preparation of Pulsatilla nigricans in Swiss albino mice. *Homeopathy*; 101(3): 171-174.
- Lamont J (1997). Homeopathic treatment of attention deficit hyperactivity disorder. *British Homoeopathic Journal*; 86(4): 196-200.
- Lewith GT, Watkins AD, Hyland ME, Shaw S, Broomfield JA, Dolan G, Holgate ST (2002). Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial. *British Medical Journal*; 324(7336): 520.
- Li AM, Bush A, Wilson A (2003). Homeopathy in childhood asthma. *Thorax*; 58(9): 826.
- Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV, Jonas WB (1997). Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo controlled trials. *Lancet*; 350(9081): 934-843.
- Lipman D, Sexton G, Schlessner J (1999). A randomized double-blind placebo-controlled evaluation of the safety and efficacy of a natural over-the-counter (OTC) medication in the management of snoring. *Sleep and Breathing*; 3(2): 53-56.
- Lokken P, Straumsheim PA, Tveiten D, Skjelbred P, Borchgrevink CF (1995). Effect of homoeopathy on pain and other events after acute trauma: placebo controlled trial with bilateral oral surgery. *British Medical Journal*; 310(6992): 1439-1442.

- Lotfollahzadeh S, Alizadeh MR, Mohri M, Mokhber Dezfouli MR (2012). The therapeutic effect of *Tarentula cubensis* extract (Theranechron(R)) in foot-and-mouth disease in cattle: a randomised trial in an endemic setting. *Homeopathy*; 101(3): 159-164.
- Lyrio C, Siqueira CM, Veiga VF, Homsani F, Marques AL, Biolchini J, Dantas F, de Matos HJ, Passos SRL, Couceiro JN, Holandino C (2011). The use of homeopathy to prevent symptoms of human flu and acute respiratory infections: A double-blind, randomized, placebo-controlled clinical trial with 600 children from Brazilian public health service. *International Journal of High Dilution Research*; 10(36): 174-176.
- Maas HPJA (1993). Ulcerative colitis treated with homœopathy. A retrospective survey. *British Homœopathic Journal*; 82(3): 179-185.
- MacLennan AH, Morrison RGB (2012). Tertiary education institutions should not offer pseudoscientific medical courses. *Medical Journal of Australia*; 196(4): 225-226.
- MacLennan AH, Wilson DH, Taylor AW (2002). The escalating cost and prevalence of alternative medicine. *Preventive Medicine*; 35(2): 166-173.
- Maiwald VL, Weinfurter T, Mau J, Connert WD (1988). Therapie des grippalen Infekts mit einem homöopathischen kombinationspräparat im vergleich zu acetylsalicylsäure. Kontrollierte, randomisierte Einfachblindstudie (Treatment of common cold with a combination homeopathic preparation compared with acetylsalicylic acid. A controlled, randomized single-blind study). *Arzneimittel Forschung*; 38: 578-582.
- Manchanda RK, Mehan N, Bahl R, Atey R (1997). Double blind placebo controlled clinical trials of homœopathic medicines in warts and molluscum contagiosum. *CCRH Quarterly Bulletin*; 19: 25-29.
- Marian F, Joost K, Saini KD, Von Ammon K, Thurneysen A, Busato A (2008). Patient satisfaction and side effects in primary care: An observational study comparing homeopathy and conventional medicine. *BMC Complementary and Alternative Medicine*; 8: 52.
- Marino R (2008). Homeopathy and collective health: The case of dengue epidemics. *International Journal of High Dilution Research*; 7(25): 179-185.
- Maronna U (2000). Comparison of the efficacy and tolerability of Zeel comp and Diclofenac for the oral treatment of osteoarthritis: Results of a Double blind equivalence study. *International Journal for Biomedical Research and Therapy* 29(3): 157-158.
- Martinez B (1990). Folliculinum: Efficacy in premenstrual syndrome. *British Homœopathic Journal*; 79(2): 104-105.
- Mathie RT, Hacke D, Clausen J, Nicolai T, Riley DS, Fisher P (2013). Randomised controlled trials of homeopathy in humans: characterising the research journal literature for systematic review. *Homeopathy*; 102(1): 3-24.
- Mathie RT, Roniger H, Van Wassenhoven M, Frye J, Jacobs J, Oberbaum M, Bordet M-F, Nayak C, Chauferin G, Ives JA, Dantas F, Fisher P (2012). Method for appraising model validity of randomised controlled trials of homeopathic treatment: multi-rater concordance study. *BMC Medical Research Methodology*; 12: 49.
- Matusiewicz R (1997). The homeopathic treatment of corticosteroid-dependent asthma. A double-blind placebo-controlled study. *Biomedical Therapy*; 15(4): 177-122.
- Mazzocchi A, Montanaro F (2012). Observational study of the use of *Symphytum 5CH* in the management of pain and swelling after dental implant surgery. *Homeopathy*; 101(4): 211-216.
- McCutcheon LE (1996). Treatment of anxiety with a homeopathic remedy. *Journal of Applied Nutrition*; 48(1-2): 2-6.
- Medew J 2012, Alternative medicine crackdown, *The Age*, March 14.
- Mohammadi R, Amini K, Charehsaz S (2012). Homeopathic treatment for peripheral nerve regeneration: an experimental study in a rat sciatic nerve transection model. *Homeopathy*; 101(3): 141-146.

- Mohan GR (2007). Efficacy of homeopathy in childhood asthmas. *Homeopathic Links*; 20(2): 104-107.
- Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999). Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. *Lancet*; 354(9193): 1896-1900.
- Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Platin N, Hummerston S, Scott JA, Panteli V, Gudmundsdottir G, Selvekerova S, Patiraki E, Kearney N (2005a). Complementary and alternative medicine use in colorectal cancer patients in seven European countries. *Complementary Therapies in Medicine*; 13(4): 251-257.
- Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AMA, Platin N, Kearney N, Patiraki E (2005b). Use of complementary and alternative medicine in cancer patients: a European survey. *Annals of Oncology*; 16(4): 655-663.
- Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J (2012). A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. *Medical Journal of Australia*; 196(1): 50-53.
- Mousavi F, Mojaver YN, Asadzadeh M, Mirzazadeh M (2009a). Homeopathic treatment of minor aphthous ulcer: a randomized, placebo-controlled clinical trial. *Homeopathy*; 98(3): 137-141.
- Mousavi F, Sherafati S, Mojaver YN (2009b). Ignatia in the treatment of oral lichen planus. *Homeopathy*; 98(1): 40-44.
- Moynihan R (2012). Assaulting alternative medicine: worthwhile or witch hunt? *British Medical Journal*; 344: e1075.
- Mroninski CRL, Adriano EJ, Mattos G (2001). Meningococcinum: Its protective effect against meningococcal disease. *Homeopathic Links*; 4(1): 230-234.
- Munstedt K, Brenken A, Kalder M (2009). Clinical indications and perceived effectiveness of complementary and alternative medicine in departments of obstetrics in Germany: A questionnaire study. *European Journal of Obstetrics & Gynecology and Reproductive Biology*; 146(1): 50-54.
- Muscari-Tomaoli G, Allegri F, Miali E, Pomposelli R, Tubia P, Targhetta A, Castellini M, Bellavite P (2001). Observational study of quality of life in patients with headache, receiving homœopathic treatment. *British Homœopathic Journal*; 90(4): 189-197.
- Myers SP, Xue CC, Cohen MM, Phelps KL, Lewith GT (2012). The legitimacy of academic complementary medicine. *Medical Journal of Australia*; 197(2): 69-70.
- Nahler G, Metelman H, Sperber H (1998). Treatment of osteoarthritis of the knee with a homeopathic medicine - Results of a randomised controlled clinical trial in comparison to hyaluronic acid. 1998;16(2):186-191. *Biomedical therapy*; 16(2): 186-191.
- National Health and Medical Research Council (2011). *Personalised medicine and genetics*, National Health and Medical Research Council, Canberra, viewed 19 Feb 2013, <<http://www.nhmrc.gov.au/your-health/egenetics/personalised-medicine>>.
- National Health and Medical Research Council (2013). *Complementary and alternative medicines*, National Health and Medical Research Council, Canberra, viewed Mar 5 2013, <<http://www.nhmrc.gov.au/your-health/complementary-and-alternative-medicines>>.
- National Institute of Complementary Medicine (2009). *Facts and Statistics*, viewed Feb 21 2013, <<http://www.nicm.edu.au/understanding-cm/facts-and-statistics>>.
- Naude DF, Stephanie Couchman IM, Maharaj A (2010). Chronic primary insomnia: efficacy of homeopathic simillimum. *Homeopathy*; 99(1): 63-68.
- Nayak C, Singh V, Singh K, Singh H, Oberai P, Roja V, Padmanabhan M, Prasad S, Arya MD, Mohanan PG, Singh O, John MD, Singh NBK, Bhagat SR, Ramteke S (2010). A

- multi-centric open clinical trial to evaluate the usefulness of 13 predefined homeopathic medicines in the management of acute rhinitis in children. *International Journal of High Dilution Research*; 9(30): 30-42.
- Neumann S, Stolt P, Braun G, Hellmann K, Reinhart E (2011). Effectiveness of the homeopathic preparation Zeel compared with Carprofen in dogs with osteoarthritis. *Journal of the American Animal Hospital Association*; 47(1): 12-20.
- Nicolai T (2005). *Homeopathy trials used and not used in Egger/Shang's meta-analysis*, PDF file, European Committee for Homeopathy, viewed 16 Feb 2013, <<http://www.homeopatia.edu.pl/pdf/HOMEOPATHY%20TRIALS%20USED%20AND%20NOT%20USED%20IN%20EGGERSHANGS%20META-ANALYSIS.pdf>>.
- Nurse P (2013). *Making science work*, Radio National, Australian Broadcasting Commission, viewed Mar 5 2013, <<http://www.abc.net.au/radionational/programs/scienceshow/paul-nurse---making-science-work/4508096>>.
- O'Brien M (2012). 'Unethical': NHMRC to reveal stance on homeopathy, Medical Observer, viewed Mar 5 2013, <<http://www.medicalobserver.com.au/news/unethical-nhmrc-to-reveal-stance-on-homeopathy>>.
- Oberbaum M, Galoyan N, Lerner-Geva L, Singer SR, Grisaru S, Shashar D, Samueloff A (2005). The effect of the homeopathic remedies Arnica montana and Bellis perennis on mild postpartum bleeding--a randomized, double-blind, placebo-controlled study--preliminary results. *Complementary Therapies in Medicine*; 13(2): 87-90.
- Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS, Branski D (2001). A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. *Cancer*; 92(3): 684-690.
- Oryan A (2012). Novel application of Theranekron® enhanced the structural and functional performance of the tenotomized tendon in rabbits. *Cells Tissues Organs*; 196(5): 442-455.
- Padilha RQ, Riera R, Atallah AN (2011). Homeopathic Plumbum metallicum for lead poisoning: a randomized clinical trial. *Homeopathy*; 100(3): 116-121.
- Papp R, Schuback G, Beck E, Burkard G, Bengel J, Lehl S, Belon P (1998). Oscillococcinum R in patients with influenza-like syndromes: A placebo-controlled double-blind evaluation. *Homeopathy*; 87(2): 69-76.
- Paris A, Gonnet N, Chaussard C, Belon P, Rocourt F, Saragaglia D, Cracowski JL (2008). Effect of homeopathy on analgesic intake following knee ligament reconstruction: a phase III monocentre randomized placebo controlled study. *British Journal of Clinical Pharmacology*; 65(2): 180-187.
- Paris A, Schmidlin S, Mouret S, Hodaj E, Marijnen P, Boujedaini N, Polosan M, Cracowski JL (2012). Effect of Gelsemium 5CH and 15CH on anticipatory anxiety: a phase III, single-centre, randomized, placebo-controlled study. *Fundamental and Clinical Pharmacology*; 26(6): 751-760.
- Patel DR, Ansari IA, Kachchhi YN, Patel RB, Patil KR, Jadhav RB, Patil CR (2012). Toxicodendron pubescens retains its anti-arthritis efficacy at 1M, 10M and CM homeopathic dilutions. *Homeopathy*; 101(3): 165-170.
- Pathak S, Kumar Das J, Jyoti Biswas S, Khuda-Bukhsh AR (2006). Protective potentials of a potentized homeopathic drug, Lycopodium-30, in ameliorating azo dye induced hepatocarcinogenesis in mice *Molecular and Cellular Biochemistry*; 285(1-2): 121-131.
- Pathak S, Multani AS, Banerji P, Banerji P (2003). Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer. *International Journal of Oncology*; 23(4): 975-982.

- Patil CR, Rambhade AD, Jadhav RB, Patil KR, Dubey VK, Sonara BM, Toshniwal SS (2011). Modulation of arthritis in rats by *Toxicodendron pubescens* and its homeopathic dilutions. *Homeopathy*; 100(3): 131-137.
- Pelletier KR, Astin JA (2002). Integration and reimbursement of complementary and alternative medicine by managed care and insurance providers: 2000 update and cohort analysis. *Alternative Therapies in Health and Medicine*; 8(1): 38.
- Pomposelli R, Codecà G, Bergonzi R, Andreoni C, Salvi GP, Costini G, Piasere V, Bellavite P (2003). Terapia omeopatica in pazienti con patologia artroreumatica. *Med Nat (Milano)*; 13(6): 44-50.
- Pomposelli R, Piasere V, Andreoni C, Costini G, Tonini E, Spalluzzi A, Rossi D, Quarenghi C, Zanolin ME, Bellavite P (2009). Observational study of homeopathic and conventional therapies in patients with diabetic polyneuropathy. *Homeopathy*; 98(1): 17-25.
- Popov AV (1992). Homœopathy in treatment of patients with fibromyoma of the uterus. *British Homœopathic Journal*; 81(4): 164-167.
- Posadzki P, Alotaibi A, Ernst E (2012). Adverse effects of homeopathy: a systematic review of published case reports and case series. *International Journal of Clinical Practice*; 66(12): 1178-1188.
- Prasad R (2007). Homoeopathy booming in India. *Lancet*; 370(9600): 1679-1680.
- Rabe A, Weiser M, Klein P (2004). Effectiveness and tolerability of a homoeopathic remedy compared with conventional therapy for mild viral infections. *International Journal of Clinical Practice*; 58(9): 827-832.
- Rahlfs VW, Mössinger P (1976). Zur behandlung des colon irritabile. Ein multizentrischer plazebo-kontrollierter doppelblindversuch in der allgemeinen praxis (Treatment of irritable colon. A multicenter placebo-controlled double-blind study in general practice). *Arzneimittel-Forschung*; 26(12): 2230-2234.
- Rahlfs VW, Mössinger P (1979). Asa foetida bei colon irritabile – Doppelblindversuch (Asa foetida in the treatment of the irritable colon – a double-blind trial). *Deutsche Medizinische Wochenschrift*; 104(4): 140-143.
- Ramchandani NM (2010). Homoeopathic treatment of upper respiratory tract infections in children: evaluation of thirty case series. *Complementary Therapies in Clinical Practice*; 16(2): 101-108.
- Rastogi DP, Singh VP, Singh V, Dey SK, Rao K (1999). Homeopathy in HIV infection: a trial report of double-blind placebo controlled study. *British Homœopathic Journal*; 88(2): 49-57.
- Reilly D (2005). Homeopathy: Increasing scientific validation. *Alternative Therapies in Health and Medicine*; 11(2): 28-31.
- Reilly D, Mercer SW, Bikker AP, Harrison T (2007). Outcome related to impact on daily living: preliminary validation of the ORIDL instrument. *BMC Health Serv Res*; 7: 139.
- Reilly D, Taylor MA, Beattie NG, Campbell JH, McSharry C, Aitchison TC, Carter R, Stevenson RD (1994). Is evidence for homoeopathy reproducible? *Lancet*; 344(8937): 1601-1606.
- Reilly DT, Taylor MA, McSharry C, Aitchison T (1986). Is homoeopathy a placebo response? Controlled trial of homoeopathic potency, with pollen in hayfever as model. *Lancet*; 2(8512): 881-886.
- Relton C, Smith C, Raw J, Walters C, Adebajo AO, Thomas KJ, Young TA (2009). Healthcare provided by a homeopath as an adjunct to usual care for Fibromyalgia (FMS): results of a pilot Randomised Controlled Trial. *Homeopathy*; 98(2): 77-82.
- Richardson WR (2001). Patient benefit survey: Liverpool Regional Department of Homœopathic Medicine. *British Homœopathic Journal*; 90(3): 158-162.

- Riley D, Fischer M, Singh B, Haidvogel M, Heger M (2001). Homeopathy and conventional medicine: an outcomes study comparing effectiveness in a primary care setting. *Journal of Alternative and Complementary Medicine*; 7(2): 149-159.
- Riveron-Garrote M (1998). Ensayo clínico aleatorizado controlado del tratamiento homeopático del asma bronquial. *Boletín Mexicano de Homeopatía*; 31(2): 54-61.
- Robertson A, Suryanarayanan R, Banerjee A (2007). Homeopathic Arnica montana for post-tonsillectomy analgesia: a randomised placebo control trial. *Homeopathy*; 96(1): 17-21.
- Robinson T (2006). Responses to homeopathic treatment in National Health Service general practice. *Homeopathy*; 95(1): 9-14.
- Rodrigues-Neto JF, Figueiredo MF, Faria AA (2009). Prevalence of the use of homeopathy by the population of Montes Claros, Minas Gerais, Brazil. *Sao Paulo Medical Journal*; 127(6): 329-334.
- Rossi E, Bartoli P, Bianchi A, Da Fre M (2012). Homeopathy in paediatric atopic diseases: long-term results in children with atopic dermatitis. *Homeopathy*; 101(1): 13-20.
- Rossi E, Crudeli L, Endrizzi C, Garibaldi D (2009a). Cost-benefit evaluation of homeopathic versus conventional therapy in respiratory diseases. *Homeopathy*; 98(1): 2-10.
- Rossi E, Endrizzi C, Panozzo MA, Bianchi A, Da Fre M (2009b). Homeopathy in the public health system: a seven-year observational study at Lucca Hospital (Italy). *Homeopathy*; 98(3): 142-148.
- Rossignol M, Begaud B, Engel P, Avouac B, Lert F, Rouillon F, Benichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L (2012). Impact of physician preferences for homeopathic or conventional medicines on patients with musculoskeletal disorders: results from the EPI3-MSD cohort. *Pharmacoepidemiology and Drug Safety*; 21(10): 1093-1101.
- Ruiz-Vega G, Perez-Ordaz L, Cortes-Galvan L, Juarez GF (2003). A kinetic approach to caffeine--Coffea cruda interaction. *Homeopathy*; 92(1): 19-29.
- Rutten AL, Stolper CF (2008). The 2005 meta-analysis of homeopathy: the importance of post-publication data. *Homeopathy*; 97(4): 169-177.
- Sackett D (1997). Evidence based medicine. *Seminars in Perinatology*; 21(1): 3-5.
- Sackett DL, Rosenberg WMC, Muir Gray JA, Haynes RB, Richardson WS (1996). Evidence based medicine: what it is and what it isn't. *British Medical Journal*; 312(7023): 72-72.
- Saruggia M, Corghi E (1992). Effects of homœopathic dilutions of China rubra on intradialytic symptomatology in patients treated with chronic haemodialysis. *British Homœopathic Journal*; 81(2): 86-88.
- Schlappack O (2004). Homeopathic treatment of radiation-induced itching in breast cancer patients. A prospective observational study. *Homeopathy*; 93(4): 210-215.
- Schmiedel V, Klein P (2006). A complex homeopathic preparation for the symptomatic treatment of upper respiratory infections associated with the common cold: An observational study. *Journal of Science and Healing*; 2(2): 109-114.
- Schneider B, Klein P, Weiser M (2005). Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials. *Arzneimittelforschung*; 55(1): 23-29.
- Schwager S (2012). *War against natural medicine*, Australian Broadcasting Commission, viewed Aug 8 2012, <<http://www.abc.net.au/unleashed/3840682.html>>.
- Seeley BM, Denton AB, Ahn MS, Maas CS (2006). Effect of homeopathic Arnica montana on bruising in face-lifts: results of a randomized, double-blind, placebo-controlled clinical trial. *Archives of Facial Plastic Surgery*; 8(1): 54-59.
- Sevar R (2005). Audit of outcome in 455 consecutive patients treated with homeopathic medicines. *Homeopathy*; 94(4): 215-221.
- Shafei HF, AbdelDayem SM, Mohamed NH (2012). Individualized homeopathy in a group of Egyptian asthmatic children. *Homeopathy*; 101(4): 224-230.

- Shang A, Huwiler-Muntener K, Nartey L, Juni P, Dorig S, Sterne JA, Pewsner D, Egger M (2005). Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. *Lancet*; 366(9487): 726-732.
- Sharma S, Sharma N (2012). Long term evaluation of homeopathy on post treatment impairment of pulmonary tuberculosis. *BMC Complementary and Alternative Medicine*; 12(Suppl 1): P223.
- Sharma S, Sharma N, Sharma R (2012). Accelerating the healing of bone fracture using homeopathy: a prospective, randomized double-blind controlled study. *BMC Complementary and Alternative Medicine*; 12(Suppl 1): O61.
- Sharples FM, van Haselen R, Fisher P (2003). NHS patients' perspective on complementary medicine. *Complementary Therapies in Medicine*; 11(4): 243-248.
- Shealy CN, Thomlinson RP, Cox RH, Borgmeyer RN (1998). Osteoarthritic pain: a comparison of homeopathy and acetaminophen. *American Journal of Pain Management*; 8(3): 89-91.
- Shipley M, Berry H, Broster G, Jenkins M, Clover A, Williams I (1983). Controlled trial of homoeopathic treatment of osteoarthritis. *Lancet*; 1(8316): 97-98.
- Siebenwirth J, Ludtke R, Remy W, Rakoski J, Borelli S, Ring J (2009). Wirksamkeit einer klassisch-homöopathischen Therapie bei atopischem Ekzem. Eine randomisierte, placebokontrollierte Doppelblindstudie (Effectiveness of a classical homeopathic treatment in atopic eczema. A randomised placebo-controlled double-blind clinical trial). *Forschende Komplementärmedizin*; 16(5): 315-323.
- Silva NL, Moletta JL, Minho AP, Filippesen LF (2008). Use of biotherapeutic in the control of natural infestation by *Boophilus microplus*: pilot study. *International Journal of High Dilution Research*; 7(22): 36-38.
- Singer SR, Amit-Kohn M, Weiss S, Rosenblum J, Maoz G, Samuels N, Lukasiewicz E, Freedman L, Paltiel O, Itzchaki M, Niska M, Oberbaum M (2010). Traumeel S for pain relief following hallux valgus surgery: a randomized controlled trial. *BMC Clinical Pharmacology*; 10: 9.
- Sinha MN, Siddiqui VA, Nayak C, Singh V, Dixit R, Dewan D, Mishra A (2012). Randomized controlled pilot study to compare Homeopathy and Conventional therapy in Acute Otitis Media. *Homeopathy*; 101(1): 5-12.
- Smallwood C (2005). *The role of Complementary and Alternative Medicine in the NHS*, Get Well UK, viewed Feb 6 2013, <<http://www.getwelluk.com/uploadedFiles/Publications/SmallwoodReport.pdf>>.
- Smith SA, Baker AE, Williams JH (2002). Effective treatment of seborrheic dermatitis using a low dose, oral homeopathic medication consisting of potassium bromide, sodium bromide, nickel sulfate, and sodium chloride in a double-blind, placebo-controlled study. *Alternative Medicine Review: A Journal of Clinical Therapeutics*; 7(1): 59-67.
- Spence DS (1991). Homœopathic treatment of eczema: a retrospective survey of 130 cases. *British Homœopathic Journal*; 80(2): 74-81.
- Spence DS, Thompson EA, Barron SJ (2005). Homeopathic treatment for chronic disease: a 6-year, university-hospital outpatient observational study. *Journal of Alternative and Complementary Medicine*; 11(5): 793-738.
- Spin-Neto R, Belluci MM, Sakakura CE, Scaf G, Pepato MT, Marcantonio E, Jr. (2010). Homeopathic *Symphytum officinale* increases removal torque and radiographic bone density around titanium implants in rats. *Homeopathy*; 99(4): 249-254.
- Stam C, Bonnet MS, van Haselen RA (2001). The efficacy and safety of a homeopathic gel in the treatment of acute low back pain: a multi-centre, randomised, double-blind comparative clinical trial. *British Homœopathic Journal*; 90(1): 21-28.

- Stange R, Amhof R, Moebus S (2008). Complementary and alternative medicine: attitudes and patterns of use by German physicians in a national survey. *Journal of Alternative and Complementary Medicine*; 14(10): 1255-1261.
- Steinsbekk A, Bentzen N, Fonnebo V, Lewith G (2005a). Self treatment with one of three self selected, ultramolecular homeopathic medicines for the prevention of upper respiratory tract infections in children. A double-blind randomized placebo controlled trial. *British Journal of Clinical Pharmacology*; 59(4): 447-455.
- Steinsbekk A, Fonnebo V, Lewith G, Bentzen N (2005b). Homeopathic care for the prevention of upper respiratory tract infections in children: a pragmatic, randomised, controlled trial comparing individualised homeopathic care and waiting-list controls. *Complementary Therapies in Medicine*; 13(4): 231-238.
- Steinsbekk A, Ludtke R (2005). Patients' assessments of the effectiveness of homeopathic care in Norway: a prospective observational multicentre outcome study. *Homeopathy*; 94(1): 10-16.
- Stevinson C, Devaraj VS, Fountain-Barber A, Hawkins S, Ernst E (2003). Homeopathic arnica for prevention of pain and bruising: randomized placebo-controlled trial in hand surgery. *Journal of the Royal Society of Medicine*; 96(2): 60-65.
- Straumsheim P, Borchgrevink C, Mowinckel P, Kierulf H, Hafslund O (2000). Homeopathic treatment of migraine: a double blind, placebo controlled trial of 68 patients [see comment]. *British Homoeopathic Journal*; 89(1): 4-7.
- Strauss L (2000). The efficacy of a homeopathic preparation in the management of attention deficit hyperactivity disorder. *Biomedical Therapy* 18(2): 197-201.
- Strosser W, Weiser M (2000). Osteoarthritis patients regain mobility. A double-blind study of a homeopathic medication *International Journal of Biomedical Research*; 29(6): 295-299.
- Studer HP, Busato A (2011). Comparison of Swiss basic health insurance costs of complementary and conventional medicine. *Forsch Komplementmed*; 18(6): 315-320.
- Sukul NC, Ghosh S, Sinhababu SP (2005). Reduction in the number of infective *Trichinella spiralis* larvae in mice by use of homeopathic drugs. *Forschende Komplementarmedizin und Klassische Naturheilkunde*; 12(4): 202-205.
- Sumner C (2010). *Faculty of Homeopathy finds Science and Technology report lacking*, Faculty of Homeopathy, viewed Feb 6 2013, <Error! Hyperlink reference not valid..
- Sunila ES, Kuttan G, Preethi KC, Kuttan R (2007). Effect of homeopathic medicines on transplanted tumors in mice. *Asian Pacific Journal of Cancer Prevention*; 8(3): 390-394.
- Swayne J (1992). The cost, effectiveness of homoeopathy. A pilot study and proposals for future research. *British Homeopathic Journal*; 81(3): 148-150.
- Swayne J (2002). Homeopathy: Principles and practice. *Homeopathy*; 91(2): 117-119.
- Tavares Carvalho JC, Vieira Campos RM, Ferreira Vaz A, dos Santos Costa K, Ezequiel Paulo Viriato EP (2009). Anxiolytic effect of the homeopathic complex Tepeex. *International Journal of High Dilution Research*; 8(28): 91-99.
- Taylor JA, Jacobs J (2011). Homeopathic ear drops as an adjunct to standard therapy in children with acute otitis media. *Homeopathy*; 100(3): 109-115.
- Taylor MA, Reilly D, Llewellyn-Jones RH, McSharry C, Aitchison TC (2000). Randomised controlled trial of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial series. *British Medical Journal*; 321(7259): 471-476.
- Teixeira MZ (2009). Effectiveness of individualized homeopathic treatment in perennial allergic rhinitis (PAR). *International Journal of High Dilution Research*; 8(28): 141-143.
- Therapeutic Goods Administration (2012). *Australian regulatory guidelines for complementary medicines (ARGCM)*, Department of Health and Ageing, Canberra, viewed 19 Feb 2013, <<http://www.tga.gov.au/industry/cm-argcm.htm>>.

- Thompson E, Barron S, D. S (2004). A preliminary audit investigating remedy reactions including adverse events in routine homeopathic practice. *Homeopathy*; 93(4): 203-209.
- Thompson EA, Montgomery A, Douglas D, Reilly D (2005). A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors. *Journal of Alternative and Complementary Medicine*; 11(1): 13-20.
- Thompson EA, Reilly D (2002). The homeopathic approach to symptom control in the cancer patient: a prospective observational study. *Palliative Medicine*; 16(3): 224-233.
- Thompson EA, Shaw A, Nichol J, Hollinghurst S, Henderson AJ, Thompson T, Sharp D (2011). The feasibility of a pragmatic randomised controlled trial to compare usual care with usual care plus individualised homeopathy, in children requiring secondary care for asthma. *Homeopathy*; 100(3): 122-130.
- Torres JA, Landazuri Llago S, González Verdecia A, Escalona Arranz J (2001). Utilidad de la homeopatía en la prevención de las crisis asmáticas en el niño (Usefulness of homeopathy in the prevention of asthma attacks in children). *Medisan*; 5(1): 5-9.
- Totonchi A, Guyuron B (2007). A randomized, controlled comparison between arnica and steroids in the management of postrhinoplasty ecchymosis and edema. *Plastic and Reconstructive Surgery*; 120(1): 271-274.
- Trichard M, Chauferin G 2003. Cost effectiveness study of treatment of Anxiety Disorders by homeopathic general practitioners, Royal London Homoeopathic Hospital, Apr 4.
- Trichard M, Chauferin G, Dubreuil C, Nicoloyannis N, Duru G (2004). Effectiveness, quality of life, and cost of caring for children in France with recurrent acute rhinopharyngitis managed by homeopathic or non-homeopathic general practitioners: A pragmatic, prospective observational study. *Disease Management and Health Outcomes*; 12(6): 419-427.
- Trichard M, Chauferin G, Nicoloyannis N (2005). Pharmacoeconomic comparison between homeopathic and antibiotic treatment strategies in recurrent acute rhinopharyngitis in children. A pragmatic, prospective observational study. *Homeopathy*; 94(1): 3-9.
- Tuffs A (2002). Three out of four Germans have used complementary or natural remedies. *British Medical Journal*; 325(7371): 990.
- Ullman D (2010). *Homeopathic medicine: Europe's #1 medical alternative*, Huffington Post, viewed Feb 13 2013, <http://www.huffingtonpost.com/dana-ullman/homeopathic-medicine-euro_b_402490.html>.
- Ullman D (2011). *Disinformation on homeopathy: Two leading sources*, The Huffington Post, viewed Feb 6 2013, <http://www.huffingtonpost.com/dana-ullman/disinformation-homeopathy_b_969627.html>.
- van den Meerschaut L, Sunder A (2009). The homeopathic preparation Nervoheel N can offer an alternative to lorazepam therapy for mild nervous disorders. *Evidence-Based Complementary and Alternative Medicine*; 6(4): 507-515.
- van Erp VMA, Brands M (1996). Homoeopathic treatment of Malaria in Ghana. Open study and clinical trial. *British Homoeopathic Journal*; 85(2): 66-70.
- van Haselen R (2000). An economic evaluation of complementary medicine: a staged approach at the Royal London Homeopathic Hospital. *British Homoeopathic Journal*; 89(Suppl 1): S23-26.
- van Haselen RA, Fisher PA (2000). A randomized controlled trial comparing topical piroxicam gel with a homeopathic gel in osteoarthritis of the knee. *Rheumatology (Oxford)*; 39(7): 714-719.
- van Haselen RA, Graves N, Dahiha S (1999). The costs of treating rheumatoid arthritis patients with complementary medicine: exploring the issue. *Complement Ther Med*; 7(4): 217-221.

- van Hootehem H (2007). Can homeopathy learn something from psychoanalysis? *Homeopathy*; 96(2): 108-112.
- van Wassenhoven M (1996). Retrospective study of rheumatological patients in a private homoeopathic medical practice. *British Homoeopathic Journal*; 85(4): 198-205.
- van Wassenhoven M (1998). Retrospective study of cardiac rhythm disorders: Retrospective study on cardiac rhythm disorders in a private homoeopathic medical practice. *British Homoeopathic Journal*; 87(2): 77-86.
- van Wassenhoven M, Ives G (2004). An observational study of patients receiving homeopathic treatment. *Homeopathy*; 93(1): 3-11.
- Varshney JP, Naresh R (2005). Comparative efficacy of homeopathic and allopathic systems of medicine in the management of clinical mastitis of Indian dairy cows. *Homeopathy*; 94(2): 81-85.
- Vickers AJ, Smith C (2006). Homoeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndromes. *Cochrane Database Syst Rev*; [Epub](3): CD001957.
- Villanueva DFD, Rodríguez AP, García LRG, Osés CAM (2012). Use of homeopathic formula in malnourished children. *International Journal of High Dilution Research*; 11(38): 25-32.
- Vincent S, Demonceaux A, Deswarte D, Scimeca D, Bordet MF (2012). Management of influenza-like illness by homeopathic and allopathic general practitioners in France during the 2009-2010 influenza season. *Journal of Alternative and Complementary Medicine*; Jul 17 [Epub].
- Vozianov AF, Simeonova NK (1990). Homœopathic treatment of patients with adenomas of the prostate. *British Homoeopathic Journal*; 79(3): 148-151.
- Walach H, Haeusler W, Lowes T, Mussbach D, Schamell U, Springer W, Stritzl G, Gaus W, Haag G (1997). Classical homeopathic treatment of chronic headaches. *Cephalalgia*; 17(2): 119-126.
- Waldschütz R, Klein P (2008). The homeopathic preparation Neurexan® vs. valerian for the treatment of insomnia: An observational study. *The Scientific World Journal*; 8: 411-420.
- Ward S (2012). What is the evidence for the treatment of asthma with homeopathy? *Homeopathic Links*; 25(4): 281-286.
- Weatherley-Jones E, Nicholl JP, Thomas KJ, Parry GJ, McKendrick MW, Green ST, Stanley PJ, Lynch SP (2004). A randomised, controlled, triple-blind trial of the efficacy of homeopathic treatment for chronic fatigue syndrome. *Journal of Psychosomatic Research*; 56(2): 189-197.
- Weiser M, Clasen B (1994). Randomisierte plazebokontrollierte Doppelblindstudie zur Untersuchung der klinische Wirksamkeit der homöopathischen Euphorbium compositum-Nasentropfen S bei chronischer Sinusitis (Randomized, placebo-controlled, double-blind study of the clinical efficacy of the homeopathic Euphorbium compositum-S nasal spray in cases of chronic sinusitis). *Forschende Komplementärmedizin*; 1: 251-259.
- Weiser M, Gegenheimer LH, Klein P (1999). A randomized equivalence trial comparing the efficacy and safety of Luffa comp. Heel nasal spray with cromolyn sodium spray in the treatment of seasonal allergic rhinitis. *Forschende Komplementärmedizin und Klassische Naturheilkunde*; 6(3): 142-148.
- Weiser M, Strosser W, Klein P (1998). Homeopathic vs conventional treatment of vertigo: a randomized double-blind controlled clinical study. *Archives of Otolaryngology--Head & Neck Surgery*; 124(8): 879-885.
- White A, Slade P, Hunt C, Hart A, Ernst E (2003). Individualised homeopathy as an adjunct in the treatment of childhood asthma: a randomised placebo controlled trial. *Thorax*; 58(4): 317-321.

- Whitmarsh TE, Coleston-Shields DM, Steiner TJ (1997). Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. *Cephalalgia*; 17(5): 600-604.
- Wiesenauer M, Gaus W, Bohnacker U, Haussler S (1989). Wirksamkeitsprüfung von homöopathischen kombinationspräparaten bei sinusitis. Ergebnisse einer randomisierten doppelblindstudie unter praxisbedingungen (Efficiency of homeopathic preparation combinations in sinusitis. Results of a randomized double blind study with general practitioners). *Arzneimittel-Forschung*; 39(5): 620-625.
- Wiesenauer M, Gaus W, Haussler S (1990). Behandlung der pollinosis mit galphimia glauca. Eine doppelblindstudie unter praxisbedingungen (Treatment of pollinosis with the homeopathic preparation Galphimia glauca). *Allergologie*; 13(10): 359-363.
- Wiesenauer M, Haussle S, Gaus W (1983). Pollinosis-therapie mit galphimia glauca (Treatment of pollinosis with Galphimia glauca). *Fortschritte der Medizin*; 101(17): 811-814.
- Wiesenauer M, Ludtke R (1995). The treatment of pollinosis with Galphimia glauca D4 - a randomized placebo-controlled double-blind clinical trial. *Phytomedicine*; 2(1): 3-6.
- Wiesenauer M, Ludtke R (1996). A Meta-analysis of the Homeopathic Treatment of Pollinosis with Galphimia glauca. *Forsch Komplementarmed*; 3(5): 230-234.
- Winston J (1999). *The Faces of Homoeopathy*, Narayana Publishers, Germany.
- Witt A, Kaufmann U, Bitschnau M, Tempfer C, Ozbal A, Haytouglu E, Gregor H, Kiss H (2009a). Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. *BJOG: An International Journal of Obstetrics and Gynaecology*; 116(11): 1499-1505.
- Witt C, Keil T, Selim D, Roll S, Vance W, Wegscheider K, Willich SN (2005). Outcome and costs of homoeopathic and conventional treatment strategies: A comparative cohort study in patients with chronic disorders. *Complementary Therapies in Medicine*; 13(2): 79-86.
- Witt CM, Lüdtkke R, Baur R, Willich SN (2009b). Homeopathic treatment of patients with chronic low back pain: A prospective observational study with 2 years' follow-up. *Clinical Journal of Pain*; 25(4): 334-339.
- Witt CM, Ludtke R, Mengler N, Willich SN (2008). How healthy are chronically ill patients after eight years of homeopathic treatment?--Results from a long term observational study. *BMC Public Health*; 8: 413.
- Witt CM, Ludtke R, Willich SN (2009c). Homeopathic treatment of patients with psoriasis--a prospective observational study with 2 years follow-up. *Journal of the European Academy of Dermatology and Venereology*; 23(5): 538-543.
- Witt CM, Lüdtkke R, Willich SN (2009d). Homeopathic treatment of patients with chronic sinusitis: A prospective observational study with 8 years follow-up. *BMC Ear, Nose and Throat Disorders*; 9(1): 7.
- Wolf M, Tamaschke C, Mayer W, Heger M (2003). Wirksamkeit von arnica bei varizenoperation: Ergebnisse einer randomisierten, doppelblinden, placebo-kontrollierten pilot-studie (Efficacy of Arnica in varicose vein surgery: results of a randomized, double-blind, placebo-controlled pilot study). *Forschende Komplementarmedizin und Klassische Naturheilkunde*; 10(5): 242-247.
- Wolschner U, Strösser W, Weiser M, Klein P (2001). Treating vertigo - homeopathic combination remedy therapeutically equivalent to dimenhydrinate. *Biologische Medezin*; 30(4): 184-190.
- Xue C, Zhang C, Lin V, Da Costa C, Story DF (2007). Complementary medicine use in Australia: a national population-based survey. *Journal of Alternative and Complementary Medicine*; 13(6): 643-650.

- Xue CC, L. Z, V. L, F. SD (2006). The use of complementary and alternative medicine in Australia. *Health Issues*; 88: 12-15.
- Xue CC, Zhang AL, Lin V, Myers R, Polus B, F. SD (2008). Acupuncture, chiropractic and osteopathy use in Australia: a national population survey. *BMC Public Health*; 8: 105.
- Yakir M, Kreitler S, Brzezinski A, Vithoulkas G, Oberbaum M, Bentwich Z (2001). Effects of homeopathic treatment in women with premenstrual syndrome: a pilot study. *British Homoeopathic Journal*; 90(3): 148-153.
- Zabolotnyi DI, Kneis KC, Richardson A, Rettenberger R, Heger M, Kaszkin-Bettag M, Heger PW (2007). Efficacy of a complex homeopathic medication (Sinfrontal) in patients with acute maxillary sinusitis: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial. *Explore (NY)*; 3(2): 98-109.
- Zhang AL, Xue CC, Lin V, Story DF (2007). Complementary and alternative medicine use by older Australians. *Annals of the New York Academy of Sciences*; 1114: 204-215.
- Zuzak TJ, Zuzak-Siegrist I, Rist L, Staubli G, Simoes-Wust AP (2010). Medicinal systems of complementary and alternative medicine: a cross-sectional survey at a pediatric emergency department. *Journal of Alternative and Complementary Medicine*; 16(4): 473-479.